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GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS
Hepatic and Renal Cysts
In general, cysts are fluid-filled, benign tumors. These structures correspond to cavities in 
organs. Cysts may be identified in multiple parts of the human body. For example, in the 
lung, pancreas, liver, kidney, spleen, bone and brain.1-5 In the majority of cases, these clinical 
manifestations are not related to a syndrome or recognized as an inherited disorder. This is 
different for hepatic and renal cystogenesis. 
Non-hereditary or acquired hepatic cysts occur in 2.5-4.7% of the general population 
and 11% of hospitalizations.6 These simple cysts are variable in size on initial detection and 
may increase in size over time. They are often asymptomatic or detected as an incidental 
finding on abdominal imaging. 
The heredity of hepatic cysts has been described since 1929.7 Hepatic cysts may already be 
present as microscopic lesions at birth. Between birth and the third decade of life development 
of new hepatic cysts is rare, but may also be asymptomatic.8 Small embryonic remnants are 
also called Von Meyenburg complexes. These small cysts usually remain silent during life in 
contrast to autosomal dominant polycystic liver disease (PCLD). The onset of symptomatic 
hepatic cysts may start around the age of 40 in PCLD. Although there is no evidence for 
genetic predisposition in woman, an increased frequency of hepatic cysts is demonstrated 
in female patients.9 
The aspect of a cyst wall is smooth, transparent, avascular, yellowish/ bluish/ white in color 
(Figure 1). Cysts are formed by a thin layer of fibrous tissue lined by a single layer of cuboidal 
Figure 1. Simple hepatic 
cyst and polycystic liver. (A) 
Protruding hepatic cyst (black 
arrow) from the free border of 
the liver.11 (B) Axial CT scan of 
a large hepatic cyst indicate by 
a white arrow. (C) Liver section 
presenting multiple large cavities. 
(D) Axial CT scan of a PCLD 
patient.
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epithelia. Hepatic cysts may contain homogeneous transudate-like, clear or straw-coloured 
fluid of low viscosity.10  
In the liver, cysts are the most common space-occupying structures. The size of hepatic 
cysts may vary from microscopically small to massively enlarged up to ~20 cm diameter.12 
PCLD patients may present over 20 hepatic cysts spread throughout the liver parenchyma.13 
Therefore, the major consequences of enlarging hepatic cysts are obstructive and mechanical 
symptoms. Frequent clinical signs of symptomatic polycystic livers consist of flank pain, 
abdominal discomfort, palpable mass or cyst-related complications.14
Hepatic cysts may co-occur with renal cysts. In PCLD, renal cysts are rarely seen and 
may be discrete lesions in the kidneys. Typically, few renal cysts are cortically located and 
distort the renal contour. The prevalence of renal cysts in the general population has been 
estimated to be 10.7-11.9%.15, 16 Large cysts in both the liver and kidneys are more frequent 
in autosomal dominant polycystic kidney disease (ADPKD). 
Ductal Plate Malformation
The morphogenesis of the intrahepatic bile ducts (IHBD) is established by a process of 
ductal plate formation after 7 weeks of gestation.17 The ductal plate is recognized as the 
source of stem cells (hepatoblasts) for bile duct neogenesis and development. At different 
developmental stages hepatoblasts express cytokeratins (CK) that are intermediate filaments 
of the cytoskeleton. For example, CK8, CK18 and CK19 are expressed in early progenitor 
hepatoblasts.18 Finally, normal IHBD express CK7 and CK19 as particular phenotypical markers 
which are absent in hepatocytes.19, 20 Development of normal bile ducts and a classification 
of three pathogenic mechanisms for ductal plate malformation (DPM) are described in 
Figure 2.21
DPM can be seen as the basic component of congenital cystic diseases in IHBD and is caused 
by an excess of embryonic biliary structures with persistent ductal plate configuration. DPM 
compromises all abnormal gestational features that may occur during the bile duct development 
until the formation of mature IHBD. Disturbed epithelial-mesenchymal interactions in DPM 
Figure 2. Concept of bile duct formation and ductal plate malformation at 8-12 weeks of human 
gestational age. This figure illustrates hepatoblast proliferation from a monolayer (A) to a double-layer 
around the portal vein (B). (C) Development of normal human bile ducts by focal dilatation between 
both layers from the 12th week of gestational age. (D) DPM and cyst formation may arise according to 
three mechanisms 21: 1) abnormal hepatoblast differentiation, 2) failure hepatoblast maturation, 3) bile 
duct expansion with normal cell differentiation and maturation.
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may cause ineffective remodeling of ductal plates, abnormal hepatoblast differentiation, and 
alterations in portal vein, bile duct configuration and cilia formation.22 
DPM may occur in multiple intrahepatic and extrahepatic disorders such as extrahepatic 
biliary atresia, congenital hepatic fibrosis, autosomal recessive polycystic kidney disease, 
Caroli syndrome and Ivemark’s syndrome.23 In addition, DPM may occur in a spectrum of 
abnormalities  at different levels of the biliary tree. For example microscopic, peripheral bile 
ducts  in congenital hepatic fibrosis, and large bile ducts in Caroli syndrome. The isolated liver 
cysts in ADPKD probably represent DPM affecting the most biliary system.24
Moreover, in liver disease of ciliopathies DPM is the main underlying pathophysiological 
mechanism.20 Ciliopathies describe a class of disorders with a dysfunctional cilium or cilium-
anchored structures. In general, these diseases are inherited and present a broad phenotypic 
spectrum affecting multiple organs. ADPKD is classified as ciliopathy and also PCLD can be 
considered as an ciliopathy.25
Polycystic Liver Disease Phenotypes
Clinical Variation in PCLD
Polycystic liver disease (PLD) is a clinical condition in adult individuals affected with PCLD or 
ADPKD. In both diseases the phenotypical expression is heterogeneous. Clinical characterization 
of PCLD patients reported presence of asymptomatic renal cystogenesis in clinically diagnosed 
PCLD patients.26, 27 Renal disease and progressive renal failure are frequently present in ADPKD 
patients. Genetically, PCLD and ADPKD are distinct diseases, however it is obvious that there 
is an overlap in phenotype between both disorders.28
A correlation between phenotype and genotype is not established in PCLD. Previous studies 
presented clinical variation in families with mutations in the PRKCSH gene.29, 30 Asymptomatic 
individuals may have microscopically small or few hepatic cysts. Absence of hepatic cysts is 
related to a certain non-penetrance in PCLD.13, 28, 30 
Variation in phenotype has not been ascribed to the causative gene mutation.28, 29 Also 
the number of hepatic cysts may not be predicted from the mutated gene.29 In several 
families mutations may occur due to founder effect in certain geographical regions of the 
Netherlands. In addition, a large number of singleton cases with a negative family history 
are identified. This observation of clinical variation suggests that the reported prevalence of 
PCLD is probably underestimated.
ADPKD Clinical Heterogeneity
First, an evident clinical heterogeneity was determined between ADPKD patients. Severely 
affected ADPKD patients were called polycystic kidney disease 1 patients because of linkage 
to the PKD1 gene. These PKD1 patients were clinically compared to non-PKD1 patients. 
Important observations in non-PKD1 carriers were the detection of fewer renal cysts at the 
time of diagnosis, less development of hypertension and diagnosis at an older age.31
APDKD is a monogenic renal disorder with a penetrance of renal cystogenesis of nearly 
~100%. The consequences of a germline mutation in the PKD1 or PKD2 gene are clearly different. 
Identification of the gene and mutation type contributes to the prediction of renal disease severity. 
Although the cyst growth rates are similar in both PKD1 and PKD2 carriers, ADPKD patients 
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carrying a PKD1 mutation develop earlier polycystic kidneys.32 In addition, affected individuals 
with PKD1 may progress 20 years earlier to end-stage renal disease compared to PKD2.33
There is an inter- and intrafamilial phenotypic variability in ADPKD. Regarding PKD1 
affected families clinical differences are poorly understood.34 Involvement of modifier genes 
have been suggested to explain the early disease progression and severity in PKD1 carriers. 
In line with these findings, there are more mechanisms reported to be associated with 
a spectrum of polycystic kidney disease phenotype. Atypical mutations or unusual mode of 
inheritance were identified during the search for a putative PKD3 locus. I will describe several 
aspects of these genetic investigations.
Genetic Mechanisms in ADPKD
1) Hypomorphic allele variants/ incomplete penetrance: Two clinically diagnosed autosomal 
recessive polycystic kidney disease (ARPKD) patients developed severe renal disease in 
utero. However the phenotype overlaps with early-onset ADPKD, the family history was 
negative. Molecular screening of both parents revealed hypomorphic PKD1 variants. 
Presence of two hypomorphic PKD1 variants in trans explained the ADPKD phenotype.35 
Therefore, the dosage of functional PKD1 protein may be critical for cyst development.36
2) Mosaicism: Exceptional cases describe the clinical relevance of mosaicism in transmission 
of the defect to offspring. This genetic mechanism may explain patients with early-onset 
of polycystic kidney disease or may be considered in case of excluding PKD1 and PKD2 
variants for living kidney donor transplantation.37-39
3) Digenic model: A family with PKD1 and PKD2 gene mutations reported different onset of 
end-stage renal disease. The most severely affected individuals carried mutations in both 
ADPKD genes in contrast to single gene mutations. A threshold model was proposed to explain 
the pathophysiological mechanism for these digenic and monogenic mutation carriers.40
4) Modifier genes: In patients with perinatal or early-onset renal disease during childhood 
additional mutations were identified in PKHD1 or HNF1β.41 This study proposed that multiple 
genes are involved in severe polycystic kidney disease phenotypes.
5) De novo ADPKD cases: Patients with an apparent negative family history may be examples 
of de novo disease manifestation.42 One study reported evidence for six de novo cases. 
6) Association or overlap with other diseases: The tuberous sclerosis complex gene is adjacent 
to PKD1 on chromosome 16. Recent studies have shown that genomic deletion of PKD1 and 
TSC2 may result in earlier and more severe renal disease in a small number of patients.43
Severe Polycystic Liver Disease
The definition of massive PLD may include several aspects such as number and size of hepatic 
cysts, distribution of cysts in both liver lobules and complications. Patients with severe PLD 
have extremely enlarged livers up to ~eight-fold in size. Disabling symptoms due to the mass-
effect impair the physical condition and quality of life in patients. 
Familial clustering of massive polycystic livers in PCLD or ADPKD is unknown. For example, 
the PKD1 mutation position is strongly related to an increased risk for cerebral aneurysms in 
ADPKD. PKD2 carriers are at risk for vascular complications.44 Such evidence is unknown for 
polycystic livers which is the most common extra-renal manifestation. 
15
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There are several aspects which may be related to progressive PLD (Figure 3). For example, 
the severity of hepatic cystogenesis in ADPKD is related to renal disease.45 Therefore, the 
type of ADPKD gene mutation and renal disease progression are important factors indirectly 
associated with PLD.45, 46
Pregnancies and estrogen administration may be considered as hormonal factors or 
as environmental influences.9 These factors are positively correlated with hepatic cyst 
enlargement.47 Finally, increasing age is associated with cyst growth. The question remains if 
there are more environmental or organ-specific factors triggering massive hepatic cystogenesis.
Polycystic Liver Disease Genes
PKD1 and PKD2 associated with ADPKD
In the early 1990s, gene discoveries for ADPKD have been conducted by positional cloning 
(Figure 4). First genetic linkage studies mapped a major locus to chromosome 16 for ADPKD.48 
The region was more concisely determined to a 600-kb interval on 16p13.3.49, 50 The European 
polycystic kidney disease consortium identified one splice site defect, two deletions and a de 
novo chromosome translocation in the PKD1 (PBP) gene.51 One deletion was also reported 
as a de novo event. These findings confirmed a causative role of PKD1 mutations in ADPKD. 
After initial linkage analysis, genetic heterogeneity of ADPKD was evident.52 Concurrent 
linkage studies searched for a second ADPKD gene. Few years later, nonsense mutations were 
identified in the PKD2 gene (chr.4q21) in three unrelated ADPKD families.53 
Since conventional approaches excluded linkage to either the PKD1 and PKD2 locus in 
several ADPKD families, involvement of another locus was suggested.54-57 These families 
presented ADPKD with mild renal phenotype or a severe associated extra-renal manifestation. 
A hypothetical PKD3 gene might explain the clinical heterogeneity.58
In addition, a rodent model with polycystic kidneys and hepatic cysts unlinked to PKD1 
and PKD2, demonstrated linkage to a locus homologous to human chromosome 8q23-24.59 
Candidate genes in this region near the proenkephalin gene (PENK gene; chr.8q12.1) in rats 
were identified on human chromosome arms 6q and 9p.
Figure 3. Determinants positively related to hepatic cystogenesis.
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More research groups reported unlinked ADPKD families with mild, but also severe 
phenotypes similar to PKD1 carriers.58, 60 For example, clinical follow-up of an unlinked ADPKD 
family with severe renal and systemic manifestations presented renal disease progression.60, 
61 This clinical heterogeneity observed in non-PKD1/PKD2 families resulted in speculations 
about a role of modifier genes.61 
Genetic Approaches in ADPKD  
Rapid technological developments enabled improved detection of variants in the human 
genome. Repeated clinical and sequence analysis of previously reported unlinked ADPKD 
families from five different origins 54, 56-58, 61, did reveal one PKD2 and three PKD1 mutations.62 
Still, direct Sanger sequencing and multiplex ligation probe-dependent amplification 
(MLPA) of PKD1 and PKD2 identified no causative mutation in 11-13% of ADPKD families 
from the Consortium for Radiological Imaging Studies of PKD (CRISP) population.43, 63 The 
same is true for another large ADPKD cohort where comprehensive mutation analysis showed 
71 mutation-negative unrelated ADPKD patients (10.1%).64 The clinical features of ADPKD 
families without PKD1 and PKD2 mutations are heterogeneous with a large proportion of 
mild phenotypes.65 These findings point to another ADPKD locus as previously described. 
Direct Sanger sequencing is the ‘golden standard’ for detection of point mutations and 
other small genetic variants, but complete sequencing of the PKD1 gene remains difficult.63 
For example, larger genetic variants are missed. Therefore, mutation-negative ADPKD families 
may also be explained by undetectable variation or chromosomal rearrangements in both 
PKD1 and PKD2 genes. 
Recent development of high-throughput sequencing technologies may give information 
about large DNA rearrangements, exonic and intronic variants with unpredicted consequences 
Figure 4. Timeline highlighting clinical studies and achievements in genetics in PLD.
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on splicing, mosaicism or hypomorphic alleles. It is likely that these yet undetected types of 
variants may contribute to ADPKD. 
The first application of next-generation sequencing (NGS) in ADPKD is a design for 
PKD1 and PKD2 targeted re-sequencing. Likely pathogenic deep intronic sequence variants, 
gene conversions and allelic drop-out were successfully called in 10% of previously mutation-
negative ADPKD patients.66
PRKCSH and SEC63 associated with PCLD
PCLD and ADPKD were clinically defined as separated entities. After identification of both 
ADPKD genes, the clinical condition of isolated polycystic livers was also designated as a 
genetically distinct condition. Pathogenic variants in the PKD1 and PKD2 gene were excluded 
in PCLD patients by three groups.67-69 In 2000 a locus on chromosome 19 was reported to 
be associated with PCLD in two large families.13 Positional cloning for the three known loci 
for polycystic liver disease, 19p13.2, 16p13.3 (PKD1) and 4q21 (PKD2), in 8 Finnish families 
considered PCLD as a genetically heterogeneous disorder.70 
Three years after the identification of locus 19p13.2-13.1, the first gene was simultaneously 
identified by two groups using linkage analysis.30, 71 Both groups reported different pathogenic 
variants in the PRKCSH gene resulting in loss-of-function. Four extended and unrelated Dutch 
families revealed two splice site mutations.30 In 6 out of 25 families unique splice site, nonsense 
and frameshift variants leading to a premature stop in the PRKCSH gene were identified.71 
In addition, linkage analysis in previously non-PKD1/PKD2 families with a clinical diagnosis 
of PCLD 68-70 identified six pathogenic variants in the SEC63 gene (chr.6q21).72 These SEC63 
mutations included nonsense, frameshift and splice site variants, and a 3-base pair deletion. 
Until now, 25 PRKCSH mutations and 22 SEC63 mutations have been identified by linkage 
mapping in combination with Sanger sequencing.73 
The identification of both genes led to investigations of the phenotype in greater detail.29, 74 
PCLD is characterized by a clear autosomal dominant inheritance pattern. The penetrance has 
been estimated less than 100%.13, 28, 71 The PCLD non-penetrance was already reported in two 
males (age 34 and 44) and one female (age 35) members of a Dutch family.30 Although incomplete 
penetrance is rare, families affected with a PRKCSH or SEC63 mutation with unaffected carriers 
have been reported.29, 30, 74 Incomplete penetrance may easily be confused with variable disease 
expression. Here, the question is: what causes such a wide range of disease severity?
In addition, extensive PRKCSH and SEC63 mutation analysis reported 78-84% PCLD families 
unlinked to both genes.28, 29, 74 This suggests a high genetic heterogeneity for PCLD. Therefore, 
I hypothesize that at least one more locus is involved.28 In addition, we question whether 
PCLD is a genetically heterogeneous monogenic disorder. Involvement of modifier genes may 
explain variable disease phenotype in patients with a similar PRKCSH or SEC63 mutation.
Characteristics of Gene Products in PLD
Although the predominant ADPKD phenotype is polycystic kidneys, a ubiquitous polycystin 
tissue expression is in line with the multi-systemic manifestations in ADPKD.53, 75 Likewise, both 
PCLD protein products, hepatocystin and Sec63p, have a wide tissue expression including 
the liver, kidney, pancreas, heart, brain and muscle.30 These findings are perhaps surprising 
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as the PCLD phenotype is restricted to the liver. In addition, expression of the PKHD1 protein 
product polyductin (fibrocystin) in ARPKD is only observed in the kidney, pancreas and at low 
levels in the liver.76 This may explain why ARPKD patients are primarily affected with polycystic 
kidneys and CHF. It is questionable whether there is another, yet unknown, locus associated 
with PCLD with confined protein expression in the liver. 
In the context of protein localization and function of hepatocystin and Sec63p, both are 
transmembrane proteins involved in glycoprotein folding and quality control.77 A possible third 
PCLD protein product may be located in the endoplasmic reticulum. In addition, hepatocystin 
and glucosidase IIα are both required for the synthesis or transfer of glycans. Following examples 
of congenital glycosylation disorders such as CDG-1, variants were repeatedly identified on 
subunits from a multi-complex protein.78, 79 It remains unclear whether protein components 
of hepatocystin and Sec63p may be functional involved in hepatic cystogenesis.80
Another hypothesis is that there exists an interaction network between PCLD and ADPKD 
genes.81 This may explain the overlap in phenotype. Therefore, molecular pathways involved 
in ADPKD are also important in the search for unknown PLD genes.
Research Strategies and Techniques 
The primary aim of PLD research is the development of treatment possibilities to improve 
patient’s health in general. Current clinical research is focused on reduction of total liver 
volume and preservation of quality of life.14, 82 There are a number of surgical and radiological 
interventions available that may be effective in selected cases.83 In patients with advanced 
PLD, these procedures are less effective or are prone to complications. Hence, the need for 
new or improved medical treatment options. These PLD treatment possibilities are mainly 
studied in in vivo animal models and in vitro cell cultures. 
Studies in PLD Animal Models
Extensive pre-clinical studies prior to drug administration are necessary to meet ethical issues 
and importantly as patient’s safety. The beneficial effects of proposed medical treatment in 
polycystic livers are carefully investigated. Likewise, the chance of adverse events and treatment 
efficacy need to be determined.84 
In the research field of PLD, the introduction of the PCK rat model accelerated the study 
of renal and hepatic cystogenesis.85, 86 This animal model harbors a spontaneous splice site 
mutation in the Pkhd1 gene. This gene is orthologous to the human PKHD1 gene causing 
ARPKD.76 Polycystic kidneys and intrahepatic polycystic liver disease were characterized in the 
PCK rat.87 This pre-clinical in vivo model showed a reduction of cyst volume upon somatostatin 
analogue octreotide administration.88 The principle of octreotide treatment relies on binding 
on somatostatin analogue receptor 2 (SSTR2) which results in decreased cholangiocyte fluid 
secretion and inhibition of cAMP production. 
This pre-clinical study resulted in further clinical research. Subsequently, a pharmaceutical 
treatment of somatostatin analogues was implemented in clinical trials. The first randomized 
placebo-controlled clinical trial including PCLD patients determined the total liver as primary 
outcome measurement. A significant polycystic liver volume reduction of 2.9% was reported 
by lanreotide administration during six months.89 
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In animal models only the effects on hepatic cystogenesis and liver volume of medical 
treatment is studied. A subset of PCLD patients reported no reduction of liver volume in 
clinical trials. In addition, discrepancies between the outcome of total liver volume and quality 
of life may occur. Several aspects may be related to treatment efficacy in PLD patients such 
as environmental influences, genetic cause and the involvement of multiple biological 
pathways. Therefore, the search for polycystic liver disease genes is required in order to 
elucidate target pathways for treatment.
Studies in 3D Cultures
An alternative approach to study PLD management are in vitro 3D cholangiocyte cultures 
of normal and PCK rats.88 Recently, hyperactivity of matrix metalloproteinases (MMPs) in 
these in vivo and 3D cell culture models were assessed.90 MMPs have critical roles in the 
embryological development, bile duct morphogenesis, tissue remodeling and breakdown 
of extracellular matrix. Altered MMP levels favor enhanced extracellular matrix degradation 
and triggers cyst formation.91, 92 Therefore, a matrix metalloproteinase inhibitor, marimastat 
has been studied. The results show inhibition of cystogenesis in PLD models, but there 
are still questions about the dose administration, toleration and therapeutic efficacy in 
PLD patients. Although this research shed new light into the onset and evaluating the 
pathogenesis of PLDs in this research field, additional replication studies are recommended 
before approval into clinical trials.
The Relevance of PCLD Gene Identification
Disease gene identification may be beneficial for patients, their family members, clinicians 
and the society. Indications and ethical issues should be considered before early molecular 
testing in PCLD.
1) Detection of a pathogenic variant in a PCLD gene establishes a definite diagnosis. Few 
examples are;
 - Cases with usually severe or unusually mild disease manifestations,
 - Early-onset disease cases,
 - Solitary cases with a negative family history.
2) The identification of a disease-related mutation enables clinicians to exclude ADPKD, 
and progressive renal, multi-systemic disease.
 - This gives an accurate prognostic information to patients.
 - In ADPKD screening is advised for potential extra-renal disease to prevent vascular 
and cardiac events.73, 93
3) A genetic diagnosis provides (pre-)symptomatic PCLD family members with information 
regarding family planning.
 - Risk for transmission accounts 50% in autosomal dominant diseases.
4) A genetic diagnosis allows asymptomatic PCLD family members to obtain information 
about their disease risk.
 - Information and estimation about personal cost of mutation carriers.
 - Evaluation of potential living related kidney donors with doubtful imaging data, or 
individuals with a negative family history, and in cases of early-onset ADPKD.37, 94
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In a research setting, there are other arguments to determine the causative gene. These 
scientific reasons aim for increased knowledge about molecular mechanisms, prediction of 
disease progression, assessment of genotype-phenotype relation and targets for treatment. 
Furthermore, mutation characterization of clinical trial cohorts may provide genetic stratification 
for the evaluation of such trials.95
Next-Generation Sequencing
Karyotyping, linkage analysis, homozygosity mapping and copy number variation (CNV) 
detection by genomic micro-arrays are established tools for disease gene identification. The 
search for genes associated with PCLD is mostly performed by conventional linkage analysis, 
usually based on rare large pedigrees.30, 71, 72 
Since 2004, NGS is introduced and has revolutionized disease gene identification for 
Mendelian disorders.96, 97 This type of massive parallel sequencing has become a more common 
instrument in genetic research.98
Targeted sequencing allows selective capture of a smaller number or single protein-
coding genomic regions of interest. Polymerase chain reaction (PCR) is the most widely used 
enrichment. This approach is generally used for classical Sanger sequencing and is still highly 
effective to validate genetic variants, but can also be combined with NGS technologies for 
a limited number of amplicons.
Recently, several new techniques have been developed to more efficiently capture a larger 
number of exons or genes. One example for a medium scale of targeted genes (ca. 1-100 
genes)  is known as molecular inversion probes (MIPs).99 This has been applied in terms of 
candidate gene analysis. Other techniques are either hybridization-based target enrichments or 
multiplexed PCR approaches. Probably the biggest advancement in disease gene identification 
is achieved by whole-exome sequencing (WES). This hybridization-based target enrichment 
technology allows sequencing of all protein-coding genes with only one reaction. The human 
exome consists of approximately 200,000 exons (1-1.5% of human genome). WES has led to 
a revolution in Mendelian disease gene identification.98 Pathogenic variants in novel genes 
can be identified in single affected individuals with an extremely rare phenotype, but also in 
families with an unsolved monogenic disorder.96, 101, 102
Whole genome sequencing (WGS) provides the genetic information of the whole 
genome simultaneously in a single experiment.102 Until now, this application has raised 
interest for disorders without identification of variants in the protein-coding part of the DNA. 
However, it can also provide the most uniform representation of the human exome as is does 
not show any enrichment biases. Another advantage is (almost) all types of genetic variants 
can be reliably detected in a single experiment including singe nucleotide variants (SNVs), 
small and large insertion-deletions (indels) as well as CNVs and other structural variants as 
inversions and translocations. The routine use of this technique is only a matter of time, until 
prices drop further and quality allows routine usage. Several population based genome studies 
are on their way, international cancer genome studies apply WGS and first clinical research 
applications have been recently shown.103-105
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WES application in ARPKD
Although exome sequencing is the most powerful tool to study all genes at one time, it can also 
be effective for screening single or few large genes like the PKHD1 gene in ARPKD.106 The PKHD1 
gene has 67 exons, an open reading frame of ~12kb, and mutations may be distributed throughout 
the gene.76 The majority of ARPKD patients have compound heterozygosity for PKHD1 variants. 
Therefore, sequencing PKHD1 in severe and mild phenotypes may efficiently confirm the diagnosis.
NGS applications in ADPKD
Because PKD1 is a complex, large ADPKD gene, NGS technologies have already been applied 
in ADPKD cohorts.66 The PKD1 gene consists of 46 exons with an open reading frame of 
~13kb and 50kb genomic DNA. In addition, both PKD1 and PKD2 present allelic heterogeneity. 
For PKD1 raises another difficulty because of existence of six non-functional gene homologs 
(pseudogenes) that share 97.7% sequence identity with the PKD1 gene (exon 1 to 33).107 As 
a consequence pseudogenes often introduce errors in sequence datasets because of close 
homology to functional genes. It has been proposed that WES is applicable for screening 
unduplicated regions of ADPKD genes.108 Currently, a long-range PCR (LR-PCR) enrichment 
followed by NGS has been reported for a high sensitive mutation-analysis in contrast to 
conventional Sanger sequencing.109
For example, a Chinese study has reported  five novel PKD1 variants detected by targeted 
NGS. PKD1 and PKD2 coding exons and flanking sequences were captured and barcoded 
before NGS in an Asian cohort.110 These variants were validated in a high percentage of cases 
by direct Sanger sequencing. Here, NGS was ideal to detect mutations, and may represent 
an efficient tool in molecular diagnostics. 
Another advantage of NGS based testing is the higher sensitivity for mosaicism, as was 
recently shown in a study of ADPKD patients with detection of PKD1 mosaicism in an affected 
father. The 19-year-old daughter presented bilateral polycystic kidneys with a de novo PKD1 
mutation truncating polycystin-1. Long-range PCR and NGS for PKD1 in the father’s peripheral 
blood lymphocytes, buccal cells, sperm and urine sediment detected low levels (range 3-10%) 
of the mutated allele.38
WES or WGS in PCLD patients were not yet applied in research. Since PCLD is a monogenic 
disease expected to affect a protein expressed in the liver, application of WES is a rapid and 
straight-forward tool for disease gene identification.
Outline of this Thesis
For many years individual patient data regarding symptoms, radiological imaging and potential 
treatment are collected. Molecular studies are performed in our laboratory to obtain a 
definite diagnosis. Since the identification of the PRKCSH gene, and rapidly thereafter the 
SEC63 gene, no other PCLD genes have been found.30, 71, 72 Therefore, the genetic cause of 
hepatic cystogenesis remained unclear in the majority (~80%) of our PCLD patients.28 For a 
better understanding and treatment of inherited diseases, a comprehensive phenotype 
assessment and identification of the cause is essential. The aim of this thesis is to identify 
the genetic cause of disease in PCLD patients in order to elucidate the pathogenesis of 
hepatic cysts. Therefore, I formulated different research questions.
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I) What are the current diagnostic criteria for adult polycystic liver disease? 
In chapter 2 I present an overview of adult polycystic liver disease phenotypes including 
VMC, PCLD and ADPKD. Several classification systems and clinical manifestations are discussed 
in detail to verify the clinical spectrum. Secondly, I explored the current diagnostic criteria for 
PCLD and ADPKD in order to correctly assess radiological imaging and family history in our 
cohort. Patients with a clinical diagnosis of PCLD may be referred for molecular genetic 
testing of both known genes, PRKCSH and SEC63, for a definite diagnosis.
In contrast to ADPKD, there are no official guidelines for genetic counseling or screening 
family members in PCLD. In this case these aspects secondarily belonged to treatment and 
follow-up of patients and their families. In addition to complications and management of 
severely affected individuals, recommendations for (genetic) screening are outlined in this 
chapter. 
II) What is the phenotype of mutation-negative PCLD patients and their family members?
Previously, the phenotype in PCLD patients with a PRKCSH (n=45) or SEC63 (n=15) germline 
mutation (~20%) was assessed.28 Investigations of a possible relation between genotype and 
phenotype revealed no significant results. The aim of this study was to assess the the clinical 
expression of the liver phenotype and inheritance pattern in mutation-negative PCLD patients. 
During this study we were able to screen family members for symptoms and phenotype by 
abdominal ultrasonography. In order to elucidate the phenotype in mutation-negative 
PCLD families, I performed clinical characterization of probands and family members (chapter 
3). This assessment was indispensable during the search for novel PCLD genes as described 
in the next chapters.
III) Are there more genes involved in PCLD?
Although the primary aim of this thesis is the identification of novel genes associated with 
PCLD in this large cohort, mutation detection has only been performed by Sanger sequencing. 
This technique is recognized as the ‘golden standard’ to identify point mutations in genes, 
but is unable to detect genomic amplifications and deletions. In addition, the fact that there 
is no evident genotype-phenotype suggests allelic heterogeneity of PCLD.28 Therefore, I 
hypothesized that a proportion of unlinked PCLD patients is explained by CNVs in the PRKCSH 
gene such as pathogenic deletions. I initiated this study to search for (large) duplications and 
deletions using MLPA analysis in chapter 4. 
IV) Can we use the mechanism of loss of heterozygosity to identify unknown PCLD genes?
Hepatic cyst formation is ascribed to a cellular recessive mechanism. Our aim was to give a 
clear overview of the type and frequency in which somatic hits are reported in hepatic cyst 
tissue from ADPKD and PCLD patients. I performed a literature search in chapter 5 and 
provide a comprehensive overview about this concept. In the following chapters 6 and 7, I 
applied different methods to identify polycystic liver disease genes.
Regarding the finding of a high frequency (78%) of somatic deletions in PRKCSH, I 
hypothesized that somatic loss of heterozygosity is a general mechanism in PCLD. The aim of 
this study was to identify genomic regions which may directly point to (candidate) polycystic 
liver disease genes. A protocol for hepatic cyst epithelium cell-sorting derived from collected 
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hepatic cyst fluid was designed. Subsequent DNA isolation, amplification and genome-wide 
array based SNP genotyping was performed to compare regions of homozygosity in cyst 
derived DNA with blood derived DNA. This allowed to study the presence of somatic cyst 
events in chapter 6. 
V) Is there another locus associated with PCLD?
I describe an extended PCLD family without pathogenic variants in known PLD genes in 
chapter 7. 
The clinical diagnosis of PCLD was obvious in about ~50% of family members and the 
pedigree clearly showed an autosomal dominant inheritance pattern in this family. 
Whole-exome sequencing in two affected family members identified private variants 
(candidate genes) for PCLD in this family. Next, a candidate-based gene approach using the 
in-house bioinformatic pipeline was performed.96, 97 Detected variants were subsequently 
prioritized, leading to the identification of LRP5 as a novel PCLD gene.111
VI) What is the role of LRP5 in ADPKD patients?
As a logical consequence of the identification of LRP5 associated with PCLD, I investigated the 
role of this gene in an ADPKD cohort. I hypothesized that LRP5 may be involved as a causative 
or modifier gene. Therefore, we collected DNA from patients with a clinical diagnosis of ADPKD 
without pathogenic variants in PKD1 and PKD2. Direct Sanger sequencing revealed LRP5 
variants in four ADPKD patients. These findings are outlined in chapter 8.
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ABSTRACT
Polycystic liver disease (PLD) is the result of embryonic ductal plate malformation of the 
intrahepatic biliary tree. The phenotype consists of numerous cysts spread throughout the liver 
parenchyma. Cystic bile duct malformations originating from the peripheral biliary tree are called 
Von Meyenburg complexes (VMC). In these patients embryonic remnants develop into small 
hepatic cysts and usually remain silent during life. Symptomatic PLD occurs mainly in the context 
of isolated polycystic liver disease (PCLD) and autosomal dominant polycystic kidney disease 
(ADPKD). In advanced stages, PCLD and ADPKD patients have massively enlarged livers which 
cause a spectrum of clinical features and complications. Major complaints include abdominal 
pain, abdominal distension and atypical symptoms because of voluminous cysts resulting in 
compression of adjacent tissue or failure of the affected organ. Renal failure due to polycystic 
kidneys and non-renal extra-hepatic features are common in ADPKD in contrast to VMC and 
PCLD. In general, liver function remains prolonged preserved in PLD. Ultrasonography is the 
first instrument to assess liver phenotype. Indeed, PCLD and ADPKD diagnostic criteria rely on 
detection of hepatorenal cystogenesis, and secondly a positive family history compatible with 
an autosomal dominant inheritance pattern. Ambiguous imaging or screening may be assisted 
by genetic counseling and molecular diagnostics. Screening mutations of the genes causing 
PCLD (PRKCSH and SEC63) or ADPKD (PKD1 and PKD2) confirm the clinical diagnosis. Genetic 
studies showed that accumulation of somatic hits in cyst epithelium determine the rate-limiting 
step for cyst formation. Management of adult PLD is based on liver phenotype, severity of 
clinical features and quality of life. Conservative treatment is recommended for the majority 
of PLD patients. The primary aim is to halt cyst growth to allow abdominal decompression 
and ameliorate symptoms. Invasive procedures are required in a selective patient group with 
advanced PCLD, ADPKD or liver failure. Pharmacological therapy by somatostatin analogues 
lead to beneficial outcome of PLD in terms of symptom relief and liver volume reduction. 
Keywords
Cystogenesis, Polycystic liver disease; Hepatomegaly; Biliary tract disease; Ductal plate 
malformation; Von Meyenburg Complex; Autosomal dominant polycystic liver disease; 
Autosomal dominant polycystic kidney disease
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DISEASE NAME
Polycystic liver disease (PLD) is a collection of  rare human disorders that result from structural 
changes in the biliary tree development.1, 2 Genetic mechanisms and/or signaling defects are 
the root cause of ductal structures to become separated from the biliary tree finally resulting 
in cyst formation.2, 3 Typically, these disconnected biliary structures are present in a very early 
disease stage, but remain asymptomatic until cyst growth initiates in adulthood.4 
Three PLD entities are recognized in adults. Von Meyenburg complexes (VMC; biliary 
hamartoma; hepatic cystic hamartoma) with characteristic small, non-hereditary nodular 
cystic lesions [ORPHA386].4, 5 Isolated polycystic liver disease (PCLD; autosomal dominant PLD) 
[OMIM#174050; ORPHA2924] with presence of innumerable hepatic cysts and autosomal 
dominant polycystic kidney disease (ADPKD) [OMIM#173900; OMIM#613095; OMIM#600666; 
ORPHA730] with cysts in both kidneys and in many cases hepatic cysts. 
This paper reviews the pathological and clinical features of these three adult cystic disorders 
that share presence of numerous hepatic cysts with an intact biliary tree architecture. 
DEFINITION
PLD is a rare inherited Mendelian disorder that is characterized by development of multiple 
hepatic cysts. The classification of PLD follows the histological changes that are due to ductal 
plate malformation (DPM) during fetal development.6, 7 Definitions of cystic malformations 
are either based on the location of the affected (cilium-related) protein or follows radiological 
findings.8, 9 
Ductal Plate Malformation
The biliary tree emerges from the endodermal hepatic diverticulum.1 Development of the 
biliary system starts from the 8th week of gestation by formation of single layered hepatoblasts 
surrounding the portal vein (ductal plate). Duplication of ductal plate cells forms a double layer 
that finally dilate to a tubular structure, the primitive bile duct. Hepatoblast differentiation 
to a biliary phenotype and tubulogenesis is stimulated by the Notch, TGF-β and canonical 
Wnt signaling pathways.2 Cell differentiation from hepatoblasts to cholangiocytes, tubule 
elongation and bile duct remodeling are completed by 30 weeks of gestation. Intrahepatic 
and extrahepatic bile duct systems are then merged and share the hepatic hilum. During the 
first year of life intrahepatic biliary epithelium maturates further.1, 2, 7 PLD develops as a result 
of ductal plate malformation. The stage that is affected by faulty remodeling determines 
the phenotype. For example, VMC is thought to result from embryonic ductal involution at 
a late stage.7, 10 
Bile duct formation requires a network of epithelial-mesenchymal interactions, and 
presence of growth and transcription factors to control appropriate cell migration, adhesion 
and cholangiocyte differentiation. Aberrant expression profiles and signaling result in deficient 
remodeling, and subsequently abnormal dilated or disconnected ductal plate cells developing 
into biliary cystic structures.3, 11 Recently, a new classification for DPM has been proposed 
on the basis of Hnf-1β, Hnf-6 and cystin-1 gene deficient mouse models. This classification 
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distinguishes three DPMs: 1) abnormal hepatoblast differentiation, 2) failure of bile duct 
maturation, 3) perturbation of ductal expansion.6 
Ciliopathy and Cholangiopathy
Ciliopathies represent an emerging class of human disorders that are caused by defects 
in distinct genes affecting ciliary structures or function. They may be inherited as simple 
recessive traits, but also in a dominant fashion. Phenotypic expressivity is under the control 
of numerous genetic modifiers.8 Ciliopathies usually result in shared clinical features, such as 
intellectual disability, retinal defects and polydactyly, but the most well-known phenotype is 
that of cystic kidneys.12 The proteins affected in ADPKD are located at the cilium which has 
led to the classification of ADPKD as a ciliopathy.13 By contrast, the proteins associated with 
PCLD are not located to the cilium. Hepatic cysts are lined by cholangiocytes and therefore 
the term cholangiopathy is used for PCLD.3 
Radiology
Radiological imaging assists in classifying PLD. Detection of macroscopically hepatic and 
renal cysts is facilitated by ultrasonography, magnetic resonance imaging (MRI) or computed 
tomography (CT)-scanning without or with (creatinine-permitting) intravenous contrast 
material.9 On ultrasound, cysts appear as homogeneous anechoic fluid-filled round spaces. 
MRI is superior over ultrasound and CT, and allows better detection of small cysts in young 
individuals.14 This technique captures biliary tree pathology and differentiates parenchym 
from biliary tree (Figure 1). 
EPIDEMIOLOGY
PCLD has a prevalence of 1/100,000 to 1/1,000,000 or 1- 9/100,000 (1/158,000 in The 
Netherlands), while the prevalence of ADPKD ranges between 1/400 to 1/1,000.13, 15 The 
incidence of VMC has been estimated up to 1/18-1/145 or 7-60/1,000 (0.69-5.6%) depending 
on the various autopsy studies.10, 16 
CLINICAL DESCRIPTION
Von Meyenburg Complexes
VMC, also termed microhamartomas, are benign cystic nodules scattered throughout the liver. 
They are usually interlobularly located and at peripheral bile ducts below the Glisson’s capsule.7 
VMC may occur isolated or in the context of PCLD and ADPKD.4, 11, 17 VMC are frequently an 
incidental finding at radiological imaging, surgery or autopsy studies. 
Histologically, they are characterized by small embryonic DPM remnants (<1.5-cm-diameter) 
or larger (small) hamartomas (>1.5 cm) delineated by regular cuboidal epithelium and embedded 
in fibrous stroma. Dilated structures initially communicate with the peripheral intrahepatic 
biliary tree, but separate with development.7, 10 
VMC usually remain silent during life and require no management or follow-up examination. 
Although mild liver test disturbances may be observed, significant hepatomegaly or liver 
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disease is rare in VMC. Incidentally, clinical features of epigastric pain, fever, cholangitis and 
jaundice appear when communication of multicystic VMC with the biliary tree cause biliary 
obstruction.18 Episodes of liver sepsis indicates antibiotic treatment and follow-up of liver 
function tests. Abdominal pain and discomfort resolves with time. The diagnosis of VMC can 
be confirmed by MRI. Extra-hepatic features are absent. 
Figure 1. Abdominal MRI and CT in patients with PLD. (A) Axial T1-weighted and (B) coronal T2-
weighted MRI present 1 large cyst and numerous cystic nodules scattered at peripheral bile ducts. (C-D) 
CT-scanning in a PCLD patient presents multiple cysts originating from medium-sized bile ducts. (E-F) 
Co-occurrence of polycystic kidneys exists in ADPKD. Both PRKCSH and PKD2 gene mutations were 
predicted to be pathogenic (GRCh37-hg19; HGMD). Hepatic cysts are indicated by white arrows. (G) 
Diffuse VMC present numerous small-sized hepatic cysts located at peripheral branches of the biliary tree 
(in green). (H) The PLD phenotypes are arbitrarily staged and indicate disease progression. The disease 
course is progressive in a subset of severely affected PLD patients.
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PCLD and ADPKD
Hepatic cysts are the major clinical feature in PCLD and the most frequent extra-renal 
manifestation in  ADPKD.14 Cysts originate from medium-sized bile ducts. Histologically, they 
are delineated by cuboidal, flattened epithelial cells surrounded by fibrous stroma.7 
They may be confined to one or more segments or spread evenly throughout the liver. 
Presence of large and numerous cysts frequently lead to hepatomegaly. One study showed 
that the overall hepatic cyst prevalence in ADPKD patients (age range15-46 years) is 83%, 
with the highest prevalence of 94% in 35- to 46-year-old patients. This corresponds with an 
increased prevalence of multiple hepatic cysts in older PLD patients.14
The variable number, size, location and distribution of cysts determines the spectrum of 
symptoms which is related to the extent of hepatomegaly.4 Pain may ensue mainly because 
of tension on Glisson’s liver capsule. Abdominal discomfort, pyrosis, early satiety, weight 
loss and anorexia may arise in advanced PLD.15, 19 Patients who have large hepatic cysts that 
exert pressure on the stomach and displacement of other abdominal organs are at risk for 
malnutrition and nutritional deficiencies.20
Females with ADPKD or PCLD usually have a more severe liver phenotype, especially for 
those with a history of multiple pregnancies and prolonged exogenous estrogen exposure.15, 21, 
22 Females have higher average liver volumes, are younger at presentation and more susceptible 
to progressive PLD, suggesting a hormonal component.14, 15, 19 In general, patients with PCLD 
have more severe symptoms and liver-related complications compared to ADPKD.23 Hepatic 
cysts are rarely present in young children, but in exceptional cases symptomatic PLD may 
develop in young ADPKD patients. 
The risk to develop severe PLD is independent from the ADPKD genotype, but is related 
to the severity of renal disease.13, 23 Here, presence of a PKD1 mutation puts the patient at risk 
for an earlier onset and outcome of renal disease compared to the PKD2.24, 25 
Hepatic Complications in PCLD and ADKPD
Complications may occur due to massively hepatomegaly or result from invasive treatment.15, 19 
It has been estimated that about half of the patients with advanced hepatic disease have had 
cyst hemorrhage, cyst rupture or a cyst infection.15, 26 These manifestations appear to be more 
frequent in ADPKD compared to PCLD.27 Here, we will discuss the clinical and diagnostic signs 
for cyst hemorrhage, rupture, infection and other rare complications in PCLD and ADPKD.
Hemorrhage
Intrahepatic cyst bleeding typically presents as acute pain in the upper right-side of the 
abdomen. Symptoms develop acutely, progress in the first day(s), but resolve spontaneously. 
Sometimes, the nature of the abdominal pain can be colicky and accompanied by vomiting. 
Ultrasonography may be helpful to assess features suggestive for cyst bleeding such a higher 
attenuation value, aggregated fibrin deposits and possibly internal septa of hematomas. High 
signal intensity on MRI supports the diagnosis of an intrahepatic cyst bleeding.9, 28
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Infection
Cyst infections are a serious complication because of its indolent course, demanding treatment 
and high risk of recurrence. Current diagnostic criteria rely on clinical, biological and radiological 
parameters including abdominal tenderness, fever (>38°C for >3 days), an increased C-reactive 
protein level and proven absence of spontaneous intra-cystic bleeding by CT-scanning. 
Hepatic cyst wall thickening and heterogeneous fluid (debris) are suggestive for infection. The 
diagnostic accuracy of MRI is unknown and CT-scanning has a low sensitivity and specificity 
to identify cyst infection.29 18F-FDG positron emission tomography (PET)-imaging technique 
is preferable to detect the exact location of the infected lesion(s).29
PLD patients may have strongly elevated CA19-9 levels.30 Extremely high CA19-9 levels 
were found in episodes with hepatic cyst infection and declining during recovery.31 Detection 
of neutrophils and infectious agent(s) in the cyst fluid aspirate confirms the cyst infection and 
indicative for targeted antibiotic treatment.29
Rupture
Cyst rupture is an exceptional rare complication and presents with acute onset of pain. 
Hemodynamic complications are  rare, but have been reported in the literature.32 Abdominal 
discomfort from prolonged ascites and increased cyst volume needs stringent follow-up. 
If intra-peritoneal (blood) fluid leakage persists, a surgical intervention is inevitable for 
hemostasis control.28
Portal hypertension and ascites
In advanced stages there are two processes that may lead up to portal hypertension. First, 
there is reduction of hepatic vein outflow. Secondly, portal vein inflow may be compressed 
in advanced disease due to the volume effect of cysts. 
Signs of hepatic vein outflow obstruction (HVOO) are abdominal pain, hepatomegaly 
and transudative ascites (90-96%).33 Hepatic vein thrombosis is commonly recognized as 
the cause of HVOO, and case series reported also the Budd-Chiari syndrome secondary to 
PLD.33, 34 The survival of hepatic vein thrombosis is low in severe cases.35 Mechanical pressure 
symptoms of hepatomegaly may extend from hepatic veins to junctions with the vena cava 
inferior (IVC). Compression of IVC is characterized by increased renal outflow pressure that 
provokes development of ascites and edema in the lower extremities.36 
In addition, hepatic cysts may cause a compromised portal venous flow.37 These 
abovementioned complications lead to development liver fibrosis. Secondary complications 
of portal hypertension are the result of severe liver fibrosis such as esophageal varices, 
splenomegaly and transudative ascites may develop, but advanced fibrosis is a rare event.26 
Typically these features are seen in the elderly. In addition, lymphatic leak and chronic renal 
disease may contribute to development of ascites in severe PLD patients.33, 37 
Jaundice
Portal hypertension may be accompanied by other signs of hepatic failure such as jaundice.38 
Although jaundice is usually seen  in advanced stages, it may occur at any stage. An uncommon 
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cause of jaundice is obstruction of the intrahepatic or extrahepatic bile ducts by hepatic 
cysts.26 Recurrent cholangitis is a rare complication of this condition.34 
End-stage liver disease
Progression to end-stage liver disease usually results in the context of extremely increased 
liver volumes. Liver failure is seen incidentally, usually in a very late stage of the disease.15, 19 
Symptomatic patients with hepatomegaly (severe PLD) frequently do not meet the Model 
for End-Stage Liver Disease (MELD). Therefore, MELD exception criteria including assessment 
of malnutrition and quality of life are used.20 Liver transplantation has excellent survival rates 
(>90% at 5 year).39, 40  
Extra-Hepatic Manifestations
Kidney
The main differentiating feature between PCLD and ADPKD is the presence of polycystic 
kidneys. While this is the primary lesion in ADPKD, renal disease is absent in PCLD.27 Disease 
progression depends on genotype, but also on environmental factors.25 The majority of adult 
ADPKD patients develop enlarged kidneys and end-stage renal disease. In contrast, few renal 
cysts may be present in 28-35% of PCLD patients, but renal failure does not occur.15, 19 
In contrast to PCLD, ADPKD is a multi-systemic disorder. Hypertension is one of the first 
signs of renal disease development and is related to progressive kidney enlargement and loss 
of renal function.41, 42 It is still unclear whether early anti-hypertensive treatment prevents 
renal function decline.43 The most common feature is abdominal/flank pain due to pressure 
symptoms and stretching of the renal cyst wall. ADPKD patients are also at-risk for other renal 
complications such as hematuria, urinary tract infections and kidney stones.21, 41
Cardiovascular system
ADPKD patients may develop hypertension, intracranial aneurysms (ICA), arterial aneurysms 
and several cardiac valvular abnormalities.44 Early assessment of cardiovascular risk factors in 
ADPKD is advised, especially in young ADPKD patients.45, 46 
Mitral valve prolapse has a higher prevalence in ADPKD up to 25-41.2% compared to 
0-10.5% in PCLD.19, 27, 47, 48 Other important connective tissue abnormalities such as aortic 
root dilatation and abdominal aorta aneurysm (AAA) have been reported in ADPKD.49 If 
the family history is positive, screening of unaffected family members by MR-angiography is 
recommended.50, 51 
Non-renal extra-hepatic cysts
The phenotype of PCLD is mainly restricted to the liver. Extensive radiological imaging of 
ADPKD patients have demonstrated that there are cysts in other abdominal organs such as 
the pancreas (9%) or seminal vesicles of the testis (43%).52, 53 These cystic manifestations 
symptomatically silent.
Arachnoid cysts is central nervous system manifestation that is seen in 8% of ADPKD 
patients. This condition may occasionally  lead to a subdural hematoma.50
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Table 1. Genetic and diagnostic determinants of PCLD and ADPKD. A detailed overview of genotype 
characteristics and diagnostic criteria for PCLD and ADPKD phenotype assessment.
Polycystic liver disease
(PCLD)
Autosomal dominant 
polycystic kidney disease 
(ADPKD) Reference
Genotype
Cytogenetic gene 
location (mutation 
frequency %)
Chr.19p13.2: PRKCSH (15%)
Chr.6q21: SEC63 (5.7%)
Chr.16p13.3: PKD1 (75.7%)
Chr.4q21: PKD2 (13.4%)
62, 78
Mutation (type; N, %)
missense
splice site
insertion/deletion
indel
nonsense
complex rearrangement
25 PRKCSH     22 SEC63
 4   (16%)           6  (27.3%)
 4   (16%)           3  (13.6%)
10  (40%)          7   (31.8%)
 1    (4%)            -
 6   (24%)           6  (27.3%)
                    -
980 PKD1     193 PKD2
250  (25%)     29   (15%)
 77   (7.8%)    32  (16.6%)
440  (45%)     80  (41.5%)
 13   (1.4%)     7    (3.6%)
202  (20%)     45  (23.3%)
  8     (0.8%)     -
[HGMD]
Gene product; 
protein localization
Cholangiopathy
Hepatocystin/ glucosidase II-β 
subunit; ER
Translocation protein SEC63 
homolog;
ER, membrane complex
Ciliopathy
Polycystin-1 (TRPP1); 
primary cilium, tight junction, 
extracellular matrix, ER 
Polycystin-2 (TRPP2);
primary cilium, tight junction, 
extracellular matrix, ER 
13, 60
Protein function Proper protein folding and 
protein quality control
Posttranslational protein 
transport
PC-1 and PC-2 form a 
mechanosensor complex on 
the primary cilium 
PC-1 for signaling detection, 
PC-2 is a TRP channel for 
calcium influx
60
13
Predominant phenotype
Liver features
PCLD diagnostic criteria:
Clinical practice:
Positive family history with:
<40 years and ≥1 hepatic cyst
≥40 years and ≥4 hepatic 
cysts
30-70 years and polycystic 
liver (>20 hepatic cysts)
Most common extra-renal 
manifestation: 83% with a 
polycystic liver (>20 hepatic 
cysts)
74
14
Kidney features
ADPKD diagnostic 
criteria:
Incidental finding without 
renal disease: 28-35% with 
renal cystogenesis 
Positive family history with:
15-39 years and 3 renal cysts# 
40-59 years and 2 renal 
cysts*
≥60 years and 4 renal cysts*
Negative family history with:
<30 years and 5 renal cysts$
30-60 years and 5 renal 
cysts$
>60 years and 8 renal cysts$
15, 19
76
75
Description of the data: A detailed overview of genotype characteristics and diagnostic criteria for 
PCLD and ADPKD phenotype assessment.
# unilateral or bilateral.
* in each kidney.
$ bilateral.
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Abdomen
Abdominal wall hernias may be present in PLD patients. Clinical series have suggested that 
(para)umbilical and inguinal hernias may be seen in up to 15-45% of ADPKD patients which 
may be explained by chronic compression due to high liver and kidney volumes.27, 41, 54 Early 
reports have suggested a higher prevalence of colonic diverticuli in PLD, but upon scrutiny 
there was no evident association or increased risk for diverticular disease.27, 55
ETIOLOGY
Germline Mutation
Genetic analyses of both PCLD genes PRKCSH [OMIM*177060] and SEC63 [OMIM*608648] 
may confirm the clinical diagnosis and differentiate it from other PLD (Table 2).56-58 These 
genes encode for the (glyco)proteins hepatocystin and Sec63p.59 Both proteins are located 
within the endoplasmic reticulum (ER) and are responsible for quality control and translocation 
of glycoproteins into the ER.60 Since about 16-22% of PCLD patients harbor a pathogenic 
variant, PCLD is assumed to be genetically heterogeneous and other loci should be involved. 
There is no clear genotype-phenotype association.15, 61
Mutations in the PKD1 gene [OMIM*601313] or PKD2 gene [OMIM*173910] are responsible 
for renal cyst initiation in >90% of the cases.62 Several ADPKD families  possess no mutations 
on PKD1 or PKD2.63, 64 It is hypothesized that these cases are linked to another (yet unidentified) 
PKD3 gene [OMIM*600666].65 PKD1 gene carriers have a higher prevalence of hypertension, 
complications and a higher risk of progressive renal failure compared to PKD2. Renal failure 
occurs at a much earlier age in PKD1 carriers compared to PKD2 carriers.41 
Second-hit Hypothesis
PLD patients have a heterozygous germline mutation and it is hypothesized that cysts arise 
through functional loss of the second allele.59 This is the rate-limiting step in the formation of 
cysts. Secondary, somatic hit mutations have been identified in PKD1 or PKD2 genes in liver 
and kidney tissues from ADPKD patients.66, 67  Similarly, loss of heterozygosity of the PRKCSH 
or SEC63 allele is present in PCLD cyst tissues. This is fitting with the second-hit-model for 
tumorgenesis which dictates that the combination of a germline and somatic mutations result 
in inactivated protein in target tissues.68, 69 
Modifier Genes and Environmental Factors
Mouse models suggest that additional genes may lead to  hepatic and renal cystogenesis.6 It 
has been shown that HNF-1β mutations affect disease progression and outcome in ADPKD.25, 70 
Once a cyst have been formed, progression to clinical significant disease requires  other 
mechanisms.8 Cyst fluid contains  serum proteins  but also cytokines and growth factors which 
contribute to cyst formation.71, 72 Expression of estrogen hormone receptors in cyst epithelium 
may trigger growth advantages.73  
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DIAGNOSIS
VMC is a radiological diagnosis.9, 10 Ultrasonography shows multiple hyperechoic areas in the 
subcapsular region. The comet-tail sign is a special form of reverberation artifact in detection 
of small cysts. This sign appears as a trail on the image if small calcific or highly reflective 
foci are interrogated on ultrasound.5 MRI is preferred above CT-scanning as it readily shows 
multiple hyperintense focal lesions on T2-imaging.9 
Current diagnostic criteria in PCLD and ADPKD rely on the age-related cystic liver 
phenotype with a positive family history of autosomal dominant inheritance (Figure 2).74-76 
Ultrasonography of the liver and kidneys is usually the first modality used to assess a cystic 
phenotype. The unified Ravine criteria for diagnosis of ADPKD relies on counting the number 
of renal cysts in at-risk individuals.75, 76 
A single laboratory test that is of discriminative value for PLD is lacking. The synthetic 
liver function is usually preserved in PLD. Mild elevations of γ-glutamyltransferase sometimes 
combined with elevated alkaline phosphatase values may be detected.15, 19 
DIFFERENTIAL DIAGNOSIS
PLD is a non-communicating biliary tree disorder and should be differentiated from other 
neoplastic, infectious and traumatic conditions.4 The diffusion and variable small-sized 
hyperechoic structures in VMC are important to differentiate from hepatic metastasis or 
microabcesses.9 
Figure 2. Comprehensive algorithm for diagnosis, management and genetic counseling in 
PCLD and ADPKD. The diagnostic criteria for PCLD and ADPKD compromises family history and 
age-related liver or kidney phenotype respectively.74, 76 PLD therapy is individually decided according to 
number, distribution and size of hepatic cysts.82 Genetic counseling has an important role in symptomatic 
individuals with a positive family history for hepatic and/or renal cystogenesis in order to differentiate 
PLD and clinical management. # Unilateral or bilateral; * In each kidney.
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Table 2. Determinants and recommendations in severe PCLD and ADPKD. This scheme indicates 
distinct factors that are related to physical health and disease progression in PCLD and ADPKD patients. 
These clinical elements listed per organ may be valuable for consideration in management. Patients’ 
mental condition and health-related quality of life should be assessed by standardized evaluation of 
symptoms in all PLD patients.81
Polycystic liver disease (PCLD)
Organ Determinant Recommendations
Liver Female sex
Aging 21, 22
Environmental factors associated with PLD disease 
course: 21, 22
Prolonged oral/exogenous female steroid use:  
estrogens, contraceptive pill or (post-menopausal) 
hormonal replacement therapy
Multiple pregnancies 
Stop exogenous estrogen use in 
female
patients 82
Advise alternative contraceptive 
strategies
Brain Similar recommendations seem appropriate
for patients with isolated ADPLD, but more
studies are required 19, 77
Indiscriminate screening is not 
recommended at present 44
Heart Similar as in the general population 47 No recommendations 
Autosomal dominant polycystic kidney disease (ADPKD)
Organ Determinant Recommendations
Kidney Environmental factors associated  
with renal cyst growth: 83
 - caffeine
 - smoking
Influencing factors for renal cystogenesis: 43, 45
 - hypertension (≤35 years) - renal infection  
 - proteinuria  - total kidney volume
 - hematuria (<30 years) - male sex
 - urinary tract infection - low birth weight
 - kidney stones  - aging
PKD1 gene mutation have a more severe disease 
course and earlier onset of end-stage renal disease 
compared to PKD2 carriers 41
 
Avoid (excessive) caffeine 
administration and nephrotoxic agents
Smoking cessation
 
Hypertension: 43, 45, 46, 80
 - Routinely standardized blood 
pressure measurement
 - Elektrocardiogram in hypertensive 
patients for LVH assessment
 - Plasma LDL cholesterol control; 
urinary albumin excretion; left 
ventricular mass index calculation 
 - Angiotensin converting enzyme 
inhibitors and/or angiotensin 
receptor blockers 
Dietary protein and salt restriction
Sufficient daily fluid intake 
Molecular diagnostics 24
In general, differentiation from communicating biliary tree disorders is important for 
management and prognosis. Bile duct ectasias or cystic dilatations belong to connected 
intrahepatic cystic diseases. These features are detected in ARPKD, Caroli disease (CD) and 
Caroli syndrome (CS). PLD is characterized by intrahepatic disease, a more late onset of disease 
in adulthood and absence of congenital hepatic fibrosis (CHF). 
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Table 2. Continued
Organ Determinant Recommendations
Liver Female sex
Aging 21, 22
Environmental factors associated with PLD disease 
course: 21, 22
 - prolonged oral/exogenous female steroid use:  
estrogens, contraceptive pill or (post-menopausal) 
hormonal replacement therapy
 - multiple pregnancies 
Renal function/glomular filtration rate 23; in 
particular females 43
Stop exogenous estrogen use in 
female patients 82
Advise alternative contraceptive 
strategies
Brain Patients at risk: 
 - positive family history of (ruptured) ICA or stroke 
<50 years old
 - previously ruptured ICA 
 - warning symptoms: unusual headaches
 - high-risk occupation (for example: airline pilot)
 - preparation for major elective surgery (for 
example: kidney transplantation) 13, 51
The position of the mutation in PKD1 is predictive 
for development of intracranial aneurysms 79
Patients with reasonable estimated life 
expectancy: periodic 3-5 years MR/
CT-
angiography screening 51
Surveillance/rescreening after negative
results in patients with a positive 
family
history: 5-10 years (high- to low-risk) 
13, 80
Smoking cessation
Blood pressure control
Hyperlipidemia control 51
Molecular diagnostics 79
Heart Screening is indicated: 13, 45
 - a murmur or systolic clicks are detected on 
examination
 - positive family history of thoracic aorta dissection
Echocardiography 13, 45
Aorta ADPKD patients receiving hemodialysis 49
Similar as in general population for AAA: 80
 - Male between the ages of 65-75 and smoked 
>100 cigarettes in a lifetime 
 - Male >60 years and a family history of AAA
AAA: routine screening of the 
aortic size, using CT or abdominal 
ultrasonography 49
1-time screening with abdominal 
ultrasonography 80
Autosomal Recessive Polycystic Kidney Disease
Young and adult ADPKD patients are difficult to distinguish with other hepatorenal fibrocystic 
diseases such as ARPKD and other ciliopathies.8 ARPKD has an incidence of 1/20,000 live 
births (ORPHA731; prevalence of 1.2/100,000) and a high peri-natal lethality. The predominant 
phenotype includes perinatal renal cysts and CHF.12 Presence of cystic dilatation of intrahepatic 
biliary tree may be confused with disconnected hepatic cysts.7 The gene product polyductin 
is located at the primary cilium suggesting molecular similarities with the ciliopathy ADPKD.77 
Caroli Disease and Caroli Syndrome
CD is characterized by saccular, cystic dilations of the more larger intrahepatic biliary system. 
In CS large and small intrahepatic bile duct ecstasies are accompanied with CHF. CS has been 
typically associated with renal disease as in ARPKD.7 The incidence of CD is approximately 
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1/1,000,000 births, but CS is more frequent (ORPHA53035; ~250 cases). Both ARPKD and 
CS have an autosomal recessive inheritance pattern.12 
Genetic Counseling 
Both PCLD and ADPKD have an autosomal dominant inheritance pattern and the recurrence 
risk is 50%. Genetic studies indicate an evident inter-familial clinical heterogeneity in PLD 
disease course among similar-aged patients. Secondly, intra-familial studies suggested a 
considerable phenotypic variability of hepatic cysts (Figure 3). Clinical asymptomatic or 
undiagnosed members contribute to underestimation of the actual disease prevalence.24, 41, 
61 It is estimated that the penetrance is ~80%.78
These considerations raise the question whether it is appropriate to screen members 
or children at-risk. Counseling should include discussion about insurance, employment and 
psychological factors. Genetic counseling is recommended in severely affected PLD and may 
afford differentiation between ADPKD and PCLD.8, 12 
Molecular diagnostics may assist the counseling process to establish a firm diagnosis in 
symptomatic patients and families. In particular ADPKD, determination of the responsible 
gene is useful for those who are at-risk in order to develop a strategy to prevent severe 
progressive disease events or complications.79 If the family history for ICA is positive in an 
ADPKD family, screening of unaffected family members by MR-angiography is recommended.50, 
51, 80 Counseling or genetic testing is not advised in asymptomatic children.77
Management and Prognosis
VMC is an asymptomatic condition without long-term consequences and treatment is not 
warranted. The primary aim of PLD therapy is to reduce symptoms by curtailing hepatic cyst 
development. The treatment of choice is driven by individual complaints.40 Although the 
primary outcome measurement of PLD management is liver volume, assessment of symptoms 
associated with quality of life is an element for focus.81 Therapeutic interventions are not 
warranted in asymptomatic patients.
The first advice in PCLD and ADPKD is to stop oral contraceptives.20, 82 Although not 
formally investigated, the use other (non-systemic) contraceptives such as an intra-uterine 
device may be an acceptable alternative. Other guidelines are presented in Table 1.80, 83 
Supportive management with analgesics is the first-line treatment in patients with acute or 
chronic abdominal pain and tenderness. 
The different invasive approaches with possible beneficial outcomes in independent 
studies include aspiration sclerotherapy, laparoscopic cyst deroofing or liver transplantation.39, 
40, 84 Current indications and considerations for invasive treatment are presented in Figure 4. 
Treatment of portal hypertension and ascites are not different from that in patients with 
other causes.
In a selected patient group were invasive procedures such as a vascular or bile duct stent 
placement optional for decompression of the portal vein, inferior vena cava or bile duct, or 
in HVOO treatment.37, 85 In general, management of vascular and bile duct complications due 
to hepatic cystogenesis consists of relieving the obstruction in order to improve venous and 
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biliary drainage.26, 35 Although no concise guidelines are available, stents may give temporal 
symptom relief of portal hypertension, ascites and jaundice. A porto-systemic shunt may 
be indicated in presence of acute thrombosis or vascular compression to establish patent 
hepatic and portal venous flow, but should be weighed against possible complications. The 
primary aim is to ameliorate symptoms by cyst decompression in these advanced cases. This 
is often achieved by final treatment strategies including liver resection, hepatic fenestration 
procedures or liver transplantation.33
Figure 3. Intra-familial clinical heterogeneity in PCLD. Description of the data: (A) Pedigree of a 
PCLD family with PRKCSH gene mutation c.374_375delAG in affected individuals. The index patient 
(*) has 4 members with symptomatic PLD. Although the family history is positive, family members 
frequently are asymptomatic carriers or the liver phenotype remains unknown. (B) Axial CT-scanning, 
abdominal ultrasonography or MRI in four PCLD patients presented a variably number of hepatic cysts 
without renal disease. 
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Recent development of pharmacological options opened up new treatment strategies for 
severe PLD patients. Long-term follow-up studies with somatostatin analogues demonstrated 
that these agents consistently lower total liver volume in PLD patients.86, 87 A recent meta-
analysis reported that somatostatin analogues is particularly effective in young females.88 
CONCLUSION
PLD compromises a clinically heterogeneous liver phenotype identified in VMC, ADPKD and 
PCLD patients. Massively enlarged livers are present in a subset of ADPKD and PCLD. Genetics 
and environmental factors such as exogenous estrogen intake and number of pregnancies 
Figure 4. Indications and considerations for treatment strategies in symptomatic PLD. Schematic 
overview of relevant indications and considerations in PLD management. Patient characteristics and liver 
phenotype such as severity of clinical symptoms, age, (surgical) history, degree of hepatomegaly, and 
number, size and location of hepatic cysts are essential aspects for this decision. In general, the choice 
of procedure is an individual process in consultation with the patient. Severely affected individuals are 
patients with massive hepatomegaly, refractory symptoms, PLD-related complications and/or end-stage 
liver failure. Care and follow-up of these patients should be managed with caution. *Notification: Results 
about treatment efficacy of prolonged or long-term somatostatin analogue use is unknown. **Arbitrary 
total liver volume (TLV), because this outcome measurement is related to other parameters such as height, 
total body surface and sex. ***For example: recurrent hepatic cyst infection, HVOO.
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contribute to disease progression. A considerable intra-familial variability in liver phenotype 
and extra-hepatic features makes screening modalities uncertain in PCLD. Evaluation of 
PLD-related symptoms and quality of life are necessary to decide beneficial management. 
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ABSTRACT
Isolated polycystic liver disease (PCLD) is characterized by a spectrum of symptoms due to 
hepatic cystogenesis ensuing hepatomegaly. Phenotypic expression and clinical features of 
cysts among relatives remain unclear.
PCLD patients were screened for PRKCSH and SEC63 gene mutations. Family history and 
symptoms were assessed in probands at diagnosis. Liver and kidney phenotype among relatives 
were determined by abdominal ultrasonography combined with archival data. 
467 unrelated patients were referred for PCLD mutation analysis between 2003 and 2014. 
In 21.6% the diagnosis was molecularly confirmed (15.2% PRKCSH; 6.4% SEC63). Consent 
was given by 162 relatives of 32 mutation-negative PCLD patients. A negative family history 
was reported in 24 families (75%), but cysts were detected in members of 22 families (91.7%). 
The majority of PCLD patients without a pathogenic variant in the PRKCSH or SEC63 gene 
present a false negative family history. Intrafamilial variability of the liver phenotype argues 
for multiple genetic and environmental factors associated with hepatic cystogenesis.
Keywords
Polycystic liver; Phenotype; Symptoms; Family history
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INTRODUCTION
Polycystic liver disease (PLD) is a heterogeneous disorder that carries a significant morbidity 
and puts  a social burden on patients, family members and environment.1 PLD is part of the 
group of fibrocystic diseases which has two major representatives: isolated polycystic liver 
disease (PCLD) and autosomal dominant polycystic kidney disease (ADPKD).2 Intrahepatic bile 
duct dilatation, hepatic fibrosis (Caroli syndrome) in combination with hepatic cysts may be 
present in autosomal recessive polycystic kidney disease (ARPKD).3 These three Mendelian 
disorders share the presence of hepatic cystogenesis, but ADPKD and ARPKD patients also 
have polycystic kidneys. As a consequence, renal disease is the dominant feature in these 
patients.3, 4 In addition, they differ in genetic background. About ~20% of unrelated PCLD 
patients harbor a mutation in the PRKCSH or SEC63 gene.5 Recently, four unique LRP5 variants 
were identified in four unlinked PCLD families.6 This contrasts with the situation in ADPKD 
where PKD1 or PKD2 germline mutations are found in most ADPKD probands (89%).7 Likewise, 
most ARPKD patients have two PKHD1 germline mutations (76-87%).8, 9 
The position of germline mutations and the effect on protein function correlate with age of 
onset of end-stage renal disease in ADPKD.10 On the contrary, clinical studies have established 
considerable variability of the renal phenotype in large PKD1 10 and PKD2 families.11 Affected 
ADPKD relatives differ in age of disease onset, symptoms and renal function.10, 11 In ARPKD 
there are notable differences with respect to the presence of liver fibrosis and biliary disease 
among families.3, 12 Here, the wide intrafamilial spectrum of phenotypical manifestations is 
ascribed to the large size of PKHD1 with a large number of mutations and multiple alternative 
transcripts.12
Reports about the presence of intrafamilial heterogeneity in PCLD patients are not available. 
It has been suggested that hepatic cysts are undetected or not carefully assessed by radiological 
imaging.5 In line with ADPKD and ARPKD family studies, we hypothesized that the clinical 
expression of the liver phenotype is not uniform among individuals from a given PCLD family.
METHODS
Study Protocol
We performed a cross-sectional study in our PCLD cohort by a comprehensive genetic and 
clinical analysis. For this family study we included probands with a clinical diagnosis of PCLD, 
which was unconfirmed by genetic analyses of PRKCSH and SEC63 genes. All probands 
possessed a polycystic liver without renal disease and did not meet the Ravine criteria.13 
Eligible mutation-negative families consisted of at least two individuals in order to assess the 
familial PCLD expression profile. A detailed family history was assessed in those probands 
without a PRKCSH or SEC63 gene mutation. Demographic characteristics are presented as 
median (range) and percentages.
PRKCSH and SEC63 Mutation Analysis
Blood samples (10 ml EDTA-anticoagulated) were collected from probands. DNA was extracted 
from blood leukocytes using the HP-PCR Template Preparation kit (Roche Applied Science, 
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Mannhein, Germany). Subsequently, molecular analyses of the PRKCSH and SEC63 gene were 
conducted by direct Sanger sequencing on ABI3730 Genetic Analyzers (Applied Biosystems). 
PCLD Relatives
All available first- and second-degree adult relatives were invited to participate. Enrolled were 
individuals willing to provide clinical data after written informed consent (Figure S1). PCLD is 
defined as presence of at least 4 hepatic cysts in individuals >40-years-of-age and a positive 
family history with a autosomal dominant inheritance pattern.14 
Abdominal Ultrasound Examination
We determined the hepatic and renal phenotype in family members ≥35 years-of-age by 
abdominal ultrasonography combined with archival radiological data. Ultrasound images 
of liver and kidneys were acquired using a 3.6MHz general-purpose clinical echo system 
(Acuson x150, Siemens AG, Germany) equipped with a curved linear array transducer. Presence 
or absence of hepatic and/or renal cysts was carefully assessed by at least two clinicians 
(W.R.C/M.C./J.P.H.D.). Phenotype screening was performed in all relatives within 8 months.
RESULTS
The study population consisted of 467 unrelated new patients with PLD referred for molecular 
diagnosis of PCLD in the time span 2004-2013. In 21.6% of the patients Sanger Sequencing 
of PRKCSH and SEC63 revealed the underlying pathogenic mutation (15.2% PRKCSH; 6.4% 
SEC63). 
For this study, we included 32 accessible and unlinked probands for clinical assessment. 
Subsequently, a detailed family history was inquired. This group consisted of 29 female 
probands (90.6%) and had a median age of 51 years (range 26-75) at clinical diagnosis. In total, 
162 family members consented for assessment of medical history and phenotype screening.
We systematically questioned relatives for symptoms prior to phenotype screening. These 
relatives were triaged according to a positive or negative family history and distributed among 
two groups. A positive family history of hepatic cystogenesis at diagnosis was confirmed by 
assessment of 59 relatives (37 affected and 22 non-affected) from 8 probands (25%). Twenty-
four probands reported a negative family history at diagnosis (75%), but after screening there 
were hepatic cysts (range 1-≥20) present in family members from 22 probands (91.7%). A cystic 
phenotype was absent in family members of two probands with a negative family history. 
After clinical assessment of our cohort probands with a negative family history consisted 
of 49 individuals with cysts and 54 unaffected family members. Affected individuals had a 
median age of 60 years (range 37-83) compared to 53 years (range 35-82) of non-affected 
individuals. Affected family members from probands with a negative family history of PCLD 
were mainly female (79.6%; median age of 57 years; range 38-83).
Five out of 22 families with an apparent negative family history had 1 affected family 
member with PCLD-related symptom(s) (Figure 1). They were all first-degree relatives (2 
mothers, 2 brothers, 1 sister) with median age of 69 years (range 44-74). None of these five 
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relatives were treated as having PCLD, while 83.3% of the probands was treated by one or 
more of the following therapies: aspiration sclerotherapy (n=17), laparoscopic deroofing (n=4) 
and/or somatostatin analogues (n=5).
DISCUSSION
This cross-sectional study establishes that solitary PCLD cases without a PRKCSH or SEC63 
germline mutation and no apparent family history frequently do have family members with 
bonafide PCLD. The phenotypes of index patients were in great contrast to those of new 
discovered affected family members. Astute clinical ascertainment established that the 
index patients were the most severely affected individuals within the family. Indeed, most 
index patients (83.3%) had sought medical care due to symptoms. We also found that there 
was great variability of the polycystic liver phenotype (in terms of number and size of cysts) 
detected in affected family members. Only few affected, disease-unaware family members 
(10.2%) had symptoms fitting with PCLD at the time of screening. Therefore, taking family 
history accurately in patients with unexplained abdominal symptoms may provide a broader 
diagnostic frame. 
There are no established clinical criteria for diagnosis of PCLD. Hitherto, most researchers 
use the Reynolds criteria that comprises age, quantitative radiological findings combined with 
a positive family history following an autosomal dominant inheritance pattern.14 Specifically, 
individuals who are above 40-years-of-age with at least 4 hepatic cysts and stem from a 
Figure 1. Results of the family study. Mutation-negative PCLD probands with a positive family history 
have almost equal asymptomatic (54.1%) and symptomatic (45.9%) affected family members. Five 
affected relatives of a proband with a negative family history presented PCLD-related symptoms (10.2%). 
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PCLD family can be labeled with PCLD.14 Symptoms are not part of this diagnostic set of 
criteria. However, symptoms such as abdominal pain and/or distension, and early satiety are 
not infrequent 1 and are part of the diagnostic process. Severe PCLD entails a syndrome of 
hepatomegaly and abdominal symptoms. Following this definition, a minority of inherited PCLD 
patients who meet the Reynold’s criteria have symptoms. Our study presents that screening 
individuals within a family with PCLD on the basis of symptoms will detect ~50% of patients. 
How do patient’s symptoms relate to the ADPKD phenotype, whose patients have polycystic 
kidneys and may have polycystic livers? In ADPKD, patients progress to renal impairment. 
The severity of polycystic liver disease is correlated with renal disease progression in females 
according to studies measuring total liver and kidney volumes.15, 16 There is an ADPKD 
genotype-phenotype correlation, as patients with PKD1 gene mutations reach end-stage renal 
failure ~20 years earlier than PKD2 mutation carriers.17 Evidence exists for significant disease 
variability within ADPKD families that carry the same mutation.11 This substantial disease 
variability includes non-progressive and progressive cases within one generation. The reason 
for such inconsistent presentation remains unexplained, but may partially result from genetic 
factors such as mutation type or presence of chromosomal aberrations (e.g. mosaicism).10, 
11 No genetic factors predict development of (severe) polycystic livers in ADPKD patients. In 
addition, there may be involvement of multiple (modifier) genes or environmental factors that 
contribute to intra- and interfamilial variation. 
The unified ultrasonographic criteria for ADPKD diagnosis excludes the medical family 
history as diagnostic criteria in cases with an unknown genotype.13 In addition, sporadic 
ADPKD patients may also harbor a PKD1 or PKD2 mutation, the only definitive diagnosis.18 
Current guidelines advise to consider screening members for ADPKD after identification of 
the index patient, even in absence of an apparent family history. This is justified in the context 
of the risk for extra-renal (vascular) complications.19 We feel that in view of the absence of 
clear extra-hepatic manifestations, genetic counseling is not warranted in PCLD. However, we 
would like to emphasize that early diagnosis in young females may offer advantages, as these 
patients should be advised to avoid exogenous estrogens as these have a growth inducing 
effect on the polycystic liver.2, 20 Radiological screening of young individuals (18-years-old or 
younger) is not indicated. In case of symptomatic PCLD patients, an extended first assessment 
is recommended: physical examination, taking family history, molecular analysis of the 
PRKCSH and SEC63 gene and abdominal ultrasonography. CT scanning may be considered 
to have a radiological presentation as a reference (first measure point). Clinical follow-up 
and ultrasonography once a year may be advised in symptomatic patients, but patients with 
progressive disease need more frequently clinical monitoring. We believe that asymptomatic 
individuals require no extended follow-up program.   
The strength of this study is the comprehensive analysis of the families of PRKCSH and 
SEC63 negative index patients. We performed ultrasonography of the liver and both kidneys, 
and analyzed additional archival radiological data. Although abdominal ultrasonography 
among at-risk members is the first investigation of choice in a screening setting 13, 21, this 
study is limited by absence of total liver volume measurement. 
In conclusion, this study shows the presence of significant intrafamilial, phenotypic 
heterogeneity in PCLD patients without a pathogenic variant in the PRKCSH or SEC63 gene. 
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An extended family history may provide arguments for abdominal disease. We advise to 
perform abdominal ultrasonography as first screening tool in symptomatic individuals. Although 
(hormonal) environmental influences are part of the disease, the presented phenotypic 
variability also suggests heterogeneity at a genetic level.
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Figure S1. Flowchart recruiting and including families. The flow chart of this study presents that 
21.6% of probands harbor a mutation in the  PRKCSH or SEC63 gene. Recruitment of probands and 
family members are schematically depicted.
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SEVERE POLYCYSTIC LIVER DISEASE IS NOT CAUSED 
BY LARGE DELETIONS OF THE PRKCSH GENE
CHAPTER 4
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ABSTRACT
Isolated polycystic liver disease (ADPLD) is an autosomal dominant Mendelian disorder. 
Heterozygous PRKCSH mutations are the most frequent cause. Routine molecular testing 
using Sanger sequencing identifies pathogenic variants in the PRKCSH (15%) and SEC63 (6%) 
genes, but about ~80% of patients meeting the clinical ADPLD criteria carry no PRKCSH or 
SEC63 mutation. Cyst tissue often show somatic deletions with loss of heterozygosity which 
was recently recognized as a general mechanism in ADPLD. We hypothesized that germline 
deletions in the PRKCSH gene may be responsible for hepatic cystogenesis in a significant 
number of mutation-negative ADPLD patients. 
In this study, we designed a multiplex ligation-dependent probe amplification (MLPA) assay 
to screen for deletions of PRKCSH exons. Genomic DNA from 60 patients with an ADPLD 
phenotype was included. MLPA analysis detected no exon deletions in mutation-negative 
ADPLD patients. 
Large copy number variations on germline level are not present in patients with a clinical 
diagnosis of ADPLD. MLPA analysis of the PRKCSH gene should not be considered as a 
diagnostic method to explain hepatic cystogenesis. 
Keywords
Exon deletion; Genetic heterogeneity; Hepatic cystogenesis; MLPA; ADPLD; PRKCSH
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INTRODUCTION
Polycystic liver disease may occur in the context of isolated polycystic liver disease (ADPLD) 
and as a common extrarenal manifestation in autosomal dominant polycystic kidney disease 
(ADPKD).1, 2 Polycystic livers have numerous cysts which may result in hepatomegaly.1 While 
ADPLD is rare, 1/158,000, ADPKD is seen in 1/400-1/1,000.3, 4 In addition, autosomal recessive 
polycystic kidney disease (ARPKD) patients are also predisposed to hepatobiliary abnormalities.5
A heterozygous mutation in PRKCSH (MIM*177060), SEC63 (MIM*608648) or LRP5 
(MIM*603506) underlie ADPLD.6-9 Currently, 27 PRKCSH, 22 SEC63 and 4 LRP5 mutations 
have been identified by conventional Sanger sequencing, with the highest mutation frequency 
of the PRKCSH gene (15%).10-12 The mutation spectrum consists of heterozygous duplications, 
small deletions, missense, nonsense, and splice site mutations.10, 12 Interestingly, 79-84% of 
patients with a clinical diagnosis of ADPLD do not harbor a pathogenic mutation on these 
loci.10, 12 The overall low mutation detection rate in ADPLD may be explained by genomic 
rearrangements missed by clinical testing. Recently, somatic mutation analysis reported loss of 
the wild-type PRKCSH allele in 76% of micro-dissected cysts.13 Extended loss of heterozygosity 
(LOH) was confirmed by investigation of the genomic region surrounding PRKCSH. Analysis 
for large deletions, mosaicism or epigenetic mechanisms such as promoter hypermethylation 
in germline DNA have not been performed for ADPLD. 
We hypothesized that aberrations in genomic DNA in and close to the PRKCSH gene may be 
responsible for hepatic cystogenesis in mutation-negative patients with an ADPLD phenotype. In 
this study, we designed probes for the PRKCSH gene and performed multiplex ligation-dependent 
probe amplification (MLPA) assays in order to identify chromosomal deletions or duplications. 
MATERIALS AND METHODS
Patient Samples
We selected individuals with severe polycystic liver disease who were referred to us between 
2004 and 2012 for molecular analysis of the PRKCSH and SEC63 gene.12 In total, 60 DNA 
samples belonging to 56 families were analyzed by MLPA. This included six family members 
from two families with a known pathogenic PRKCSH variant causing ADPLD, which was 
absent in two affected family members. 
Thirty-nine patients were affected with >20 hepatic cysts and 21 patients presented <20 
large, dominant hepatic cysts. The mean age was 54 years (range 32-79) and 41 patients 
required treatment because of symptomatic ADPLD. Invasive treatment such as aspiration 
sclerotherapy and/or surgery was performed in 36 patients (60%). Somatostatin analogues 
was given to 13 patients (21.7%; mean liver volume 5,402 liter) during clinical trials.14-17 
Isolation Genomic DNA
Genomic DNA was isolated from peripheral blood using the High Pure PCR Template Preparation 
kit (Roche Diagnostics GmbH, Mannheim, Germany). To yield a high DNA concentration, 
RNase was used to remove all RNA in the blood samples, and DNA was eluted with 100µl 
elution buffer. 
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Direct Sanger Sequencing
Conventional PCR mutation detection was conducted with specific primers for PRKCSH and 
SEC63. All 18 PRKCSH exons, 21 SEC63 exons and flanking intronic sequences were screened 
by bidirectional Sanger sequencing on ABI3730 Genetic Analyzers (Applied Biosystems, 
Waltham, Massachusetts, USA).12 Amplified fragments were purified using the QIAEX-II Gel 
Extraction Kit (Qiagen, Hilden, Germany).
PRKCSH MLPA Probe Set Design
The longest open reading frame of PRKCSH consists of 1,584bp with the start codon located 
in exon 2 and stop codon in exon 17 (DNA Genebank accession number: NM_002743.3; and 
genomic DNA Genebank accession number: NC_000019.9.18 Therefore, genomic sequence 
of 16 coding exons of the PRKCSH gene and the first exon of the nearby gene in opposite 
transcriptional direction, exon 7 of the ELAVL3 gene, were retrieved for probe design (Figure 
1A). In total, the design strategy consisted of 17 synthetic left probe oligonucleotide (LPO) 
and right probe oligonucleotide (RPO) without stuffer sequences according to manufacturers’ 
instructions; criteria by MELTingeny software v1.0.1 (Ingeny, Goes, The Netherlands) (Table S1). 
We excluded two exons (11 and 16) of the PRKCSH gene because of conservation rates 
and extent of the kit (MRC Holland, Amsterdam, The Netherlands). In addition, both exons 
are flanked by the shortest intronic regions. Exon 11 is located 277bp and 96bp from exon 10 
and exon 12 respectively. The intronic regions adjacent to exon 16 are even smaller, consisting 
of only 87bp and 88bp. Exon 11 is not highly conserved, contains several polymorphisms 
and no pathogenic mutations were identified in this region. Solitary splice site variants were 
identified in exon 16.10 These facts implicate that these exons are probably not the hotspots 
for mutations involved in ADPLD development. Moreover, the probe design options for 
exons 11 and 16 were not in line with the high quality design compared the other developed 
PRKCSH candidate probe set.
To reduce presence of SNPs and for melting temperature analysis, candidate sequences 
were analyzed by SNPcheck v.3 (https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck.htm) and 
RaW Probe Software (RaW-Soft v.015β) respectively. A standard probe set for 4 Q-fragments, 
2 D-fragments, 15 genomic references, the X-chromosome and Y-chromosome was available 
for validation and analysis (SALSA P300-A2, MRC-Holland).
MLPA Reactions
The experiments were conducted according to the general instructions. Each experiment 
included eight reactions in which 5µl genomic DNA (10ng/µl) from each of seven samples 
and from a negative control was used (Supplemental Information).
Ethics Statement
Blood samples of patients were obtained and stored in the course of treatment following the 
Dutch Code for the proper secondary use of human samples. All patients provided verbal 
informed consent for molecular diagnostics of two genes (PRKCSH and SEC63) associated 
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with ADPLD during management. Participant’s verbal consent was written in his/her medical 
record by the physician. This consent procedure and use of DNA for research was reviewed 
and approved by the regional ethics review board “Commissie Mensgebonden Onderzoek 
(CMO) regio Arnhem-Nijmegen” (CMO 2012/317). 
Figure 1. MLPA probe design and results. Each reaction consisted of 16 synthetic PRKCSH probes and 
1 synthetic probe for exon 7 of the ELAVL3 gene. Rationale of probe design. The direction of the open 
reading frame (ORF) of PRKCSH (5’→3’) is in opposite direction of the ORF of the ELAVL3 gene (3’←5’). 
The stopcodon of ELAVL3 is located in exon 7. Large or single exon deletion of ELAVL3 exon 7 may 
result in a transcriptional read-through into PRKCSH with subsequent promotor hypermethylation and 
reduced hepatocystin expression. DNA fragment analysis in genomic DNA samples from 56 mutation-
negative ADPLD patients demonstrated no CNA for PRKCSH nor deletion of the probes for ELAVL3. 
Box plots present the performance of each probe set by indicating mean dosage quotient with range 
(minimum-maximum) and standard deviation.
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RESULTS
MLPA Performance
Two genomic DNA samples of sufficient quality were included for the analysis as negative and 
reproducibility controls. Repetitive test runs with controls and genomic DNA samples were 
conducted for optimization of the experiments. The probe design for 14 exons of PRKCSH 
and ELAVL3 exon 7 yield sufficient coverage. 
The dosage quotient (DQ) is related to the amount of fluorescence detected within DNA 
fragment analysis. The ratio of the peak height of the synthetic or reference probe over the 
average of at least 12 reference (control) probes of a sample was determined. Signal intensity 
was absent for PRKCSH exons 2 and 12 in controls and all patient samples. These exons were 
not included for subsequent MLPA analyses. The reference probe set was within a normal 
DQ range (0.85-1.15). These results were used to investigate copy number aberrations (CNAs) 
in genomic DNA. 
The genomic DNA samples in our study were within normal range of 0.68-1.18 for 14 
PRKCSH probes. The probe for the final PRKCSH exon 18 had a mean DQ of 1.00 with a 
wider range (0.59-1.47). MLPA analysis on 56 mutation-negative patients showed no CNA 
in PRKCSH (Figure 1B). In addition, we investigated whether germline deletions were present 
in two mutation-negative ADPLD patients from PRKCSH-affected family. In both patients no 
exon deletions were identified (Figure S1, Table S2).
DISCUSSION
This study is the first report that describes the diagnostic properties of MLPA for PRKCSH in a 
cohort of patients with severe polycystic liver disease. Current molecular diagnostic testing of 
clinically diagnosed ADPLD patients consists of direct Sanger sequencing of the PRKCSH and 
SEC63 genes. We hypothesized that large deletions and genomic rearrangements of PRKCSH 
may account for a proportion of mutation-negative ADPLD cases. Identification of somatic 
deletions of the PRKCSH gene suggests that this gene may be predisposed to deletions.13 
ADPLD is clinically and genetically heterogeneous and germline deletions may explain the 
majority of mutation-negative patients (~80%).10, 12 Our findings revealed no large germline 
deletions or duplications in the PRKCSH gene from ADPLD patients without pathogenic 
variants in PRKCSH and SEC63. This negates a substantial role for MLPA in the diagnostic 
setting algorithm of ADPLD (Table 1). 
These findings contrast studies that demonstrate exon deletions in ARPKD19-21 and ADPKD22-
26. About ~90% of ARPKD patients harbor a pathogenic variant in the PKHD1 gene. The same 
is true for ADPKD patients with PKD1 or PKD2 mutations.27, 28 There is a wide spectrum of 
genetic variation in ARPKD and ADPKD as nonsense, splice site, missense mutations, small 
deletions/insertions, but also extensive genomic rearrangements may be present. Previously, 
large deletions were detected in PKD1 (n=4) and PKHD1 (n=3) by long-range PCR and 
quantitative real-time PCR techniques.19, 26 Recently, MLPA identified gross rearrangements 
of both ADPKD genes in 4% of the ADPKD-CRISP cohort.22 Other studies found genomic 
deletions in 0-2.4% of PKD1 carriers.23, 25 Large deletions seem to be more frequent in ADPKD 
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compared to ARPKD. Only 2 out of 16 ARPKD probands harbored a large PKHD1 deletion.21 
In addition, there were no PKHD1 rearrangements in 39 Dutch/Caucasian families.20 These 
results suggest that large deletions are rare in polycystic kidney diseases.25 Gross genomic 
rearrangements of PKD1 are associated with deletion of the adjacent TSC2 gene and referred 
as the TSC2/PKD1 contiguous syndrome (PKDTS).22-24 In line, we designed additional probes 
for exon 7 of ELAVL3, a gene located 361bp upstream in antisense direction of PRKCSH. The 
deletion of this exon could result in transcriptional read-though (Figure 1A). Consequences 
of this mechanism may be PRKCSH promoter methylation and gene silencing. This type of 
epigenetic inactivation has been suggested for development of polycystic kidneys.29 This 
mechanism was also found to be involved in Lynch syndrome. Patients presenting with Lynch 
syndrome, but no mutation in causative gene MSH2, were found to have a deletion of the 
last exon (including the stop codon) of upstream gene EPCAM. Formation of an extended 
EPCAM transcript inactivates MSH2 due to promoter methylation.30
In tumorgenesis and polycystic kidney and liver disease, LOH is a common mechanism. 
Somatic PKD1 deletions are demonstrated in cystic kidney and liver tissues from ADPKD 
patients.31 Indeed, the ‘second hit hypothesis’ was confirmed for PRKCSH and SEC63 on the 
somatic level in ADPLD.13, 32 For PRKCSH, the mutation rate in genomic DNA (15%) and LOH 
regions in somatic DNA (76%) are the highest.10, 13 Detection of somatic deletions by MLPA 
is challenging, but suggested to be applicable.22 
Surprisingly, we have not identified germline deletions nor duplications in a large cohort 
of mutation-negative ADPLD patients. No unstable genomic regions which may be prone to 
rearrangements in the PRKCSH gene are identified, as such is known for duplicated regions 
Table 1. Overview of PRKCSH germline mutations. Deletions and duplications in PRKCSH germline 
DNA (NM_002743.2). Small deletions/ duplications are defined as ≤20 deleted/inserted base pairs 
(GRCh37; hg19)
Germline mutation  
(c.DNA) 
Predicted protein 
effect 
Study group/ 
reference
Small deletions c.368delA p.E123GfsX130 Waanders et al.10 
c.374_375delAG p.E125VfsX145 Drenth et al.34
c.668delA p.D223VfsX231 Waanders et al.10
c.684-3_684delCAGG p.V229X Waanders et al.10
c.1336delC p.G447AfsX463 Waanders et al.10
c.1440+2_1440+3delTG p.T448CfsX457 Li et al.7
Small duplications c.76_79+4dupACCAGTGA p.N27SfsX117 Waanders et al.12
c.215dupA p.N72KfsX81 Li et al.7
c.353dupA p.K119EfsX122 Waanders et al.10
c.1170dupC p.p.I391HfsX401 Li et al.7
Gross deletions - - This study
Gross duplications - - This study
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in the large PKD1 gene.33 In addition, we expected to identify an exon deletion in two 
mutation-negative ADPLD patients coming from a family with a known PRKCSH mutation. 
Germline deletions in two other ADPLD genes, SEC63 and LRP5, are not ruled out by 
this study. The frequency of small deletions in the SEC63 gene (n=4; 21%) or in the PRKCSH 
gene (n=7; 26%) are almost similar.10 Currently, only LRP5 missense mutations are associated 
with ADPLD. Therefore, the possibility of large germline deletions in the SEC63 or LRP5 gene 
is probably minimal or absent. We hypothesize that in these affected individuals and other 
patients with a clinical diagnosis of ADPLD harbor mutations in yet unidentified gene(s) 
associated with hepatic cystogenesis. 
In conclusion, no large deletions and duplications are present in the PRKCSH gene in 
germline DNA from mutation-negative ADPLD patients. This suggests that a fourth as yet 
unidentified locus is involved in ADPLD development.
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SUPPLEMENTARY METHODS
MLPA Reactions
DNA was denaturated for 5 minutes at 98°C in a thermocycler (iCycler, BioRad Laboratories 
Inc, Hercules, California, USA). After cooling to room temperature the samples were subjected 
to a hybridization step by adding 1.5µl probe mix and 1.5µl SALSA/MLPA buffer. The probe 
mix included a solution of (2/3) the SALSA reference probe mix and (1/3) the synthetic basic 
probe mix (1µM oligo solution LPO and RPO). The final mix was denaturated for 1 minute 
at 95°C and hybridized during 16 hours at 60°C. After cooling the samples to 54°C, the 
ligation reactions were processed for 15 minutes at 54°C by adding 32µl Ligase-65 master 
mix to each sample. An additional incubation for 5 minutes at 98°C inactivated the ligase 
enzyme. Next, a polymerase mix was added to conduct a PCR amplification with 35 cycles 
(30 seconds; 95°C, 60°C, 72°C) and finally 20 minutes at 72°C.
MLPA Fragment Analysis
PCR products were analyzed for quality on a 2% agarose gel. For fragment analysis PCR 
products were diluted 1:9 with Liz-Formamide mix containing 1/44 500LIZ Size Standard 
(Applied Biosystems). DNA fragment separation was performed by capillary electrophoresis 
on an ABI-3730 (Applied Biosystems), and data of peak height and DQ were analyzed using 
Gene mapper software (v.1.01 Applied Biosystems) according to manufacturers’ instructions. 
Ligation quality (D-fragment) and DNA quality (Q-fragments) were assessed for the DNA 
fragment analysis of each reaction.
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Calculations
Calculated dosage quotient (DQ) is related to the amount of fluorescence detected within 
DNA fragment analysis. The ratio of the peak height of the synthetic or reference probe 
over the average of at least 12 reference (control) probes of a sample was determined. 
Secondly, the value of this ratio was divided by the average of the corresponding probe of all 
samples. Reference DQ-values were provided by MRC-Holland to identify potential deletions 
or duplications. A heterozygous deletion is defined as a DQ between 0.35 and 0.65, and a 
heterozygous duplication when DQ is between 1.35 and 1.55. A normal copy number status 
is a DQ reference value between 0.85 and 1.15 according to manufacturers’ instructions 
(MRC Holland).
SUPPLEMENTARY FIGURE
Figure S1. Two Dutch ADPLD families with a known PRKCSH mutation. Two families presented 
clear autosomal dominantly inherited ADPLD. Except 1 patient each, all affected individuals from both 
families presented a known PRKCSH mutation by diagnostic Sanger sequencing.6, 34 Family 1 harboured 
c.374_375delAG (p.Glu125fs*21) and ADPLD patients from family 2 carried c.292+1G>C (p.D98AfsX100). 
Pedigree of ADPLD family 1 and 2 in which the patients (206 and 105) without PRKCSH mutation 
are indicated by an arrow. Clinical liver and kidney features of mutation-negative ADPLD patients by 
abdominal MRI or CT scanning. Patient 206 has a multiple cysts scattered throughout the liver (white 
arrow) and several small renal cysts (dotted white arrow). A large hepatic cyst (white arrow) caused 
major complaints in patient 105 with clinical diagnosis of ADPLD. 
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Table S2. Baseline characteristics of two mutation-negative ADPLD patients belonging to a 
PRKCSH-positive family.
ADPLD patient 206:  
Family 1
ADPLD patient 105:  
Family 2
Mutation status affected family 
members (c.DNA and predicted 
protein effect)
c.374_375delAG 
(p.Glu125fs*21)
c.292+1G>C (p.D98AfsX100)
Nature of mutation; location Deletion; exon 6 Splice site substitution; IVS4
Protein domain - LDLa
Sex Male Female
Age at diagnosis (MRI/CT scan) 39 49
Clinical symptoms Abdominal swelling Abdominal pain, fatigue,  
back pain, vomiting
Treatment strategy - Anti-reflux therapy

Wybrich R. Cnossen, Joost P.H. Drenth
Department of Gastroenterology and Hepatology, Institute for Genetic and Metabolic 
Diseases, Radboud university medical center, Nijmegen, The Netherlands
Journal of Carcinogenesis and Mutagenesis, 2013 December 5:154
SOMATIC HITS IN POLYCYSTIC LIVER DISEASES
CHAPTER 5
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ABSTRACT
Polycystic liver disease (PLD) encompasses a number of disorders with the development of 
multiple cysts distributed throughout the liver either focally or equally. Hepatic cysts are fluid-
filled cavities lined by benign epithelium. PLD is the major phenotype of isolated polycystic 
liver disease (PCLD) and autosomal dominant polycystic kidney disease (ADPKD). 
The molecular principles in carcinogenesis indicate that there is an accumulation of multiple 
(somatic) mutations. This concept assumes that presence of a germline mutation (‘first hit’) in 
an inherited disorder requires a ‘second hit’ at the somatic level for cyst development to occur. 
The second hit is the rate-limiting step and results in somatic inactivation of the normal allele.
Studies have identified secondary, somatic hits in human liver cyst tissues in PCLD and 
ADPKD. Inactivation of both copies in PLD is demonstrated through somatic mutations or 
loss of heterozygosity (LOH). The frequency of somatic mutations varies between genes and 
genomic disorders. Genetic studies detected LOH in 9% and somatic mutations in 8-29% in 
ADPKD derived hepatic cysts. In PCLD, almost ~80% of hepatic cysts from PRKCSH carriers 
had completely lost the PRKCSH gene. 
There is important clinical heterogeneity among PLD patients. Differences in phenotypical 
expression may be explained by age, gender and environment, but also modifier genes or 
inactivating somatic events may play key roles. This review will give an overview of the data 
gained from genetic studies in liver cyst tissues from PCLD and ADPKD patients in relation 
to the clinical manifestations.
Keywords
Second hit hypothesis; Somatic mutation; LOH; Loss of function; PLD; PCLD; ADPKD
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INTRODUCTION
Polycystic liver disease (PLD) comprises a group of diverse congenital disorders that have 
presence of multiple hepatic cysts in common. There are 2 major conditions that possess this 
benign phenotype, isolated polycystic liver disease (PCLD) and autosomal dominant polycystic 
kidney disease (ADPKD).1, 2 Both Mendelian disorders are autosomal dominantly inherited and 
share similar liver features.3 PCLD is characterized exclusively by presence of hepatic cysts, 
and polycystic livers are the most common extrarenal manifestation in ADPKD.4 Development 
of polycystic kidneys is a key feature in ADPKD, but also cardiovascular manifestations, 
intracranial aneurysms, pancreatic cysts and renal complications with end-stage renal disease 
may be present.1, 3 
The origin of hepatic cystogenesis probably starts in early embryological phase with biliary 
tree development. The formation of the ductal plate is needed for development of healthy 
bile ducts. In genetic disorders leading up to PLD this process is compromised, hence the term 
ductal plate malformation.5 It is likely that the nidus needed for cyst formation (microcysts) 
is already present in childhood of germline carriers. These microcysts are undetectable by 
routine radiological methods, but may develop later in life.4
Following Knudson ‘second-hit’ hypothesis, it was proposed that cysts arise as a result 
of a second mutational event. Patients carrying a germline mutation (the ‘first hit’ in a PLD 
gene) are prone for cyst development. However, the single mutated allele does not necessarily 
lead to hepatic cysts, but a  second somatic event is required for individual cysts to develop.6
In this short review we present a comprehensive overview of somatic mutations and 
genetic mechanisms that have been associated with hepatic cystogenesis in PLD. 
GENETIC BACKGROUND
PCLD and ADPKD are distinct disorders and associated with germline mutations in separate 
genes. About ~25% of PCLD patients carry a bonafide gene mutation in the PRKCSH gene 
or SEC63 gene.7-10 Both protein products, hepatocystin and Sec63p, are involved in protein 
folding, quality control and transduction in the endoplasmic reticulum.11 Almost all ADPKD 
patients carry a pathogenic germline PKD1 gene (~85%) or PKD2 gene (~15%) mutation.12-14 
The corresponding protein products polycystin-1 (PC-1) and polycystin-2 (PC-2) function as a 
mechanosensory receptor-channel complex at the primary cilium for calcium influx.1 
The primary cilium is an extending organelle at the plasma membrane of the bile duct 
epithelium cell (cholangiocyte). Pathofysiological processes are functionally engaged with 
this structure by detection of the luminal flow. Defective polycystin expression contributes 
to decreased intracellular calcium and increased cAMP levels.15 The combination of these 
abovementioned mechanisms and overexpression of PKA and Epac cause cholangiocyste 
hyperproliferation through the mitogen-activated protein kinase/extracellularly regulated 
kinase (MAPK/ERK) pathway and cyst fluid hypersecretion in PLD.16 Current somatostatin 
analogue treatment affects secretin-mediated pathways (Figure 1).17 
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TUMORGENESIS
General Principle in Tumorgenesis
In 1953 Nordling was the first to propose the multi-mutation hypothesis for the origin of 
cancer. His  theory stated that accumulation of DNA mutations in a cell as a consequence of 
Figure 1. Somatostatin treatment decreases cholangiocyte hyperproliferation and fluid 
hypersecretion in PLD. Hepatic cysts are delineated by bile duct epithelium cells. The primary cilium 
at the plasma membrane is continuously exposed to luminal bile flow. Mechanical flow rate is sensed by 
bending the organelle. Under healthy conditions this stimulates calcium signaling and inhibits forskolin-
stimulated cAMP signaling intracellularly.  
PC-2 co-localizes with PC-1, and PC-2 is a calcium channel expressed at the endoplasmatic reticulum. 
Cholangiocytes possess numerous transporters and exchangers. Basolateral secretin stimulates intracellular 
cAMP signaling and bicarbonate fluid rich secretion by activation of apical CFTR chloride channel. 
Subsequently, secreted bicarbonate drives passive AQP1-mediated water transport to the extracellular 
compartment. 
This figure illustrates a defective molecular mechanism in PLD. Decreased intracellular calcium and 
accumulation of second messenger cAMP contributes to hepatic cystogenesis.15 Phosphorylation of 
PKA and Epac are associated with increased MAPK/ERK signaling in PLD. In response to this activated 
pathway fluid secretion and cell proliferation is facilitated.16 
Somatostatin acts via SSTR-2 somatostatin receptors to increase cGMP which inhibits secretin-
mediated cAMP synthesis. Secretin-stimulated chloride, bicarbonate and water secretion are inhibited 
and absorption is induced by somatostatin analogues (in red). 
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normal cell proliferation, environmental exposure and increasing age results in carcinogenesis.18 
Clinical and epidemiological observations prompted Knudson to reformulate this hypothesis 
with the example of dominantly inherited and acquired retinoblastoma.19 He proposed a 
‘second hit’ hypothesis which implicates that a second mutation is required in addition to a 
‘first hit’ for tumor development.
Since then, several studies in common malignant diseases, particularly those caused by 
tumor suppressor genes such as ovarian and colon cancer, have produced data consistent with 
the mutational origin of cancer. This concept is refined and proof is provided that occurrence 
of 2 (somatic) ‘hits’ may be sufficient for tumor development in sporadic malignant diseases.20, 
21 The result from both mechanisms is biallelic inactivation through loss of the wild-type copy. 
Second hits are usually small deletions or insertions resulting in a truncated protein, but large 
deletions at the gene locus with loss of heterozygosity (LOH) are also seen.20-24 
Identification of Somatic Inactivation in ADPKD and PCLD
Subsequent to the identification of the first causative PKD1 gene for ADPKD, researchers have 
speculated about presence of somatic mutations that would lead to the inactivation of the 
second PKD1 allele.12 In order to address this issue, methods have been developed to isolate 
cyst-lining epithelial cells to access DNA from single cysts. These studies confirmed the second 
hit hypothesis in renal cyst epithelium from PKD1 affected patients.23, 25, 26 
Table 1. Somatic mutations with the predicted effect on protein level in liver cyst tissue from 
PLD patients. Types of somatic hits included 5 substitutions, 3 deletions and 1 insertion mutation at the 
similar gene locus (GRCh37-hg19). These mutations resulted in pathogenic missense changes or truncated 
protein products. *TranscriptID. PRKCSH (NM_002743.2); PKD1 (L33243.1); PKD2 (NM_000297.2)
PLD
sampleID.
Germline 
mutation(s)*
Predicted 
protein effect Somatic mutation*
Predicted protein 
effect Ref.
ADPKD1
JHU415
PKD1 c.12378C>G p.Tyr4126X PKD1 c.12551insGC p.His4185Argfs*13 33
ADPKD1
JHU452
PKD1 c.7165T>C
PKD1 c.9047A>G
-
p.Gln3016Arg
PKD1 c.8900C>G
PKD1 
c.10050+2del20
PKD1 c.8558T>C
PKD1 c.7567G>T
PKD1 c.8733del16
p.Ser2967X
aberrant splicing 
p.Phe2853Ser
p.Glu2523X
p.Asp2912Argfs*77
33
ADPKD2
UT1500
PKD2 c.2152insA p.Asn720Lysfs*5 PKD2 c.710-8del19 aberrant splicing 30
PCLD 
patient 1
PRKCSH c.1341-
2A>G
aberrant splicing PRKCSH c.224T>C
PRKCSH c.1499G>A
p.Phe75Ser
p.Cys500Tyr
34
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Figure 2. An overview of reported somatic hits in liver cyst tissues from PLD patients. Identification 
of LOH or somatic mutations in PKD1 or PKD2 in ADPKD28, 30, 33, and in PRKCSH or SEC63 in PCLD34, 35 
presented by a colored part per patient. Grey pieces represent no detected somatic hits in hepatic cysts. 
Kidney
Genetic analyses using microsatellite markers established loss of the healthy PKD1 allele in 
4-24% of renal cysts from PKD1 affected ADPKD patients. Somatic mutations were reported 
in 17% of renal cysts from a PKD1 mutation carrier.23, 25-28 Likewise, renal cysts from ADPKD 
patients harboring a PKD2 germline mutation had LOH at the PKD2 locus with a frequency 
of 0-12% and (milder) somatic PKD2 mutations were present in 15-64% of renal cysts.29-32 In 
addition, these analyses showed that the majority of single renal cysts in ADPKD presented 
epithelial cell populations derived from 1 cell. These experiments fueled the idea that cysts 
consist of a monoclonal cell population build from a single cell affected by 2 hits.23, 25 
Liver
Analysis of hepatic tissues (21 cysts) from 2 ADPKD patients that were PKD1 mutation 
carriers showed that the other allele was lost in both cases because of LOH (9%) or somatic 
mutations (29%) (Figure 2; Table 2).33 Another study in an ADPKD patient unlinked to PKD1, 
the healthy PKD1 allele in hepatic cyst epithelium was lost in 20% because of LOH.28 The 
situation was different in a PKD2 carrier. Somatic hits were detected in 1/13 (8%) cysts using 
classic intragenic and microsatellite marker analyses.30 By contrast, direct Sanger sequencing 
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studies at the somatic level in 71 cysts from PCLD patients (PRKCSH carriers) detected a LOH 
incidence of 76% at the PRKCSH locus.34 This is different from SEC63 mutation carriers where 
SEC63 LOH was present in 2%.35 
Identical to the situation in common tumors, the type of somatic mutations in PLD can 
be substitutions, small deletions or insertions leading to a missense change or premature 
stopmutation (Table 1).30, 33, 34 PCLD patients harboring a PRKCSH germline mutation are 
highly at risk for somatic mutational inactivation. Loss of the PRKCSH protein influences 
progression of hepatic cystogenesis. Therefore, it is possible that PRKCSH acts as a tumor 
suppressor gene.
Somatic Inactivation in Sporadic Hepatic Cysts
Sporadic cysts may arise as an incidental finding or as an acquired hepatic cyst  from a 
traumatic or an infectious condition. Simple hepatic cysts occur in about ~10% of the general 
population and are frequently asymptomatic.6 However, sporadic cysts may increase in volume 
and cause pressure on surrounding organs.
Germline mutations are required for cyst formation in congenital PLD, but are usually 
absent in individuals with a sporadic cyst. It is likely that loss of PLD genes occurs through 
Table 2. Overview of the number of hepatic cyst tissues per PLD patient for evaluation of 
somatic hits. An extended number of hepatic cysts in several patients have been analyzed in PCLD 
compared to ADPKD; n=71 cysts and n=52 cysts in PRKCSH and SEC63 affected individuals respectively. 
*TranscriptID. PRKCSH (NM_002743.2); PKD1 (L33243.1); PKD2 (NM_000297.2)
Study group Phenotype Patients germline mutation(s)*
Hepatic 
cysts (n) Ref.
Watnick et al. 1998 ADPKD1 JHU415. PKD1 c.12378C>G 12 33
ADPKD1 JHU452. PKD1 c.7165T>C and PKD1 
c.9047A>G
9
Pei et al. 1999 ADPKD2 UT1500. PKD2 c.2152insA 13 30
Badenas et al. 2000 ADPKD1 3. Germline mutation  not available 15 28
Janssen et al. 2011 PCLD 1.  PRKCSH c.1341-2A>G 14 34
PCLD 2.  PRKCSH c.1341-2A>G 12
PCLD 3.  PRKCSH c.1341-2A>G 9
PCLD 4.  PRKCSH c.1341-2A>G 9
PCLD 5.  PRKCSH c.292+1G>C 5
PCLD 6.  PRKCSH c.292+1G>C 13
PCLD 7.  PRKCSH c.292+1G>C 7
PCLD 8.  PRKCSH c.1341-2A>G 2
Janssen et al. 2012 PCLD 1.  SEC63c.1703_1705delAAG 34 35
PCLD 2.  SEC63 c.1703_1705delAAG 4
PCLD 3.  SEC63 c.958G>T 14
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somatic inactivation. Depending on the target tissue, loss of ADPKD alleles may lead to renal 
as well as hepatic cysts.30, 33. This mechanism has not (yet) been identified in PCLD patients. 
A loss-of-function model could be hypothesized as a common molecular mechanism in 
PLD. Different mutation types, deletions or LOH of a region including a PLD gene has been 
stated, but LOH may be also the result of errors during meiosis I or II. In acquired uniparental 
disomy an individual received 2 chromosomes from 1 parent. This abnormal normal haplotype 
leads to disease in case this allele is non-functional. The consequence of this gene conversion 
is that the patient carries a copy number neutral LOH. For example, LOH in combination with 
these mechanisms are detected in other benign tumors such as neurofibromatosis, but also 
in malignancy.22, 24
Protein Expression Levels in Liver Cyst Tissue
Immunohistochemistry analyses of gene products may indicate the presence or the expression 
level of proteins. Patients harboring a truncating heterozygous germline mutation usually have 
a second, wild-type allele. Following the second hit hypothesis in PLD, this wild-type allele will 
be lost and no protein expression will be detected by staining experiments. Indeed, studies 
of liver cyst tissues from patients with a germline PRKCSH mutation demonstrated that the 
PRKCSH protein was absent in cyst epithelium, but Sec63p was expressed.34, 36 Vice versa, 
the cyst that harbored somatic LOH of SEC63 showed reduced expression of the Sec63p, 
but positive PRKCSH staining.35 These findings suggest that both PCLD protein products do 
not interact. 
On the contrary, genetic studies in human liver cyst tissues from PKD2 affected patients 29, 32 
found that the majority represented polycystin-2 expression and equal polycystin-1 expression.37 
Molecular studies showed that polycystins interact by coiled-coil domains to form multimeric 
complexes. Interaction studies in ADPKD showed that polycystin-1 is a regulator of polycystin-2 
activity in liver and kidneys.38 This argues that PKD mutation carriers share the predominant 
phenotype of polycystic kidneys. 
Trans-Heterozygous Model
The first hypothesis of a trans-heterozygous model was confirmed with experiments in renal 
cysts in a PKD1 affected ADPKD family. This study revealed that PKD1 germline derived cysts 
could have somatic PKD2 mutations.27 Next, clonal PKD1 somatic hits were discovered in 
renal cysts from PKD2 carrier.31 These observations demonstrate an alternative pathogenic 
mechanism for cyst formation. To date, the trans-heterozygous model has been excluded in 
PCLD. Co-existence of second hits at the PKD1 or PKD2  locus in PCLD may compromise the 
functional network in PLD.39, 40 
Clinical Heterogeneity in Polycystic Liver Disease 
The liver phenotype of inherited PLD may range from a single or few cysts to an advanced 
polycystic liver with numerous cysts. Usually, several liver segments remain unaffected and 
the liver function is preserved, even in severe PLD.2, 3 
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Individual and inter-patient differences of cyst size, localization and growth suggest that 
other factors are involved in the pathogenesis. The type of somatic mutations may explain to 
some extent the individual variability. For example, the number and type of somatic mutation 
in the tumor suppressor gene APC has important implications on the protein function resulting 
in growth advantages of the cell.41
As indicated, the diversity of clinical presentation in families is high. The penetration 
of the disease has been estimated at ~80% and even if the disease become penetrant, its 
variability is high.10 Some affected family members may develop early and severe disease, 
while others only develop minor symptoms. This may occur among those sharing identical 
germline mutations. Although family history is frequently negative in PLD, an asymptomatic 
carrier can transmit the disease to offspring who may become affected.
PLD patients may be asymptomatic for many years. The number and size of hepatic cysts 
increase progressively by the age of 30 resulting in advanced disease in patients in their fifth 
decade.4 This variation reminds us of the situation in retinoblastoma. An early-onset of disease 
could be explained by the high rate of a second hits in embryonic cells.19 The mutation rate of 
the somatic hit determines the progression of the disease. It is likely that in PLD these somatic 
hits are the rate-limiting step for PLD development.
DISEASE MODEL
Examination of the second hit model has afforded us insight in the molecular mechanisms 
of PLD. Genome-wide copy number and (copy number neutral) LOH regions from liver cyst 
tissues are of high interest, because these investigations may guide us to putative candidate 
genes for hepatic cyst formation. Next, LOH regions in cysts of target tissue (liver or kidney) 
may indicate modifiers or novel genes at the germline level which contribute to monoclonal 
hyperproliferation of cholangiocytes in congenital and sporadic cysts. 
It is likely that more disrupted gene products are involved in PLD, because multiple 
pathways and modifiers affecting cystogenesis are identified. These reasons might explain 
similarities and differences in clinical presentation. For example, the polycystins are 
functionally part of similar signaling pathways. A recent study in animal models provided 
functional evidence for presence of trans-heterozygous mechanisms in PLD. Reduced 
hepatocystin or Sec63p expression leads to hepatic and renal cystogenesis, but also affects 
the functional polycystin complex. These data provide evidence for a PLD protein network 
responsible for cystogenesis. Perturbation of polycystin-1 levels regulate the disease severity 
in a dosage-related fashion.39
CONCLUDING REMARKS
The nature of individual cyst formation has been associated with genetic mechanisms that 
are common in tumorgenesis. For initiation and promotion of a malignant or benign tumor, 
more than 1 mutation is required.6, 19 In case of a hepatic cyst, both alleles of PLD-related 
genes are inactivated by a two-step process. The first hit is the inherited mutation present 
in the germline and the second hit is the onset of somatic events. Somatic hits can cover the 
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spectrum from missense mutations to LOH. A fine example is the situation in liver cyst tissue 
from PRKCSH mutation carriers with a high LOH rate of 76%.34 
There is a high variability of liver phenotype in PLD patients that are of similar sex, age and 
share identical germline mutations. The focal character of intra-familial variability in PLD may 
be explained at least partially by genetic mechanisms at the somatic level. This paper lists the 
evidence supporting that inactivation of 2 PLD-gene copies underlies hepatic cyst formation. 
Development of multiple fluid-filled cysts expands over time and affects the normal 
biliary architecture. These processes are influenced by age, gender (hormones), somatic hit 
rate and frequency, but probably also a significant dosage effect through accumulation of 
multiple mutations.18, 39, 40 
The genetic threshold is low in inherited PLD because there exists already loss of 1 allele. On 
the other hand, somatic inactivation of 2 PLD alleles is also possible and in those cases isolated 
cysts arise. Both modes result in clonally proliferation, growth and individual cyst formation. 
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SOMATIC LOSS OF ALLELES FROM HEPATIC 
CYST EPITHELIUM IDENTIFIES CANDIDATE 
GENES IN POLYCYSTIC LIVER DISEASE
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ABSTRACT
Autosomal dominant polycystic liver disease (PCLD) is characterized by presence of multiple 
fluid-filled hepatic cysts. Germline mutations in PRKCSH, SEC63 or LRP5 underlie ~20% of 
PCLD cases and despite ubiquitous gene expression, the phenotype is restricted to the liver. 
We hypothesized that the second allele of these genes is affected by a somatic mutation in 
the cyst epithelium, as previously shown for PRKCSH cases. Identifying regions underlying 
somatic loss of heterozygosity (LOH) may also be a method to identify novel PCLD genes. 
Somatic LOH in cyst fluids can be detected by genome-wide SNP microarrays and may therefore 
directly point to the location of the germline mutation (the first hit). 
We collected cyst fluid samples from patients with isolated hepatic cysts. Cyst fluid samples 
were obtained by aspiration sclerotherapy and subjected to centrifugation, cytokeratin-19 
staining and fluorescent-activated cell sorting of cholangiocytes. Only cyst fluid with a lucid, 
clear content was eligible to process for further analysis and thus for a subset of 8 cases 
flow-sorted cells were lysed and DNA was amplified using whole-genome-amplification. 
Genome-wide SNP analysis followed to identify regions with somatic LOH after comparison 
with array results of genomic, blood-derived DNA. 
Here, we identified large somatic LOH events in 2 out of 8 cases; one case harboring a 
heterozygous pathogenic PRKCSH mutation and a somatic LOH encompassing the PRKCSH 
gene; one other case presenting with a large LOH of chromosome 16p encompassing PKD1 
and several other genes. Surprisingly, we also identified several large germline events in 
some cases. In one patient we identified a 2.9Mb deletion as well as two large regions of 
homozygosity. We speculate that either the CNV itself or a homozygous point mutation 
may be involved in the PCLD phenotype of this patient. To address the latter, whole-exome 
sequencing of genomic DNA was applied.
Keywords
Polycystic liver disease; Cholangiocytes; Cell sorting; Loss of heterozygosity; Microarray; 
Candidate genes
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INTRODUCTION
Isolated polycystic liver disease (PCLD) is an autosomal dominantly inherited disorder characterized 
by the progressive development of multiple biliary epithelial liver cysts.1 A heterozygous germline 
mutation in the PRKCSH, SEC63 or LRP5 gene cause polycystic livers in about ~20% of PCLD 
patients.2-6 The molecular mechanism of hepatic cystogenesis is recessive on the cellular level 
for PRKCSH and SEC63 mutation carriers. Loss of the second, wild-type PRKCSH or SEC63 allele 
in hepatic cyst epithelium may initiate cyst formation in these patients.7, 8 
Approximately ~80% of PCLD patients harbor no PRKCSH, SEC63 or LRP5 mutations by 
extensive direct Sanger sequencing.6, 9 PCLD is genetically heterogeneous and it is likely that 
at least one more gene is associated with hepatic cystogenesis.6, 9 PCLD candidate genes may 
correspond to characteristics of known PCLD protein products such as hepatocystin and Sec63p 
located at the endoplasmic reticulum.1 In addition, the Wnt signaling which is associated with 
LRP5 and DKK3, but also other biological pathways may reveal new genes related to PCLD.10
Micro-dissected hepatic cyst epithelium from PRKCSH and SEC63 carriers presented loss 
of heterozygosity (LOH).7, 8 We hypothesized that this ‘two-hit model’ is a general principle 
for development of hepatic cysts in PCLD. Therefore, somatically deleted alleles in hepatic 
cyst epithelium may also occur for yet unknown PCLD genes. Loss of somatic allele copies in 
cyst fluid-derived epithelium cells, which can be detected by genome-wide SNP microarrays, 
may directly point to the location of the germline mutation. When validated in other cohorts, 
these data may lead to novel PCLD genes and new pathways associated with the pathogenesis 
of polycystic livers.
Another approach with the similar aim to identify candidate genes was successfully applied 
for related disorders such as autosomal dominant polycystic kidney disease (ADPKD). In order 
to elucidate molecular pathways involved in ADPKD, microarray studies of renal epithelial 
cells profiled expression levels of numerous candidate genes.11-13 Aberrant DKK3 expression 
directed to identification of 3 SNPs in the DKK3 gene modifying disease progression in PKD1 
affected ADPKD patients.13 
In this study we report a novel approach for the identification of PCLD genes. These 
findings may give clues for further genetic analysis.
MATERIALS AND METHODS
Patients and Samples
Symptomatic PCLD patients were referred to our hospital for aspiration sclerotherapy.14 We 
collected 68 cyst fluid aspirates from 50 unrelated PCLD patients between January 2011 
to December 2012. Only lucid, clear fluids could be used for further processing and thus 8 
samples remained. Written informed consent from all subjects and ethical approval from the 
Medical Ethics Committee of the Radboudumc, The Netherlands was obtained.
SkChA-1 cells
For technical performance of immunofluorescence staining and cell counting assays the 
SkChA-1 cell line was used for test runs, protocol settings and as control sample for processing 
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cyst fluid samples.15 SkChA-1 cells were cultured in DMEM supplemented with 10% FCS FCS 
(Life Technologies, Carlsbad CA).
Protocol Cholangiocyte Isolation
Processing cyst fluid
Cyst fluid aspirates were collected in a sterile environment and processed directly after the 
invasive procedure. The total amount of cyst fluid was equally divided in 50ml Falcon tubes for 
subsequent centrifugation. After 15 min 2,500rpm centrifugation, pellets were resuspended in 
a small aliquot of cyst fluid and transferred to 3ml tubes. Supernatant was manually eliminated. 
In case of total cyst fluid ≥200 ml, a maximum of 2 pellets derived from each 50ml cyst fluid, 
were combined in one 3ml tube.
Staining hepatic cyst cholangiocytes
For fixation 100µl medium A (Fix, Life Technologies) was added to the pellet and placed in the 
dark at room temperature for 20 minutes. A negative control (no medium A) and a positive 
control (SkChA-1 cells with medium A) was included during each run. Cells were washed with 
2ml 0.5% BSA/PBS. Subsequently, after 5 minutes 500rpm centrifugation, supernatant was 
discharged. 100µl medium B (Perm, Life Technologies) with 1:100 diluted cholangiocyte marker 
anti-cytokeratin-19 (MU246-UC, mouse monoclonal, LOT MU2460706, Biogenex,Fremont 
CA)16 in 0.5% BSA/PBS was added. The samples were placed in the dark at room temperature 
for 30 minutes. The washing step with 2ml 0.5% BSA/PBS, centrifugation and supernatant 
removal was repeated twice. After incubation of 100µl with 1:200 diluted FITC antibody 
(anti-mouse, Abcam, Cambridge UK) during 15 minutes washing and centrifugation steps, 
the pellet was resuspended in 150-300µl 0.5% BSA/PBS. 
Cell counting assays
A first fluorescent cell sorting measurement for cell quality performance was conducted by 
Cyan analysis (Beckman Coulter, Brea CA). Subsequently, the cytokeratin-19 positive cells were 
sorted by a five-colour flow cytometry (FC500) according to a standardized protocol established 
during test settings (Beckman Coulter). Negative controls were routinely included. Cytokeratin-19 
positive cells (cholangiocytes) were collected in 50-100µl 0.5% BSA/PBS and stored at -20°C.
Cell lysis and whole genome amplification
For 8 cases hepatic cyst DNA isolation and amplification of all samples were processed 
simultaneously. Cell lysation and DNA amplification was performed using whole-genome-
amplification (WGA, Repli-G single cell kit, Qiagen, Hilden Germany).17 
DNA Isolation and Sanger sequencing
Genomic DNA was extracted from blood leukocytes using the HP-PCR Template Preparation 
kit (Roche Applied Science, Penzberg Germany). PCR products from 8 subjects for all exons 
of the PRKCSH, SEC63 and LRP5 genes were analyzed by traditional Sanger sequencing on 
ABI310 or ABI3100 Genetic Analyzers (Applied Biosystems, Carlsbad, CA). 
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Genetic Analysis by Microarray and Whole-Exome Sequencing
Whole genome amplified DNA from hepatic cyst cells and genomic DNA from all 8 patients 
were analyzed using the CytoScan Genome-Wide Human SNP array (Affymetrix, Santa 
Clara CA). Capture of exomes from patient #1 was performed using Agilent’s v4 (50Mb) 
exomes, and SOLiD sequencing (5500XL sequencer; Life Technologies). Sequence reads were 
mapped to the reference human genome (hg19) using LifeScope v2.1 (Life Technologies). 
Called variants were annotated with an in-house pipeline containing information from 
dbSNP134.18, 19 We restricted our analysis to rare homozygous variants, encompassing 
regions of homozygosity that were identified in patient 1. Variant filtering was applied as 
previously reported.19-22 In brief, we only selected non-synonymous variants affecting coding 
exons and canonical splice sites in chromosome 3, 9 and 13. Rare variants (frequency of 
<0.25% in both dbSNP134 and our in-house database containing >5,000 exomes) with 
high quality were analyzed.
Data Analysis
Per case all large regions of homozygosity of the autosomes (>3.0Mb) and large CNVs (>1.0Mb) 
were considered in the cyst-derived DNAs. Regions spanning the centromere were excluded 
because of the high degree of false positive findings. For each case a comparison of the array 
results derived from cyst cell DNA (somatic) and germline DNA (genomic) was performed to 
ensure the identification of somatic events. Genes in LOH >3.0Mb were prioritized by Mouse 
Genome Database (MGD) with the criteria phenotype (liver/ biliary phenotype, tumorgenesis 
or growth/ size phenotype, and (fetal) liver tissue expression (Genedistiller) for filtering and 
analyzing of possible candidate genes.23 Unexpectedly, large germline events, i.e. CNVs >1.0Mb 
and regions of autozygosity (>5.0Mb) were also further addressed. 
RESULTS
Patient Characteristics
From eight unrelated patients with a clinical diagnosis of PCLD cyst fluid was processed and 
hepatic cyst cholangiocytes were isolated (Table S1 and S2). All patients had severe symptoms 
and the mean age was 58 (range 44-83) years (Supplementary Text). One patient (patient #8) 
harbored a pathogenic mutation, PRKCSH c.292+1G>C (p.D98AfsX100). The remaining seven 
patients showed no causative mutation on the PRKCSH, SEC63 or LRP5 gene. Consanguinity 
was not reported in these affected individuals.
Performance of Cholangiocyte Sorting
In 89% of the aspiration procedures the cyst fluid was turbid or contaminated. The first hepatic 
cyst aspiration in patients frequently generates elucidated cyst fluid without macroscopic 
contaminants, or many blood or bile. This is the most favorable material for the work-up of 
cholangiocyte isolation. Hundreds to thousands cells were sorted.
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Large Somatic LOH Identified Hepatic Cyst DNA
Patient #8 with germline PRKCSH mutation presented a large somatic LOH encompassing the 
PRKCSH conform with the second-hit hypothesis (Table 1). The only other obvious somatic 
hit identified >30Mb homozygous region of chromosome 16p in patient #7. Because our 
patients had no renal disease or extra-renal ADPKD symptoms, we prioritized genes associated 
with these somatic events according to tumorgenesis, growth/ size and liver/ biliary mouse 
phenotype, and (fetal) liver expression.
Large Germline Events
Our analysis also allowed the identification of large germline events. Remarkably, we identified 
a large CNV (2.9Mb) in patient #1 as well as several regions of homozygosity. This CNV in 
chromosome 9 has a low frequency in a normal, healthy cohort. Also in patient #7 we identified 
large regions of homozygosity in the blood derived DNA (Table 2). 
Table 1. Identified mosaic 16p-isochromosome and LOH region in somatic DNA. Highly interesting 
genes are indicated in bold. *Selected genes by Genedistiller (criteria: MGD phenotype liver/biliary, 
growth/size or tumorgenesis, and (fetal) liver expression)22
Pt
Sample 
g.DNA
Sample cyst 
DNA Chr. Candidate genes*
Region 
cyst 
Size 
(Mb)
7 PN01-1296 PN01-1128 16p LMF1, SOX8, SSTR5, CACHA1H, 
CLCN7, IGFALS, MSRB1, TSC2, PKD1, 
MLST8, E4F1, DNASE1L2, CCNF, 
PDPK1, CLCN6, TNFRSF12A, MEFV, 
CLUAP1, NLRC3, SLX4, CREBBP, 
VASN, DNAJA3, MGRN1, RBFOX1, 
PMM2, USP7, CLEC16A, SOCS1, 
ERCC4, MKL2, NTAN1, RRN3, MYH11, 
SMG1, COQ7, UMOD, SCNN1G, 
SCNN1B, GGA2, PALB2, PLK1, 
CACNG3, RBBP6, KDM8, IL4R, EIF3CL, 
CLN3, EIF3C, SH2B1, CD19, LAT, 
SPN, TAOK2, TBX6, MAPK3, MYLPF, 
ITGAL, CTF1, HSD3B7, BCKDK, KAT8, 
PRSS8, FUS, PYCARD, SLC5A2
LOH cyst 
complete 
16p
 34.6
8 PN01-1107 PN01-1108 19p13.3-
13.11
PTPRS, SAFB, MLLT1, C3, INSR, 
MCOLN1, PNPLA6, RETN, CLEC4G, 
MAP2K7, ELAVL1, CCL25, ANGPTL4, 
PIN1, COL5A3, ANGPLT6, DNMT1, 
S1PR2, ICAM1, TYK2, KEAP1, 
CDKN2D, ILF3, DNM2, CARM1, 
SMARCA4, LDLR, RAB3D, EPOR, 
PRKCSH, ECSIT, MAN2B1, JUNB, 
DNASE2, KLF1, FARSA, CALR, 
GADD45GIP1, DAND5, NFIX, 
CACNA1A, CC2D1A, RLN3, IL27RA, 
PRKACA, PTGER1, GIPC1, NOTCH3, 
BRD4, PGLYRP2, RAB8A, KLF2, SIN3B, 
PLVAP
LOH cyst 12.9
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Whole-Exome Sequencing
Because microarrays of blood-derived DNA showed large homozygous regions in patient #1, 
whole-exome sequencing of this genomic DNA was performed. These homozygous regions 
may indicate a candidate region for a recessive PCLD gene. Whole-exome sequencing in patient 
#1 showed 96% with ≥20x coverage, and captured the genetic alterations in chromosome 
3, 9 and 13. These large regions of homozygosity presented no unique homozygous variant 
in genomic DNA.
Loss of Heterozygosity Reveals Possible Candidate Genes
Our analysis indicated several possible candidate genes for hepatic cystogenesis based on 
protein expression, function and/ or pathway. These findings are explained in the discussion.
DISCUSSION
This study describes the processes to obtain DNA of hepatic cyst epithelium cells from cyst 
fluids in PCLD patients for further studies. Genome-wide analysis showed large somatic 
changes such as LOH in chromosome 19p and 16p in two cases. In addition, surprisingly 
large germline events were identified. Large regions of homozygosity may be used to map 
possible novel recessive candidate genes in sporadic cases. This study shows that genome-
wide analysis in somatic and genomic DNA is an alternative tool that may assess mechanisms 
of cyst formation as well as identification of candidate genes with the first hit. 
Table 2. Identified large CNV and LOH regions in genomic DNA. Highly interesting genes are 
indicated in bold.
Pt
Sample 
g.DNA
Sample 
cyst DNA Chr. Candidate genes* Region cyst 
Size 
(Mb)
1 PN01-1290 PN01-1124 3p22.1-
21.1
CTNNB1, ULK1, VIPR1, CYP8B1, 
ABHD5, CDCP1, CXCR6, CCR1, 
CCR2, CCR5, LTF, TMIE, PTH1R, 
SETD2, PTPN23, SCAP, CDC25A, 
TREX1, COL7A1, CELSR3, IP6K3, 
ARIH2, LAMB2, GPX1, DAG1, 
MST1, IP6K1, TRAIP, SEMA3F, 
GNAI2, HYAL1, HYAL2, TUSC2, 
RASSF1, CACNA2D2, RAD54L2, 
RPL29, ALAS1, BAP1, STAB1, 
PBRM1
Homozygous 
region in 
genomic DNA
12.7
1 PN01-1290 PN01-1124 9q22.2-
22.31
SYK, NFIL3, ROR2 Large 
germline CNV
2.9
1 PN01-1290 PN01-1124 13q22.1-
31.1
TBC1D4, UCHL3, LMO7, MYCBP2, 
EDNRB
Homozygous 
region in 
genomic DNA
5.4
7 PN01-1296 PN01-1128 1p33-32.3 TAL, STIL,CDKN2C, NRD1, 
RAB3B, ZCCHC11, GPX7, SCP2, 
MAGOH, LRP8, DIO1, HSPB11
Homozygous 
region in 
genomic DNA
6.9
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Second hits are postulated as the general molecular mechanism for hepatic and renal cyst 
formation in ADPKD.23-25 Recently, this loss-of-function model is described to be identical for 
hepatic cystogenesis in PCLD affected individuals.7, 8 All these previous studies used surgical 
tissue sections to analyze hepatic and renal cyst DNA. These invasive cyst fenestrations are 
rather infrequent because in each patient the clinical indication and individual advantages of 
this procedure is highly considered. In addition, there exists a high risk of surgical complications 
in contrast to the less invasive hepatic cyst aspirations. Therefore, we choose for hepatic 
cyst fluids to extract cyst-lining epithelium cells (cholangiocytes) for genome-wide analysis. 
Subsequently, we expected to indirectly assess novel PCLD candidate genes. 
One PCLD patient (#8) harbored a pathogenic mutation in the PRKCSH gene (c.292+1G>C, 
p.D98AfsX100). Hepatic cyst DNA from patient #8 presented a large LOH of 12.9Mb 
encompassing the PRKCSH gene. Sanger sequencing of the somatic DNA identified that 
PRKCSH c.292+1G>C was present in a homozygous state. This finding is in line with previous 
reports of somatic loss in polycystic livers. In 76% of PRKCSH mutation carriers a somatic 
second hit is present in hepatic cysts. This mechanism was previously described in cases with 
PRKCSH cases by hepatic cyst tissue studies8, but can serve as a proof-of-concept here. This 
study is furthermore the first presenting cases in which cyst fluid derived cells were used 
to show this. Only a small clear aliquot of cyst fluid is sufficient for the work-up. Next, we 
assessed the somatic and genomic DNA in seven PCLD patients without pathogenic variants 
in PRKCSH, SEC63 and LRP5.
Genome-wide study of chromosome 16p in patient #7 demonstrated extremely diminished 
heterozygous calls indicating complete homozygosity of the short arm (Figure 1A). Interestingly, 
this mosaic loss of 16p reveals multiple genes associated with cystogenesis. It includes a known 
ADPKD gene, PKD1, but also genes directed to the pathophysiology. For example, the SSTR5 
gene encodes for the somatostatin receptor which is currently the target of non-invasive 
management by somatostatin analogues. 
Another interesting finding is a smaller somatic LOH region (~3Mb) in patient #6. This 
included identification of the CHD1 gene which encodes for E-cadherin. This protein functions 
as a calcium-dependent cell-cell adhesion molecule with pivotal roles in epithelial cell behavior, 
tissue formation, and suppression of cancer. Previous histology studies identified loss of the 
E-cadherin protein in hepatic cyst tissue sections derived from PCLD patients.23 
Following genome-wide study of somatic events, we assessed large CNVs and homozygous 
regions in germline DNA. Firstly, patient #1 showed multiple homozygous regions of which 
the largest is 12.7Mb on chromosome 3p22.1-21.1 (Figure 2). This region showed selected 
genes which may be relevant for hepatic and/ or renal cystogenesis. For example, the 
CTNNB1 gene encodes a central protein in the Wnt signaling and controls cell proliferation 
and differentiation. Previous studies reported that β-catenin interacts with polycystin-1 
through the ubiquitin-dependent proteasome pathway.26 Secondly, for the CDC25A gene is 
reported that protein overexpression leads to hepatic cystogenesis. Cell cycle progression and 
hyperproliferation can be targeted by Cdc25A blockers, for example vitamin K3 suppletion 
in rodent models.25 In addition, the 5.4Mb homozygous region included detection of the 
EDNRB gene which is reported in rodent models as a major modifying factor for cystic disease 
progression in ADPKD.27
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Surprisingly, we also identified a very large CNV loss of chromosome 9 (2.9Mb) in patient 
#1. This deletion encompasses three genes associated with tumorgenesis, growth/ size and/ 
or liver phenotype, including ROR2. Deletions of this region and size are extremely rare, and 
make it a possible candidate region for a novel dominant PCLD gene. Although we have no 
direct proof that this deletion is causally linked to the PCLD phenotype, ROR2 is a known 
protein in the Wnt signaling pathway and somatic loss has been described in tumorgenesis. 
A reduced expression of the tumor suppressor gene ROR2 in hepatocellular carcinoma tissue 
sections was identified leading to impaired canonical Wnt signaling.28 
A large homozygous region of 6.9Mb revealed multiple candidate genes relevant for 
cystogenesis in patient #7. CDKN2C is a tumor suppressor gene which contributes to medullary 
Figure 1. Microarray detection from hepatic cyst epithelium cells-derived DNA. (A) Microarray 
of chromosome 16 from germline DNA in patient #7. (B) Chromosome 16p with somatic LOH in patient 
#7. (C) Chromosome 19 from blood-derived DNA in patient #8. (D) Homozygous region in hepatic cyst 
DNA from patient #8 with a germline PRKCSH mutation. The numbers 1 to 3 chronologically indicate 
B-allele frequency, chromosomal position and LOH call.
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Figure 2. Microarray detection from blood-derived DNA. (A) A large CNV of 2.9Mb on chromosome 
9 in patient #1. (B) Homozygous region of 12.7Mb on chromosome 3 in patient #1. (C) Homozygous 
region of 5.4Mb on chromosome 13 in patient #1. (D) Homozygous region of 6.9Mb on chromosome 
1 in patient #7. The numbers 1 to 4 chronologically indicate the log2 intensity ratio, LOH calls, B-allele 
frequency and the chromosomal position.
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thyroid carcinoma, Hodgkin lymphoma and feochromocytoma for example.29 Somatic loss 
of CDKN2C suggests a direct role of selective growth advantages.
PCLD classically develops through a germline mutation in an autosomal dominant fashion. 
Although the hepatic cystogenesis is a developmental process, somatic DNA alterations may 
be early events in PCLD without onset of symptoms. Our findings present a high frequency of 
homozygosity in germline DNA. This is a remarkable finding in the normal human population. 
If patients indeed stem from non-consanguine parents, the genes in these homozygous 
regions may have a role as a recessive gene. 
We explored the somatic and genomic DNA of 8 unrelated PCLD patients. Our findings 
indicate a role for multiple mechanisms of cyst formation and methods for gene discovery. 
We believe that the molecular mechanism of hepatic cystogenesis is a loss-of-function model. 
Dissection of relevant genes in PCLD is a major issue to understand the pathophysiology. The 
role of genes associated with tumorgenesis is unclear. A multistep process of cystogenesis is 
not excluded because at which stage the second, somatic event occurs is unknown. These 
somatic genetic aberrations may present early in life or later. Therefore, genomic alterations 
may explain the heterogeneity in PCLD patients. 
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SUPPLEMENTARY TEXT
Clinical Characteristics of Polycystic Liver Disease Patients
Patient #1
Four years ago this male patient presented to us with acute abdominal pain. For already 
five years he had abdominal distension with mechanical symptoms, dyspnea d’effort and 
early satiety. At the age of 37-year-old he had an acute myocardial infarct. He administered 
a β-blocker to control hypertension. There was a positive family history of polycystic liver 
disease in his mother and a cousin. Abdominal ultrasonography showed a polycystic liver with 
several small cortical cysts in both kidneys. Theoretically, these clinical features correspond 
to the ADPKD criteria.
He underwent two times an aspiration sclerotherapy at the age of 57 and enrolled the 
ELATE trial in 2010.30, 31 During this clinical trial he was treated with octreotide (40mg/ 28days) 
and everolimus (2.5mg/ day) for 12 months. Next, he developed symptoms of a large hepatic 
cyst. After completion of the ELATE trial, aspiration sclerotherapy was indicated. The collected 
cyst fluid was proceeded for this study. In addition, he was treated again with a somatostatin 
analogue, lanreotide 120mg/ 28 days during the 6-month RESOLVE trial.32  
Molecular diagnostics of both PCLD genes, PRKCSH and SEC63, identified no pathogenic 
variants.
Patient #7
This 82-year-old female from Indonesian origin presented increased abdominal distension. Her 
hypertension is under control using a calcium antagonist combined with a selective type 1 
angiotensine II-receptor-antagonist and hydrochlorothiazide. The family history for polycystic 
diseases is negative. Both parents died when they reached the age of 90. She had no history 
of clinical important diseases and delivered 12 children. Presence of polycystic liver disease in 
these individuals is unknown. Two daughters died because of colon cancer or cervix cancer.
CT scanning showed a polycystic liver with large hepatic cysts. One large cyst was 15.1 x 
11.2 x 11.6cm and located ventral. Another large, dorsal cyst measured 15.4 x 11.3 x 12.0cm. 
In addition, a multi-septal cyst (size 12 x 13 x 9cm) in the right kidney was present. 
This patient was referred for aspiration sclerotherapy. Drainage of two cysts was performed 
which resulted in 200ml lucid, achromatic cyst fluid and 800ml lucid, brown cyst fluid. The 
first aspirate was pursued for this study. No further treatment was indicated.
Molecular diagnostics of both PCLD genes, PRKCSH and SEC63, identified no pathogenic 
variants.
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Patient #8
A 44-year-old female patient presented to us with episodes of acute abdominal pain and 
pyrosis. Clinical examination revealed hepatomegaly and palpable abdominal swelling. 
Ultrasonography showed multiple cyst spread throughout the liver. Mechanical symptoms 
increased and she was referred for aspiration sclerotherapy of the largest cyst (13.3 x 12.3cm). 
No further treatment was indicated.
Her family history was negative for polycystic liver disease, hepatic or renal disease. 
Since family members had no symptoms of hepatic or renal disease, abdominal screening 
for polycystic diseases was not performed. In addition, the children were younger than 18-
years-old. Molecular diagnostics identified germline mutation c.292+1G>C in exon 4 of the 
PRKCSH gene.2 This mutation is a known pathogenic variant. Segregation analysis was not 
performed in asymptomatic family members.
SUPPLEMENTARY FIGURES
Figure S1. PCLD patient #1. (A) Pedigree of patient #1 indicated by an arrow. Squares indicate male 
sex, and circles indicate female sex. Solid symbols denote affected individuals, and open symbols are 
individuals without or unknown for PCLD. A slash indicates that the individual is deceased. (B) Positioning 
of the drain in the hepatic cyst during  the aspiration sclerotherapy procedure. (C) Axial CT scan before 
aspiration sclerotherapy. (D) Coronal CT scan before aspiration sclerotherapy. The treated cysts are 
indicated by a white arrow.
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Figure S2. PCLD patient #7. (A) Pedigree of patient #7 indicated by an arrow. (B) Axial and coronal CT 
scanning of patient #7 indicating large hepatic cysts by white vertical arrows. Horizontal white arrows 
indicate a large renal cyst.
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Figure S3. PCLD patient #8.  (A) Pedigree of patient #8 indicated by an arrow. (B) Axial CT scan of 
patient #8. The third figure shows an abdominal ultrasound of the large hepatic cyst.
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Table S1. Overview of collected hepatic cyst fluid samples.
Patient Cyst fluid sample Volume cyst fluid (ml) Aspect of the cyst fluid Sorted cells (n)
1. 242 1,020 Lucid, light-brownish 125,000
2. 247 290 Lucid, light-yellow 13,000
3. 250 70 Lucid, light-yellow 5,000
4. 253 1,300 Lucid, light-yellow 16,000
5. 264 2,400 Lucid, light-yellow 3,800
6. 266 1,100 Lucid, light-orange 25,000
7. 268 3,650 Lucid, achromatic 2,200
8. 274 490 Lucid, light-brown 8,500
Table S2. Patient characteristics per cyst fluid sample. *Age at aspiration sclerotherapy
Patient
Cyst fluid 
Sample no.
Sex 
(M/F)
Age 
(y)* Liver and kidney phenotype
Germline 
mutation
1. 242 M 61 Severe polycystic liver; bilateral cortical renal 
cysts
WT
2. 247 F 58 Polycystic liver; cortical right renal cyst WT
3. 250 F 60 Polycystic liver WT
4. 253 F 50 Severe polycystic liver WT
5. 264 F 59 Polycystic liver, large hepatic cyst WT
6. 266 F 55 Polycystic liver, large hepatic cyst WT
7. 268 F 83 Polycystic liver, large hepatic cysts, large renal 
cyst
WT
8. 274 F 44 Polycystic liver, large hepatic cysts PRKCSH 
c.292+1G>C
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ABSTRACT 
Polycystic livers are seen in the rare inherited disorder isolated polycystic liver disease (PCLD) 
and are recognized as the most common extrarenal manifestation in autosomal dominant 
polycystic kidney disease (ADPKD). Hepatic cystogenesis is characterized by progressive 
proliferation of cholangiocytes, ultimately causing hepatomegaly. Genetically, polycystic liver 
disease is a heterogeneous disorder with incomplete penetrance and caused by mutations in 
PRKCSH, SEC63, PKD1 or PKD2. Genome-wide SNP-typing and Sanger sequencing revealed 
no pathogenic variants in hitherto genes in an extended PCLD family. We performed whole-
exome sequencing of DNA samples from two members. A heterozygous variant c.3562C>T 
located at a highly conserved amino acid position (p.R1188W) in the low density lipoprotein 
receptor-related protein 5 (LRP5) gene segregated with the disease (logarithm of odds score 
4.62), but was not observed in more than 1,000 unaffected individuals. Screening of LRP5 in 
a PCLD cohort identified three additional mutations in three unrelated families with polycystic 
livers (p.V454M, p.R1529S, p.D1551N), again all undetected in controls. All variants were 
predicted to be damaging with profound structural effects on LRP5 protein domains. Liver 
cyst tissue and normal hepatic tissue samples from patients and controls showed abundant 
LRP5 expression by immunohistochemistry. Functional activity analyses indicated that mutant 
LRP5 led to reduced wingless signal activation. In conclusion, we demonstrate that germline 
LRP5 missense mutations are associated with hepatic cystogenesis. The findings presented 
in this study link the pathophysiology of PCLD to deregulation of the canonical wingless 
signaling pathway. 
Keywords
Polycystic liver disease; Hepatomegaly; Whole-exome sequencing; Lipoprotein; 
Wingless signaling
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INTRODUCTION  
Polycystic liver diseases (PLD) consists of a group of inherited disorders characterized by 
abnormal proliferation and differentiation of bile duct epithelium.1 Ductal plate malformation 
results in development of multiple fluid-filled cysts spread throughout the liver parenchyma. 
Progressive hepatic cystogenesis and cyst growth cause hepatomegaly and symptoms such 
as abdominal distension and pain, pyrosis, anorexia and dyspnea.
Congenital PLD are clinically heterogeneous and two major types can be distinguished. 
Autosomal dominant polycystic kidney disease (ADPKD) is a potentially lethal condition 
afflicting about 1:400 to 1:1,000 persons in the United States.2 Patients may develop end-stage 
renal disease resulting from polycystic kidneys and 83% have the simultaneous presence of 
multiple hepatic cysts.3 Formal diagnostic criteria for ADPKD include age, number of renal 
cysts for each kidney, and family history of renal disease.4, 5 Isolated polycystic liver disease 
(PCLD) shares the phenotype of a polycystic liver, but is distinct from ADPKD because renal 
disease is absent.6 Some patients may, however, have sporadic renal cysts. Diagnosis of PCLD 
is made by a family history consistent with autosomal dominant inheritance and presence of 
at least one (<40 years) or more than three (>40 years) hepatic cysts.7 
The natural course of PCLD and ADPKD depends on a spectrum of factors that include 
age, sex, contraceptives, pregnancy and mutation(s).8-10 Classical linkage analysis has identified 
four genes that underlie both inherited disorders. Mutations in polycystic kidney disease 
1 or 2 (PKD1 or PKD2) genes (NM_601313 and NM_173910, respectively), which encode 
polycystin-1 and polycystin-2, are responsible for almost all ADPKD cases.11-13 Both proteins 
are located in the cilium and are important in renal tubular cell morphogenesis and signaling 
functions, including the wingless (Wnt) signaling pathway (β-catenin pathway). Mutations 
in protein kinase C substrate 80K-H (PRKCSH) and Saccharomyces cerevisiae homolog 63 
(SEC63) are linked to PCLD (NM_002743.2 and NM_007214.4, respectively), and both gene 
products are located to the endoplasmic reticulum and are involved in processing and folding 
of glycosylated proteins.14-16 In addition, the canonical Wnt signaling may be deregulated 
by the interaction partner nucleoredoxin of the Sec63 protein during oxidative stress.17 In 
contrast to ADPKD, only 25% of PCLD cases can be explained by mutations in already known 
genes18, indicating that mutations in several other as yet unidentified genes are involved 
in this disease. We hypothesized that another PCLD gene is involved in an extended PCLD 
family negative for the known disease genes and performed whole-exome sequencing. This 
unique approach has proven to be successful for the identification of the genetic cause of 
other Mendelian disorders.19-21
MATERIALS AND METHODS
Human Subjects
Ultrasound images of liver and kidneys were acquired using a 3.6-MHz general purpose clinical 
echo system (Acuson x150, SiemensAG) equipped with a curved linear array transducer. Blood 
samples were collected from all 40 subjects and DNA was extracted from blood leukocytes 
using the HP-PCR Template Preparation Kit (Roche Applied Science). Formalin-fixed paraffin-
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embedded liver cyst tissue specimens were available from proband III/18 after laparoscopic cyst 
fenestration. DNA samples from 1,000 Dutch and 525 Moroccan healthy unrelated individuals 
were used as controls. All subjects provided written informed consent for all investigations. 
This study was approved by the Medical Ethics Committee of the Radboud university medical 
center, The Netherlands.  
Sanger Sequencing
PCR products of proband III/18 for all exons of the PRKCSH, SEC63, PKD1, PKD2 genes were 
analyzed by traditional Sanger sequencing on ABI310 or ABI3100 Genetic Analyzers (Applied 
Biosystems). Complete sequence analysis for PKD1 variants was conducted by an experienced 
Center (Bioscientia). Exon and exon-intron boundaries of LRP5 were determined using the 
Genome Bioinformatics Group of University of California, Santa Cruz (UCSC) Genome Browser, 
and unique primers were designed (Primer3). Heterozygous changes in LRP5 were detected by 
high-resolution melting curves (RotorGene-Q; Qiagen) and validated by Sanger sequencing. 
Genome Wide Copy Number Variation Analysis
DNA from whole blood was analyzed on the CytoScanHD which contains 2.6 million probes 
(Affymetrix). Hybridizations were performed according to the manufacturer’s protocol. 
Genotype calls and copy number variation analysis were made using Affymetrix Chromosome 
Analysis Suite v1.2.0.225. 
Whole-Exome Sequencing
Exome enrichment was performed using the SureSelect Human All Exon 50-Mb Kit (Agilent), 
covering ~23,000 genes. Emulsion PCR and bead preparation were made by using the EZbead 
system according to the manufacturer’s instructions followed by SOLiD4 sequencing (Life 
Technologies). Reads were mapped to the hg19 reference genome using SOLiD Bioscope 
software v1.3 and annotated as described previously.19, 20 All nonsynonymous variants shared 
in both affected individuals, absent or with very low frequency in dbSNP, were tested and 
validated in healthy and affected members of PCLD-1 family for cosegregation by high-
resolution melting curve analysis and Sanger sequencing.
Linkage Analysis
We calculated the two-point logarithm of odds (LOD) score for linkage in the extended family 
using the SuperLink-v1.6 program in EasyLinkage-v5.08 software package. To determine 
the actual two-point LOD score for the LRP5 mutation that was detected in this family, the 
mutation was considered to be a microsatellite marker in close proximity of LRP5 (D11S4117). 
An autosomal dominant mode of inheritance was assumed with a penetrance of ~80%, and 
the disease allele frequency was estimated at 0.0001 (Supplementary Text).
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Clinical Investigations
Because LRP5 mutations are associated with bone density disorder, metabolic and ocular 
developmental diseases, we performed additional clinical investigations of members from 
the PCLD-1 family with a clear genotype-phenotype relation. An ophthalmologist (C.E.N.) 
performed an eye examination by a slit lamp to exclude retinal disorders such as familial 
exudative vitreoretinopathy (FEVR). At the same time, we analyzed metabolic and renal 
parameters in blood from these 22 individuals of the PCLD-1 family. We assessed bone density 
of the lumbar spine and left hip by dual energy X-ray absorptiometry (DXA scan; Hologic 
Discovery A, TROMP). Results are reported as T- and Z-scores which reflect the number of 
standard deviations by which a patient’s value differs from the mean of a group of young or 
age-matched normal controls.
In Silico Analysis and Homology Modeling
We used three computational tools for the prediction of the functional effect of mutational 
variants (PolyPhen-2, Mutpred, and SIFT). LRP5 protein structure was created by using a LRP6 
template as a start homology model and reconstruction by the YASARA&WHAT-IF Twinset. 
PDB files were available as templates for homology modeling of WD40 domains (β-propeller 
subdomains) to incorporate the identified extracellularly located LRP5 mutations. Separate 
models were visualized for analysis of structural effects by YASARA.
Immunohistochemistry Studies
Formalin-fixed paraffin-embedded liver cyst tissue from proband III/18, four unrelated PCLD 
patients with a PRKCSH c.1341-2A>G mutation, and normal human liver tissue were available 
for immunohistochemistry studies. Staining intensity for the presence of LRP5 was compared 
between LPR5 and PRKCSH mutants. 
Expression Constructs
Total RNA was isolated from liver tissue using TRIzol Reagent (Invitrogen), and oligodT cDNA 
was obtained by RT Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Sciences). 
Full-length WT LRP5 was obtained using the Faststart High Fidelity PCR System (Roche). LRP5 
was cloned into the mammalian expression vector pcDNA3.1_V5_His TOPO-TA (Invitrogen) and 
checked by Sanger sequencing. An extracellularly c.3562C>T (p.R1188W) and intracellularly 
located c.4651G>A (p.D1551N) LRP5 construct were generated by mutating the pcDNA.LRP5.
WT vector using the Quick Change-II-XL Site-Directed Mutagenesis Kit (Agilent Technologies). 
Luciferase Activity Assays
We used three cell lines to assess the functional effects of WT and mutant LRP5. For the 
activity assay 5.0x103 Chinese hamster ovary (CHO) cells; 5.0x103 human embryonal kidney 293 
(HEK293) cells; 5.0x103 Human cholangiocyte 69 (H69) cells per well were seeded in a 96-wells 
plate in triplicate. After 24 hours, cells were transiently transfected using X-tremeGeneHD 
(Roche) with 100ng LRP5 construct (LRP5WT; LRP5R1188W; LRP5D1551N), or empty vector and 100ng 
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Figure 1. Identification of LRP5 variants. LRP5 variant p.R1188W in an extended Dutch PCLD-1 family 
(A) and three additional LRP5 variants in three unrelated PCLD families were identified. Generations 
are denoted with Roman numerals, and individuals are numbered in a counterclockwise way. Squares 
indicate male sex, and circles indicate female sex. Solid symbols denote affected individuals, and open 
symbols are individuals without or unknown for PCLD. A slash indicates that the individual is deceased. 
(B) Simplified pedigree from PCLD-1 family with the clinical features by abdominal CT scanning and 
ultrasound of the liver of both probands (III/18 and II/18) in which whole-exome sequencing was performed 
(green arrow). (C) LRP5 is located at chromosome 11q13.2, and the sequence electropherogram shows 
heterozygous germline mutations. (D) All LRP5 missense mutations were located at highly evolutionary 
conserved amino acid regions with ortholog proteins from human to frog.
119
7
LRP5 M
U
TA
TIO
N
S A
N
D
 W
N
T SIG
N
A
LIN
G
 IN
 H
EPA
TIC
 C
Y
STO
G
EN
ESIS
of TCF/LEF1 Reporter, or 100ng negative control according to manufacturer’s instructions 
(Cignal TCF/LEF1 Reporter Assay Kit, Qiagen). Sixteen hours after transfection, medium was 
replaced by medium with or without 250ng/ml human Wnt3a (5036-WN, R&D Systems) 
to initiate Wnt signaling. Cells were cultured for another 24 hours, and luciferase activity 
was detected using the Dual-Glo Luciferase Assay System (Cat. No. E2920, Promega) in an 
InfiniteM200-Pro plate reader (Tecan). Firefly luciferase activity was normalized to Renilla 
luciferase activity for variations in transfection efficiencies. Values are reported as means ± 
standard deviation. These experiments were conducted in triplicate and performed three 
times. Western blotting was also performed to analyze possible differences in expression 
levels between the WT and mutant LRP5.
Quantitative PCR
We conducted transient transfections of HEK293 cells with LRP5 constructs as described 
previously. The signaling was activated by addition of Wnt3a for 24 hours. Total RNA was 
extracted with TRIzol (Invitrogen). Template cDNA was obtained using the iScript cDNA 
Synthesis Kit (Biorad). Expression levels of Wnt target genes were assessed twice by quantitative 
PCR (qPCR) experiments (in triplicate) using the CFX96 real-time detection system (Biorad). 
Immunofluorescence Imaging
A total of 4.0x104 CHO cells per well were seeded on poly-L-lysine-coated Ø12mm cover 
glasses on a 24-well plate and transiently transfected with 100ng of LRP5WT or mutant LRP5 
construct. After 24 hours, medium was refreshed, and cells were cultured for another 24 
hours followed by paraformaldehyde fixation and immunofluorescence staining. 
Statistics
Groups were compared using descriptive statistics and compared by the Student T test. 
Both groups were compared by using the nonparametric Mann-Whitney U test. P<0.05 was 
considered statistically significant. All analyses were calculated by SPSS software v18.0.
RESULTS
Extended Polycystic Liver Disease Family
We assessed a 49-year-old female (III/18) by clinical history taking and physical and radiological 
examination. She presented to us with a severe symptomatic polycystic liver without renal 
cysts and complained of abdominal distension, pain, dyspnea and pyrosis. There was no 
history of renal disease, hypertension or intracranial aneurysms. She used contraconceptives 
for a total of 30 years and had 2 pregnancies. CT scanning revealed numerous cysts with 
diameters of 5-18 cm in liver segments I-III and VII. Despite aspiration sclerotherapy and 
laparoscopic deroofing of the liver cysts, her symptoms persisted, and she enrolled a clinical 
trial for long-acting octreotide treatment.22 We expanded our clinical analysis and identified 
a 40-member Dutch family with three generations of early- and late-onset cystogenesis 
inherited in an autosomal dominant fashion (PCLD-1). Next, we studied 19 individuals with 
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cystogenesis of which 16 were affected with a polycystic liver according to the Reynolds 
criteria5, 7 and 3 members affected with renal cysts that came from the 40-member Dutch 
family (Figure 1A). The proband (III/18) possessed no pathogenic variants affecting any of the 
known PCLD or ADPKD genes. 
Whole-Exome Sequencing Identifies Pathogenic LRP5 Variant
We performed exome sequencing on genomic DNA in 2 members (III/18 and II/18) from 
PCLD-1 family with an advanced polycystic liver phenotype (Figure 1B). Exome capture and 
sequencing were performed using the Agilent SureSelect target enrichment system with SOLiD4 
sequencing. We identified 24,178 and 25,332 genetic variants per proband, respectively (Tables 
S1 and S2). Variants were annotated by a bioinformatics pipeline as described previously.19, 20 
Variant follow-up required the presence of at least five unique variant reads (different start sites), 
and the variant had to be present in at least 20-80% of all reads suggestive for heterozygous 
changes in a dominant model of disease. Next, we prioritized variants based on predicted 
amino acid consequences and overlap with common variation (presence in dbSNP v134 and/or 
an in-house database containing 1,300 analyzed exomes of predominantly European ancestry). 
We identified 11 unique nonsynonymous variants present in both affected relatives (Table S3). 
All 11 variants were tested for segregation in both probands and all other family members by 
Sanger sequencing. The only private nonsynonymous variant that cosegregated completely 
with the disease was a missense mutation (c.3562C>T with evolutionary conserved amino acid 
change p.R1188W) located on chromosome 11q13.2 in the low density lipoprotein receptor-
related protein 5 (LRP5) gene (NM_002335.2) (Figures 1C and 1D). We checked sequence 
coverage and excluded the presence of potential pathogenic variants in the 2 Mb surrounding 
LRP5. All 19 individuals with cystogenesis possessed LRP5 c.3562C>T (Table S4 and Figure 
S1). Analysis of the sequence data revealed linkage at the LRP5 locus with the disease with a 
significant LOD score of 4.62 (Figure S2). This LRP5 variant (c.3562C>T ) was not detected in 
genome-wide sequence data from the 1,000 Genomes Project23, 6,500 individuals from the 
National Heart, Lung, and Blood Institute Exome Sequencing Project24, or exome data from 
1,300 individuals of predominantly European ancestry sequenced in-house19, 20, and excluded 
by Sanger sequencing in a control set of 1,000 Dutch DNAs of healthy, unrelated individuals. 
This LRP5 mutation affected a highly conserved amino acid and was predicted to be damaging 
by PolyPhen-2, MutPred and sorting intolerant from tolerant (SIFT) models (Table 1).
LRP5  is a known disease gene causing severe skeletal bone or retinal disorders and is 
associated with metabolic disease (Figure S3). Therefore, we actively investigated the possible 
presence of subtle clinical signs in our family by slit-lamp eye examination. These investigations 
excluded FEVR in any of the family members (Supplementary Text). We assessed bone density 
of the lumbar spine and left hip in 13 patients and 9 unaffected relatives. The lumbar T-score 
was lower in LRP5 mutation carriers, but within the normal range, and no member had a 
bone density disorder. Routine laboratory testing, including renal parameters, did not reveal 
differences between individuals with and without the LRP5 mutation (Table 2). Therefore, 
other LRP5-related disorders were ruled out in this index family.
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Table 1. Summary and in silico analysis of four LRP5 variants in polycystic liver disease.
Family Ethnicity
Genomic 
position chr.11  
(hg19; GCRh37)
Mutation  
(c.DNA)
(NM_002335.2) Exon
Predicted 
effect on 
protein PolyPhen2 MutPred SIFT
PCLD-1 Caucasian 
(Dutch)
g.68193580 c.3562C>T 16 p.R1188W Probably 
damaging 
(1.00)
0.552 Deleterious  
(0.00)
PCLD-2 Caucasian 
(Dutch)
g.68154128 c.1360G>A 6 p.V454M Possibly 
damaging 
(0.872)
0.520 Deleterious  
(0.01)
PCLD-3 Moroccan g.68216277 c.4587G>C 23 p.R1529S Possibly 
damaging 
(0.610)
0.288 Deleterious 
(0.00)
PCLD-4 Caucasian 
(Dutch)
g.68216341 c.4651G>A 23 p.D1551N Probably 
damaging 
(0.999)
0.235 Deleterious  
(0.00)
Additional LRP5 Variants in Polycystic Liver Disease
To confirm our results, we sequenced LRP5 in a cohort of 150 unrelated PCLD probands without 
PRKCSH, SEC63 or PKD2 gene mutations. We identified two additional PCLD families (one 
Dutch and one Moroccan) and one Dutch PCLD singleton case with private LRP5 missense 
variants. Mutations c.1360G>A (p.V454M) and c.4587G>C (p.R1529S) segregated with the 
disease in both families, and unaffected relatives of the singleton case (c.4651G>A; p.D1551N) 
did not carry the mutation (Figure S4). 
Mutation c.1360G>A (p.V454M) was present in an 86-year-old polycystic liver patient. 
Her mutation-positive daughter had several bilateral renal cysts and small hepatic cysts on 
CT scanning. Her daughter died as a result of a metastasized liposarcoma at the age of 49. A 
43-year-old Moroccan female had multiple dominant hepatic cysts without renal disease. Her 
71-year-old mother had several hepatic cysts without renal cysts. Both carried the c.4587G>C 
(p.R1529S) mutation in the LRP5 gene. A fourth mutation, c.4651G>A (p.D1551N), was present 
in a 65-year-old male with a polycystic liver and three renal cysts. There was no evidence 
for renal failure. The phenotype of his deceased parents was unknown, and both his healthy 
children were without hepatic or renal cysts, and did not harbor the LRP5 mutation. None 
of the LRP5 variants were detected in chromosomes from healthy, unrelated and ethnically 
matched controls (Dutch, n=1,000; Moroccan, n=525), nor present in the in-house or online 
exome sequencing datasets. In addition, all four LRP5 missense variants affected highly 
conserved amino acids, and again were predicted to be damaging or deleterious by PolyPhen-
2, MutPred and SIFT (Table 1). 
LRP5 Expression in Liver Cyst Tissues
LRP5 has a wide tissue distribution, including liver and kidney, and expression has been 
reported in Kupffer cells, macrophages, stellate cells, cholangiocytes and hepatocytes.25 In line 
with Northern blotting experiments26, we found abundant LRP5 protein presence in normal 
liver tissues and relevant for PCLD. In the affected proband (III/18), we observed intense 
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Table 2. Baseline characteristics of PCLD-1 family. 
No hepatic cystogenesis 
and no LRP5 mutation 
(n=9) 
Hepatic cystogenesis 
and LRP5 mutation 
(n=13) P-value 
Age – yr 55 ± 12 56 ± 13 NS
Female sex – no. (%) 6 (67) 9 (69) NS
Bone density: Hip 
T-score 
Normal range -1.0-1.0 
High-Normal range: 1.0-2.5
-0.19 ± 0.78 -0.08 ± 0.93 NS
Z-score 
Normal range -1.0-1.0 
High-Normal range: 1.0-2.0
0.69 ± 0.68 * 0.95 ± 0.94 NS
Bone density: L1-L2-L3-L4 
T-score 
Normal range -1.0-1.0 
High-Normal range: 1.0-2.5 
1.18 ± 0.95 * 0.19 ± 0.88 0.042 
Z-score 
Normal range -1.0-1.0 
High-Normal range: 1.0-2.0
1.81 ± 0.89 * 1.18 ± 1.03 NS
Creatinin (µmol/l) 
Normal range 45-90
69 ± 14 73 ± 20 NS
Cholesterol (mmol/l) 
Normal 0.0-6.5
5.39 ± 0.71 5.44 ± 1.01 NS
GFR (MDRD) (ml/min/1.73m²) 
Normal >60
87 ± 13 85 ± 25 NS
BMI (kg/m²) 
Normal range 18.5-24.9 
Overweight 25-29.9 
25.7 ± 2.5 26.4 ± 5.2 NS
Triglycerides (mmol/l)  
Normal range 0.80-2.00
1.35 ± 0.71 1.80 ± 0.93 NS
HDL (mmol/l) 
Normal >1.10
1.34 ± 0.40 1.38 ± 0.32 NS
LDL (mmol/l) 
Normal range 3.5-4.5
3.44 ± 0.82 3.25 ± 0.78 NS
Non HDL (mmol/l) 
Normal range
4.06 ± 0.93 4.07 ± 0.93 NS
HbA1C (%) 
Normal range 4.0-6.0
5.5 ± 0.6 5.7 ± 0.8 NS
HbA1C (mmol/mol) 
Normal range 20-42
37 ± 6 39 ± 9 NS
NS, not significant. *There was one missing value because of degenerative abnormalities of the 
lumbar spine in an 85-year-old woman.
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LRP5 staining of cyst-lining epithelium and bile ducts. The intensity of LRP5 expression was 
comparable in cyst tissue sections derived from a PRKCSH mutant and to bile duct epithelium 
(Figure 2A and 2B). This abundant LRP5 expression in cyst tissue indicates that there is no 
significant loss of structural LRP5 protein from relevant tissue in LRP5 carriers.
For analysis of structural effects of the LRP5 variants, we generated separated models 
for these domains (Figure 2E and 2F and Table S5).27 The human LRP5 protein contains 1,615 
amino acids and includes a long extracellular region, a single-span transmembrane, and a 
relatively short (208 amino acids) intracellular region. The extracellular region consists of four 
β-propeller domains with subsequent epidermal growth factor (EGF)-like domains. Near the 
transmembrane region are three LDL receptor class A repeats, whereas on the cytoplasmatic 
side, five PPPSP motifs are present. The β-propeller domains all consist of six segments of 
which most carry a characteristic YWTD motif. Arginine 1188 creates hydrogen bonds and 
ionic interactions in the core of the β-propeller structure, which is predicted to be lost by the 
tryptophan mutation (p.R1188W). Additionally, the larger tryptophan side-chain will cause 
steric clashes, which will most likely disturb the whole β-propeller domain. Valine 454 induces 
several hydrophobic interactions, but is also partly exposed to the solvent. Mutant methionine 
is predicted not to have major structural effects as both amino acids are hydrophobic and the 
methionine side-chain appears to fit at this position (p.V454M). Both p.R1529S and p.D1551N 
mutations are intracellularly located in between PPPSP motifs and an intracellular homology 
model is absent.
Reduced Activation of Canonical Wnt Signaling 
To identify the underlying mechanism of mutated LRP5 on the Wnt pathway, we conducted 
luciferase activity assays with LRP5WT, one extracellularly (LRP5R1188W) and one intracellularly 
located (LRP5D1551N) mutant, and an empty expression vector as control. Immunofluorescence 
imaging in WT and both mutant constructs presented similar localization of LRP5 (Figure 
2C and 2D). Western blots of the cell lysates showed comparable protein expression of all 
constructs (Figure 2G). Overexpression of the LRP5 constructs in CHO cells increased basal and 
Wnt3a-induced luciferase activity compared with the empty vector (P<0.0001). In presence 
of Wnt3a, signal activation was significantly down-regulated by 30 and 45%, taken into 
account the basal activity in both LRP5 mutants compared with the LRP5WT. We also detected 
a significant decreased (P<0.001) activity of LRP5 mutant p.D1551N without the presence of 
Wnt3a (Figure 2H). Luciferase activity assays were repeated in HEK293 and human liver-derived 
H69 cells, where comparable significant results were obtained (Figure S5).
Altered Expression Levels of Wnt Target Genes
Subsequently, we conducted qPCR experiments of transducers and transcription factors 
associated with the canonical Wnt signaling. Our analyses show that HEK293 cells transfected 
with mutant LRP5 led to altered expression levels of target genes compared with LRP5WT 
(Figure S6). There was a significant increased gene expression of transducers adenomatous 
polyposis coli (APC), glycogen synthase kinase 3β (GSK3β), leucine-rich repeat-containing 
G-protein-coupled receptor 5 (LGR5), and transcription factor v-myc avian myelocytomatosis 
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Figure 2. Functional and structural analyses of LRP5 variants in polycystic liver disease. (A) 
Immunohistochemistry of liver cyst tissue from proband III/18 of PCLD-1 family with LRP5 mutation 
c.3562C>T (p.R1188W). The cyst lining cholangiocytes present positive staining for LRP5 compared with 
the negative control next. (B) PCLD patient with a PRKCSH c.1341-2A>G mutation shows similar staining of 
liver cyst tissue and expression of LRP5 compared with (A). (C) Localization of LRP5 protein was analyzed 
by immunofluorescence microscopy. CHO cells were transfected with constructs expressing LRP5WT, (D) 
LRP5R1188W, or LRP5D1551N and compared to negative controls. No differences in LRP5 localization between 
all constructs was detected. (E) Presentation of the human LRP5 protein and homology modeling of the 
β-propeller domains highlighting the amino acid changes to emphasize the impact on the configuration 
and surrounding protein domains. (F) Homology modeling of the LRP5 domains and detailed view of 
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viral oncogene homolog (c-Myc) in LRP5R1188W  or LRP5D1551N, compared with LRP5WT. Similarly, 
axis inhibitor-1 (AXIN-1), axis inhibitor-2 (AXIN-2), lymphoid enhancer-binding factor 1 (LEF1), 
SRY-box 9 (SOX9), fibroblast growth factor 18 (FGF18), and cyclin D1 (CCND1) were also up-
regulated. In the presence of the extracellular regulator Wnt3a, expression levels of several 
Wnt signaling components changed (Figure S7). Decreased expression levels were found 
for GSK3β, AXIN-1, AXIN-2, LGR5, c-Myc, CCND1 and LEF1 compared with LRP5WT in both 
mutated LRP5 constructs. These results are in line with the functional consequences of these 
LRP5 mutations as shown with luciferase activity assays (Figures S8 and S9).  
DISCUSSION
This study identifies LRP5 as a novel gene associated with hepatic cystogenesis in patients 
clinically diagnosed with PCLD. The initial discovery was made in two affected relatives from 
an extended Dutch family by exome sequencing.21 A private missense mutation c.3562C>T 
(p.R1188W) in the LRP5 gene segregated with 18 affected relatives (>40 years), with a 
significant LOD score of 4.62. These findings are corroborated by the presence of three 
additional private missense LRP5 variants in two PCLD families and one PCLD singleton. All 
unique variants identified in LRP5 affected highly conserved amino acids and were predicted 
to be damaging or deleterious. The identification of LRP5 as a causative gene follows that 
of PRKCSH (15%) and SEC63 (6%) for isolated polycystic liver disease in a PCLD cohort.18 
LRP5 is a single-span transmembrane protein that acts as a coreceptor with Frizzled 
protein family members for transducing signals by Wnt proteins. Wnt signaling directs a 
number of fundamental physiological mechanisms such as cell proliferation, cell polarity 
and cell fate determination during embryonic development.28 Until now, LRP5 variants were 
linked to a spectrum of Mendelian genetic diseases. LRP5-related disorders include autosomal 
dominant conditions with abnormal bone density, such as endosteal hyperostosis and 
osteosclerosis29-32, but also in eye disorders such as recessive and dominant forms of FEVR.29, 
33, 34 Our findings expand the clinical spectrum of LRP5-associated phenotypes because there 
were no extrahepatic features in patients with LRP5 mutations in our studies. Specifically 
metabolic disorders, diabetes mellitus, skeletal bone and retinal diseases were absent in the 
index family, and these were not reported for the other three families. We performed specific 
the amino acid changes shows extracellular LRP5 mutation (*indicated) p.R1188W located at the sixth 
blade of the fourth β-propeller domain, and LRP5 mutation p.V454M at the third blade of the second 
β-propeller domain. Both intracellular mutations p.R1529S and p.D1551N are located between PPPSP 
motifs A and B, and PPPSP motif B and C, respectively. (G) CHO cells were transiently transfected with 
empty, WT, or mutant LRP5 vector. Whole cell lysate was analyzed by Western blotting using the V5 
antibody and anti-β-actin. LRP5 protein expression levels (normalized to β-actin) are similar between 
LRP5WT and both mutant constructs LRP5R1188W and LRP5D1551N. (H) Canonical Wnt signaling activity was 
analyzed by firefly luciferase activity and normalized to renilla luciferase activity with (in gray) or without 
addition of 250ng/ml Wnt3a. All LRP5 constructs showed a significant increase in Wnt signaling activity 
compared with the empty vector (P<0.0001). Both LRP5 mutants showed a decreased Wnt3a-induced 
signal activity (*P<0.001; **P<0.0001). Activity of LRP5D1551N without Wnt3a was significantly decreased 
compared to LRP5WT.
126
7
LRP5 M
U
TA
TIO
N
S A
N
D
 W
N
T SIG
N
A
LIN
G
 IN
 H
EPA
TIC
 C
Y
STO
G
EN
ESIS
clinical investigations in the extended family 1 and excluded FEVR in individuals with LRP5 
germline mutations by slit-lamp eye examination. Bone density measurements ruled out bone 
diseases in individuals with and without PCLD. Hepatic or renal cystogenesis has not been 
observed in association with FEVR or with bone diseases. 
Why different LRP5 mutations can result in such a wide spectrum of complex diseases 
that targets different tissues remains to be determined. LRP5 is detected by Northern blot 
analysis, immunohistochemistry and in situ hybridization studies in several tissues including 
the liver and kidney.25, 26 Until now, LRP5 mutations were linked to pathological retina or bone 
development. In the extended PCLD-1 family, we identified the LRP5 c.3562C>T mutation in 
22 individuals, of which 19 had hepatic and/or renal cystogenesis. Two members were too 
young (<40 years) to develop hepatic cysts and one individual is an example of incomplete 
penetrance. Indeed, there was considerable clinical heterogeneity in affected members without 
complaints or patients with severe abdominal discomfort in the PCLD-1 family. This clinical 
heterogeneity has been described in families with PRKCSH- and SEC63-associated PCLD14, 18, 
and penetrance of PRKCSH-associated PCLD is estimated at  ~80%. Intrafamilial phenotypic 
variability suggests that modifier genes and/or environmental factors play a major role in 
PCLD disease expression. Similarly, the clinical expression of LRP5-associated bone and eye 
diseases is highly variable.27
There have been efforts to recapitulate the involvement of LRP5 mutations in a number 
of bone and eye disorders in mice. A targeted knock-out Lrp5tm1Jsak/Lrp5tm1Jsak mouse suffers 
from unspecified hepatobiliary abnormalities that might implicate phenotypic overlap with 
our observed human phenotypes.35 Human and mouse LRP5 share a high degree of amino 
acid identity to coreceptor low density lipoprotein receptor-related protein 6 (LRP6) and 
have a similar domain structure.36 Furthermore, there has been speculation about functional 
redundancy between both transmembrane coreceptors of the canonical Wnt signaling 
pathway.37 The homozygous knock-out Lrp6 mouse is embryonic lethal and possesses 
polycystic kidneys37 compatible with the ADPKD phenotype. There is further experimental 
data to suggest that renal cystogenesis in ADPKD is linked to defective canonical Wnt 
signal transduction. Perturbations of polycystins cause inappropriate levels of β-catenin, 
and activation and inactivation of the Wnt signaling pathway are reported in different 
polycystic kidney disease mice models during embryonic or postnatal development.38-42 
Our findings provide a direct link between canonical Wnt signaling and polycystic liver 
disease as Wnt signaling is reduced in mutant LRP5 compared with WT LRP5. A moderate 
reduction of signaling activity is in line with known LRP5 missense mutations in retina and 
bone disorders.43, 44 These observations support a role of an imbalanced canonical and 
noncanonical Wnt signal transduction in the pathogenesis of LRP5-associated polycystic 
diseases. We speculate that LRP5, along with other genes implicated in hepatic cystogenesis, 
PKD1, PKD2, PRKCSH and SEC63, is part of the functional genetic network. Experimental 
studies have observed that reduced dosage of these gene products, and in particular 
polycystin-1, is required to cause cyst formation.45, 46 
The identification of LRP5 associated with hepatic cystogenesis affords a better 
understanding of the pathophysiology of PCLD. Positivity for immunoreactive LRP5 in cyst 
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epithelium suggests that the protein is structurally intact. Functional assays in three different 
cell systems indicate that the mutation renders the protein to be less functional and that leads 
to inhibition of the canonical Wnt signaling.41, 42 
In conclusion, PCLD is a genetically heterogeneous disorder that may be caused by LRP5 
gene mutations. Our results link hepatic cystogenesis to dysregulated canonical Wnt signaling 
and are in line with data that were generated from ADPKD models.41, 42 Polycystins modulate 
Wnt signaling during organ development and contribute to hepatic and renal cystogenesis.42, 47, 
48 Our study provides evidence that mutations in LRP5 are related to hepatic cyst development 
and fuels the hypothesis that canonical Wnt signal transduction is important in polycystic 
diseases. It is possible that disruption of other (downstream) members of the Wnt signaling 
pathway may be associated with initiation of hepatic and renal cyst formation.  
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Investigations in PCLD-1 Family
Ultrasonography 
Ultrasound images of liver and kidneys were acquired using a 3.6 MHz general purpose clinical 
echo system (Acuson x150, Siemens AG) equipped with a curved linear array transducer in 
all 39 members of proband III/18. Presence or absence of hepatic and/or renal cysts was 
investigated and noted carefully by at least two clinicians (W.R.C., M.C., J.P.H.D.). These 
ultrasound examinations were conducted in all 39 members within 2 weeks. During the 
project, five members (II/13; III/13; III/14; III/21; and III/26) were reevaluated by abdominal 
ultrasonography (Table S4). Member III/22 could not undergo a second evaluation due to 
chronic health issues. A complete clinical analysis of the liver and kidney phenotype in these 
individuals by CT or MRI scanning was not ethically approved for this project.
Ophthalmoscopy
Indirect ophthalmoscopy of the fundus was performed after full mydriasis of the pupil of both 
eyes by tropicamide 0.5% and phenylephrine 5% (wt/vol) eye drops. By performing slit-lamp 
biomicroscopy (Kowa SL90 slit-lamp and Volk S +70D lens), the posterior and peripheral retina 
was examined with special attention to the configuration of the retinal vasculature and signs 
of FEVR. The ophthalmologist (C.E.N.) was ignorant for our whole-exome sequencing results 
and blinded for this examination in 20 individuals: 11 affected (with LRP5 c.3562C>T ) and 9 
healthy relatives (without LRP5 c.3562C>T ) in the extended polycystic liver disease PCLD-1 
family. These indirect ophthalmoscopy examinations were performed in all 20 members 
within 1 day.
Laboratory Parameters
At the same time, we analyzed metabolic and renal parameters in blood from 22 individuals 
of this family. All presented values within normal ranges and showed no significant differences 
between individuals with and without the LRP5 mutation (Table 2).
Bone Densitometry
We assessed bone density of the lumbar spine and left hip by a DXA scan (Hologic Discovery 
A, TROMP). Results are reported as T- and Z-scores, which reflect the number of standard 
deviations below the average for, respectively, a young adult at peak bone density and an 
average person of similar age. No relative was known for a bone diseases, nor was this 
detected by DXA scanning. The lumbar T-score was lower in LRP5 mutation carriers, but no 
relative had a severe bone density disorder. The T- and Z-scores were within the normal-high 
range: 1.0-2.5 for T-scores and 1.0-2.0 for Z-scores. No significant differences were observed 
in hip T- and Z-scores and nonpathogenic high-normal values (T- and Z-scores within normal 
range, -1.0 to 1.0; Table 2). 
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SUPPLEMENTARY METHODS AND RESULTS
Luciferase Activity Assays
We performed the luciferase activity assays three times (and in triplicate) in human embryonal 
kidney cells (HEK293; ATCC CRL-1573). These results were in line with the findings with 
the CHO cell line for each LRP5 construct. Both cell lines, HEK293 and CHO cells, are well-
established study models with good transfection efficiencies and applicable to assess functional 
mechanisms in various disorders.58 Here, we present the results of the luciferase activity assay 
in transiently transfected HEK293 cells (Figure S5).
The H69 cells are SV40-transformed normal human liver cholangiocytes originally derived 
from normal human liver and have been extensively characterized.44, 59 Therefore, we also 
conducted these experiments in these cells, again three times (and in triplicate), and comparable 
results were obtained (Figure S5). 
Quantitative PCR Experiments
To elucidate the mechanism of LRP5 mutations in PCLD, we conducted transient transfections 
of HEK293 cells as previously described. We activated the signaling pathway by addition of 
Wnt3a for 24 hours, similar to former experiments. Expression levels of Wnt target genes APC, 
AXIN-1, AXIN-2 and GSK3β, and c-Myc, CCND1, LEF1 and other target genes were assessed 
by RNA isolation and subsequently by qPCR experiments (twice in triplicate). These genes are 
listed at http://www.stanford.edu/group/nusselab/cgi-bin/wnt/ 
Our analyses show that HEK293 cells transfected by mutant LRP5 led to altered expression 
levels of target genes compared with WT LRP5. Transfected cells expressed LRP5 >5,000 times 
more. This high number indicates adequate transfection efficiency. 
When expression levels for each construct were corrected, there was a significant increased 
gene expression of APC, GSK3β, c-Myc and LGR5 in mutant LRP5, LRP5R1188W  and LRP5D1551N, 
compared to the wild-type LRP5 (Figure S6). Also, AXIN-1, AXIN-2, CCND1, LEF1, SOX9, 
Wnt3a and FGF18 showed increased expression, but this was not significant.
Secondly, gene expression levels were compared between basal and activated signaling 
activity by addition of Wnt3a. We corrected activated signaling for basal gene expression for a 
better understanding of the consequences of mutant LRP5 on the expression of genes in the 
up-regulated pathway. Our results indicate unchanged gene expression for APC. Decreased 
expression levels were found for GSK3β, AXIN-1, AXIN-2, LGR5 and FGF18 compared to WT 
in both LRP5R1188W  and LRP5D1551N (Figure S7A and 7B). 
The same holds true for target genes at the nuclear end point (Figure S7C). CCND1, LEF1 
and c-Myc expression levels decreased in mutated LRP5. Our results for gene expression levels 
demonstrate similar effects compared to the luciferase activity assays. 
Disease Model
Wnt signaling has essential roles in normal tissue development and tumor growth. Wnt signal 
transduction depends on several proteins interfering with the amount of cadherin binding (at 
the plasma membrane) and cytoplasmic β-catenin. In absence of extracellular Wnt ligand, the 
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cytoplasmic pool of β-catenin is depleted by the β-catenin destruction complex (proteasome 
complex) consisting of AXIN, APC and GSK3β (Figure S8A). The GSK3β phosphorylates sites 
of the β-catenin and subsequent destruction by ubiquitination and proteolysis is initiated.
Wnt binding activates cytoplasmic Dishevelled (Dsh) to form a signalosome for LRP5 
phosphorylation and proteasome destabilization. Subsequently, β-catenin accumulates in 
the cytoplasm and may be translocated to the nucleas. Binding of β-catenin to Tcf promotes 
the transcription and expression of Wnt responsive genes (Figure S8B).
We translated our results to this basic scheme of linear canonical Wnt signaling (Figure S9). 
We identified no activated signaling by luciferase activity (LEF1/Tcf) assays in mutant LRP5. 
This result resembles our findings from abovementioned additional experiments. Although 
the signal transduction is affected in mutant LRP5, we hypothesize that the proteasome 
complex remains active. Second, we hypothesize that a portion of β-catenin accumulates in 
the cytoplasm, and some β-catenin is destroyed (indicated by a cross with interrupted lines). 
In addition, it has been proven that β-catenin also binds to cadherins at the plasma membrane 
in PCLD.60 Therefore, β-catenin does not enter the nucleus to bind Tcf for modulation of 
expression levels of genes associated with proliferation.
LEF1 is able to activate transcription independently from the presence of β-catenin. We 
found increased LEF1 expression in mutated LRP5, but lower levels compared with WT after 
addition of Wnt3a. There could be other factors influencing the equilibrium between the 
membrane and cytoplasmic β-catenin.61 The exact mechanism needs to be explored, and the 
network of protein interactions in this pathway is major and complex.
In conclusion, in presence of Wnt3a, signal activation is down-regulated in LRP5R1188W  
and LRP5D1551N.
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SUPPLEMENTARY FIGURES
Figure S1. PCLD-1 family with genotype analysis. This additional figure illustrates the information 
from Table S4. (A) Pedigree of family PCLD-1 presents hepatic and/or renal cystogenesis phenotype 
(n=19, of which 16 with a polycystic liver) of the 40 members included for analysis (Figure 1) marked 
with genotype status (x in red; or - in blue). (B) Both affected relatives (II/18 and III/18) are indicated 
by an arrow (in green) and included for exome sequencing. (C) Figures S1A and S1C indicates which 
member possessed the heterozygous LRP5 c.3562C>T variant (x in red) and individuals with the normal 
variant (- in blue). Generations are denoted with Roman numerals, and individuals are numbered in a 
counterclockwise way. Squares indicate male sex and circles female sex. Solid symbols denote affected 
individuals, and open symbols are individuals without or unknown for PCLD. A slash indicates that the 
individual is deceased.
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Figure S2. LOD score calculation in PCLD-1 family. The index family (PCLD-1) is a large pedigree 
segregating LRP5 c.3562C>T (p.R1188W). We calculated the LOD score in this family using the FastLink 
v2.51 program in the EasyLinkage v5.08 software package.49 To determine the actual two-point LOD 
score for the LRP5 mutation detected in PCLD-1 family, the mutation was considered to be a microsatellite 
marker in close proximity of LRP5 (e.g., D11S4117; Figure S2). Both for the simulation and the LOD 
score calculation, an autosomal dominant mode of inheritance was assumed with a penetrance of 0.8 
(80%), and the disease allele frequency was estimated at 0.0001. Individuals below the age of 40 (fouth 
generation; n=5) were not included in this analysis due to the age of onset of the phenotype. We analyzed 
the sequence data from 35 family members (n=18 members with cystogenesis; n=17 healthy members). 
Based on the number of individuals with LRP5 c.3562C>T (n=19), genome-wide SNP analysis combined 
with linkage analysis would likely have resulted in a genome-wide significant LOD score for a genomic 
region harboring the pathogenic mutation. Because we did not use SNP genotyping, in retrospect, we 
calculated the highest possible (maximum with θ=0) LOD score for this family (n=35), which was found 
to be 7.88. However, nonpenetrance is frequently observed in PCLD, which was supported by the fact 
that in this index PCLD-1 family, one healthy member and two individuals with bilateral renal (and splenic) 
cysts, without a hepatic cyst did carry the pathogenic mutation. Taking this into account, we assumed 
our mutation to be a microsatellite marker and included all family members above the age of 40 years 
that were genetically tested (n=35). Our analysis resulted in a two-point LOD score of 4.62 that, despite 
the presence of individuals without a hepatic cyst that carried the mutation (n=3), is considered to be 
genome-wide significant.
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Figure S3. Extracellular and intracellular LRP5 mutations. This figure summarizes the location 
and number of all nonsense and missense mutations in the highly conserved LRP5 gene resulting in a 
truncated or an amino acid change of the LRP5 protein. There are 88/117 (75%) nonsense and missense 
mutations identified in the LRP5 gene causing multiple complex diseases: autosomal dominant and 
autosomal recessive retina or bone diseases. Hepatic or renal cystogenesis has not been observed in 
association with FEVR or with bone diseases. 
A considerable genetic locus heterogeneity in LRP5 is present. Mutations in the LRP5 gene are spread 
throughout the extracellular (A) and intracellular LRP5 protein domains (B). One exception are missense 
mutations in high bone mass disease patients, which are only located to the first β-propeller domain 
in LRP5. Remarkably, more mutations at the extracellular LRP5 domains were identified. This overview 
indicates that the relationship between a retina or bone phenotype for specific domains or protein 
change is not obvious (unclear), which could explain the distribution of the identified LRP5 mutations 
in polycystic liver patients. 
In conclusion, we identified four missense mutations in three unrelated families and one singleton 
patient with severe hepatic cystogenesis. All LRP5 mutations were predicted to be damaging or deleterious 
with profound structural effects on the LRP5 protein, especially the extracellular domains. We have 
not detected these variants in either DNAs from healthy unrelated individuals from similar ancestry or 
assessed in the in-house data (1,300 individuals) and online sequence data (6,500 individuals from the 
ESP cohort; 1,000 Genomes Project).23, 24 We performed additional clinical and functional investigations 
to underline our findings. 
Protein domain information was derived from MRS database; v6 (latest version); http://mrs.cmbi.
ru.nl/m6/entry?db=sprot&id=lrp5_human&rq=lrp5_human;52 LRP5 mutations were derived from a recent 
review by Nikopoulos K. et al.27 and the Human Gene Mutation Database (www.biobase-international.
com/hgmd).53 Small indels (n=2), deletions (n=13), insertions (n=4) and splice site (n=8) mutations were 
not included in this figure.
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Figure S4. CT scanning of the proband and pedigree of three additional PCLD families with 
a LRP5 missense mutation. The LRP5 mutation cosegregated with the disease phenotype in PCLD 
families 1, 2 and 3. All missense mutations were predicted to be pathogenic. For each family, (A) CT 
scanning of the proband (blue arrow in B) and (B) the pedigrees of family PCLD-2, PCLD-3 and PCLD-4. 
(C) Positions of the mutations are denoted according to the hg19 human reference genome (GCRh37).50, 51
PCLD-2 family: LRP5 g.68154128, c.1360G>A; p.V454M. 
PCLD-3 family: LRP5 g.68216277; c.4587G>C; p.R1529S.
PCLD-4 family: LRP5 g.68216341; c.4651G>A; p.D1551N.
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Figure S5. Luciferase activity assays. 
Luciferase activity assays for  LRP5WT and both 
mutant constructs LRP5R1188W and LRP5D1551N 
performed in CHO, HEK293 and H69 cells. 
Firefly luciferase activity was normalized to 
renilla luciferase activity by calculating the 
ratio. Wnt3a-induced signal activity was 
reduced in all cell systems compared to the 
LRP5WT (P<0.001). 
Figure S6. qPCR experiments. Basal gene expression levels of genes involved in the canonical Wnt 
signaling pathway (for example). No Wnt3a was added to activate signaling. We corrected results for 
LRP5WT levels. *Significant increased expression levels. The y-axis presents the relative gene expression level.
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Figure S7. qPCR experiments. (A) Gene expression levels of APC, AXIN-1, AXIN-2, and GSK3β involved 
in β-catenin degradation. (B) Expression levels of other target genes of the canonical Wnt signaling. 
(C) Expression levels of target genes at the nuclear end point of the canonical Wnt signaling pathway. 
In all panels (A, B, C), the first bar presents the unstimulated situation (basal gene expression levels). 
Expression levels of the second bar are the result of activation of the Wnt signaling by extracellular ligand 
Wnt3a. Activated gene expression levels are corrected for basal gene expression of the respective LRP5WT, 
LRP5R1188W, and LRP5D1551N constructs. *Significant decreased expression levels. The y-axis presents the 
relative gene expression level.
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Figure S8. Canonical Wnt signaling under normal conditions. Canonical Wnt signaling without 
extracellular regulator (A) and activated with Wnt3a (B) under normal conditions. In red, the effects 
and signaling direction are indicated.
Figure S9. Disease model: proposed canonical Wnt signaling with LRP5D1551N. Canonical Wnt 
signaling without extracellular regulator (A) and activated with Wnt3a (B) in PCLD (LRP5 mutation 
p.D1551N). Brown arrows indicate the altered expression levels of the involved target genes from our 
experiments.
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Table S1. Summary of whole-exome sequencing performance in two probands of PCLD-1 family.
III/18 II/18
Total mapped bases in regions 3.9G (79.0%) 2.8G (76.8%)
Total mapped bases near regions 0.41G  (8.3%) 0.30G (8.0%)
Total mapped bases outside regions 0.62G (12.7%) 0.56G (15.2%)
Total reads 126M 108M
Total mapped reads 103M (81.6%) 80M (74.13%)
0 mismatches 58M 36M
Uniquely placed reads 85M 64M
Median target coverage 58.07x 41.70x
% Targets covered ≥10x 83.9% 83.4%
% Targets covered ≥20x 76.5% 74.4%
Table S2. Prioritization of private variants.
III/18 II/18
Number of called private variants* 24,178 25,332
Exonic and canonical splice sites 11,705 12,083
Non-synonymous and splice sites 5,743 6,004
Novel dbSNP v13456 334 373
Absent in in-house database** 72 11
Shared variants*** 11
*Private variant: A unique nucleotide change (on DNA level) derived from an individual in which 
exome sequencing was performed (in this study). These private variants may be benign or 
pathogenic depending on many factors (for example size/ location/ effect on amino acid or protein). 
Interesting candidate genes for unexplained disorders in patients may be unknown private variants 
not listed as a known SNP (polymorphism) or have a very low frequency in a population. **In-house 
database: 1,300 whole-exome sequence data from individuals of predominantly European ancestry. 
***Shared variant: A private variant that is present in two affected individuals (in this study: affected 
members III/18 and II/18).                                                                    
SUPPLEMENTARY TABLES
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Table S3. Eleven private variants shared in both affected probands from PCLD-1 family.
Chr.
Position 
(hg19) Reference Variant Gene name
Amino 
acid 
change PhyloP
Variant in 
members 
with 
PCLD*
Variant in 
members 
with no 
PCLD
chr1 g.247769018 C A OR2G3 p.T44N 0.17 6/16 4/16
chr11 g.65633353 G T MUS81 p.G526V 5.181 9/16 15/16
chr11 g.68193580 C T LRP5 p.R1188W 0.016 16/16 0/16
chr11 g.99932087 G A CNTN5 p.R375H 3.051 8/16 3/16
chr12 g.13102792 T C GPRC5D p.Y176C 5.247 6/16 7/16
chr15 g.31341712 C A TRPM1 p.V458L 5.479 8/16 7/16
chr15 g.43712642 A T TP53BP1 p.R1509E 0.791 8/16 4/16
chr16 g.71674378 T A MARVELD3 p.S227W -0.534 11/16 8/16
chr6 g.129581891 A G LAMA2 p.Y711C 0.302 8/16 9/16
chrX g.105190439 G A NRK p.V1446M 2.433 7/16 4/16
chrX g.149840060 C T MTM1 p.H602Y 4.244 6/16 2/16
*Eight members excluded during high-resolution melting curve analysis and direct Sanger sequencing 
(<40 year old and/or renal cystogenesis/no PCLD): II/13, III/22, III/26, IV/1, IV/2, IV/4, and IV/5.
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Table S4. Clinical presentation of PCLD families included for genotype analysis.
Inclusion (n=40) 
PCLD-1 Sex
Age 
(y)
Liver 
phenotype
(n=16)
Kidney 
phenotype
(n=12)
Diagnosis
(PCLD n=16;
renal cyst(s) n=3)
LRP5 
Mutation
(n=22)
>40 years
I/1 F 42† n.a. n.a. n.a. n.a.
I/2 M 70† n.a. n.a. n.a. n.a.
II/1 $ F 81† Y Y PCLD n.a.
II/3 F 47† n.a. n.a. n.a. n.a.
II/4 F 85 N N No PCLD Normal
II/5 F 82† n.a. n.a. n.a. n.a.
II/7 F 72† n.a. n.a. n.a. n.a.
II/9 F 80 Y N PCLD p.R1188W
II/11 F 79† n.a. n.a. n.a. n.a.
II/13 ** M 78 N Y Renal cysts p.R1188W
II/15 M 56† n.a. n.a. n.a. n.a.
II/16 F 76† n.a. n.a. n.a. n.a.
II/18 2E F 72 Y Y PCLD p.R1188W
II/20 F 57† n.a. n.a. n.a. n.a.
III/1 F 58 Y Y PCLD p.R1188W
III/3 F 56 Y Y PCLD p.R1188W
III/5 F 55 Y Y PCLD p.R1188W
III/6 M 54† Y N PCLD p.R1188W
III/7 F 52 N N No PCLD Normal
III/9 # M 51 Y Y PCLD/ADPKD p.R1188W
III/10 F 50 N N No PCLD Normal
III/11 M 47 N N No PCLD Normal
III/12 M 46 N N No PCLD Normal
III/13 M 42 Y Y PCLD p.R1188W
III/14 F 44 Y N PCLD p.R1188W
III/15 M 58 N N No PCLD Normal
III/16 M 54 N N No PCLD Normal
III/17 M 48 N N No PCLD Normal
III/18 1E F 53 Y N PCLD p.R1188W
III/19 F 51 Y N PCLD p.R1188W
III/20 F 48 N N No PCLD Normal
III/21 F 52 N N No PCLD Normal
III/22 M 49 N N No PCLD p.R1188W
III/23 M 42 N N No PCLD Normal
III/24 M 42 N N No PCLD Normal
III/25 F 51 Y N PCLD p.R1188W
III/26 M 50 N Y Renal cysts p.R1188W
III/27 F 44 Y Y PCLD p.R1188W
III/28 F 43 Y N PCLD p.R1188W
III/29 M 51 Y Y PCLD p.R1188W
III/30 F 47 Y Y PCLD p.R1188W
III/31 F 46 N N No PCLD Normal
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Table S4. Continued
Inclusion (n=40) 
PCLD-1 Sex
Age 
(y)
Liver 
phenotype
(n=16)
Kidney 
phenotype
(n=12)
Diagnosis
(PCLD n=16;
renal cyst(s) n=3)
LRP5 
Mutation
(n=22)
III/32 F 48 N N No PCLD Normal
III/33 M 47 N N No PCLD Normal
III/34 M 45 N N No PCLD Normal
<40 years
IV/1 F 36 N N No PCLD Normal
IV/2 M 34 N N No PCLD Normal
IV/3 F 33 N N No PCLD p.R1188W
IV/4 M 30 N N No PCLD p.R1188W
IV/5 M 26 N Y Renal cyst p.R1188W
Inclusion (n=14) Sex
Age  
(y)
Liver 
phenotype
(n=6)
Kidney 
phenotype
(n=2)
Diagnosis
(PCLD n=6;
ADPKD n=0)
LRP5 
Mutation
(n=6)
PCLD-2
I/1
I/2
II/1 (index)
II/3
II/4
II/5
III/1
M
F
F
M
F
M
F
75*
79*
86
83
77
67
49*
n.a.
n.a.
Y
N
N
N
Y
n.a.
n.a.
N
N
N
N
Y (4 small 
cysts)
n.a.
n.a.
PCLD
No PCLD
No PCLD
No PCLD
PCLD
n.a.
n.a.
p.V454M
Normal
Normal
Normal
p.V454M
PCLD-3
I/1
I/2
II/1
II/2 (index)
II/3
M
F
F
F
F
67*
71
48
43
40
n.a.
Y
Y
Y
N
n.a.
N
N
N
N
n.a.
PCLD
PCLD
PCLD
No PCLD
n.a.
p.R1529S
p.R1529S
p.R1529S
Normal
PCLD-4
I/1
I/2
II/1
II/2
II/3 (index)
III/1
III/2
M
F
M
M
M
F
M
73*
82*
70
67
65
38
35
n.a.
n.a.
N
N
Y
N
N
n.a.
n.a.
N
N
Y (3 cysts)
N
N
n.a.
n.a.
No PCLD
No PCLD
PCLD
No PCLD
No PCLD
n.a.
n.a.
Normal
Normal
p.D1551N
Normal
Normal
Abbreviations: 
F, female); M, male); n.a., no data available; N, no cysts present; Y, yes, cysts present; * deceased 
and age of death; ** splenic cysts; # PCLD phenotype correlates with the ADPKD Ravine criteria (6, 
7); $ Radiological data resources ; 1E Exome sequencing performance 1 in individual III/18; 2E Exome 
sequencing performance 2 in individual II/18.
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Additional text for Table S4.
We performed abdominal ultrasound screening of the liver and kidneys in 39 members of 
proband III/18 from the PCLD-1 family. Ultrasound images of liver and kidneys were acquired 
using a 3.6-MHz general-purpose clinical echo system (Acuson x150, Siemens AG) equipped 
with a curved linear array transducer. Presence or absence of cysts was carefully noted in all 
living relatives. 
For almost all deceased relatives, DNA from blood or tissue and radiological imaging 
was not available. An abdominal CT scan for only one diseased patient (II/1) was present and 
showed a severe polycystic liver, but no DNA was available. Member III/6 died after inclusion 
during the research process. We restricted our inclusion to the five oldest members from the 
fouth generation of PCLD-1 family because of the late onset of hepatic cystogenesis (>40 
years), especially in males. These members are recognized as individuals at risk for PCLD, 
which is associated with age-dependent occurrence and development of hepatic cysts.7 
Individual IV/5 was known with a large dominant renal cyst and his father (III/9) showed a 
severe polycystic liver and multiple cysts in both kidneys. Finally, 40 members were included 
for genotype analysis (excluding patient II/1). 
Three males (II/13, III/22, III/26) were categorized as “No PCLD” because they did not 
fully met the Reynolds criteria for PCLD, even after reevaluation in II/13 and III/26 (See 
Supplementary Text).7 Two males had bilateral renal cysts (and splenic cysts in individual II/13) 
with a positive family history of PCLD. All three members possessed the LRP5 c.3562C>T 
(p.R1188W) missense mutation. The mild or indeterminate phenotype in these members can 
be explained by the age-dependent factor for hepatic cyst formation, but even more by the 
predominant hepatic cystogenesis development in females and an evident known incomplete 
penetrance of ~80% in PCLD.8, 9, 10  
There was no renal disease nor renal failure present in this PCLD family; however, 12 
members possessed several renal cysts. Only patient III/9 was affected with numerous cysts 
in both kidneys closely associated to the ADPKD criteria.4, 5 
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Additional text for Table S5.
We identified four unique LRP5 variants of which are in two located extracellularly and two 
are located intracellularly. The LRP5 protein structure was created by using a LRP6 template 
as start homology model and reconstruction by YASARA&WHAT-IF Twinset.62 PDB files for 
homology modeling were available for four WD40 domains (β-propeller subdomains). Two LRP5 
variants are located at the second and fourth WD40 domains, respectively (Figure 1). Separate 
models for these domains and the mutations were visualized and analyzed using YASARA.
Table S5. Location of  mutations in LRP5 protein domains.
Family Amino acid change LRP5 domain Location
PCLD-1 p.R1188W 4th β-propeller; 6th blade Extracellular
PCLD-2 p.V454M 2nd β-propeller; 3th blade Extracellular
PCLD-3 p.R1529S Between PPPSP motif A and B Intracellular
PCLD-4 p.D1551N Between PPPSP motif B and C Intracellular
Table S6. Templates for homology models of the LRP5 protein domains.
Domain in LRP5 PDB-file LRP5 identity (%) Reference
1st WD40 3SOV 73 63
2nd WD40 3S94 79 64
3rd WD40 4A0P 80 65
4th WD40 4A0P 65 65
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URLs
 - Primer3, v.0.4.0 (latest version); http://frodo.wi.mit.edu/primer3/;54
 - SNP Check, v.3 (latest version); a tool for performing batch checks for the presence of SNPs in 
predicted PCR primer binding sites; https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck.htm
 - Human genome browser gateway; http://genome.ucsc.edu/cgi-bin/hgGateway; v.hg19 
human reference genome (GCRh37);50, 51
 - 1000 Genomes Project, a deep catalog of Human Variation; http://www.1000genomes.org/
data#DataAccess (in 1,000 individuals variants were assessed in the project);55
 - Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA; November 
2012 accessed; http://evs.gs.washington.edu/EVS/ (in 6,500 individuals variants were assessed 
in the project);24 
 - Database of Single Nucleotide Polymorphisms (dbSNP); http://www.ncbi.nlm.nih.gov/projects/
SNP/;  Bethesda (MD): National Center for Biotechnology Information, National Library of 
Medicine; NCBI dbSNP Build 137; 26th June 2012 available;56 
 - Mouse Genome Informatics; v.MGI 5.12 (last database update 03-13-2013); http://www.
informatics.jax.org/searches/allele_report.cgi?_Marker_key=37359; MGD57
 - Human gene mutation database (HGMD® Professional) (www.biobase-international.com/
hgmd) from BIOBASE Corporation; Professional 2012.4, 14th December 2012 accessed;53
 - MRS database; v.6 (latest version); http://mrs.cmbi.ru.nl/m6/entry?db=sprot&id=lrp5_
human&rq=lrp5_human;52
 - The Wnt homepage; 1997-2013 Roel Nusse; Last up-dated June 2013; http://www.stanford.
edu/group/nusselab/cgi-bin/wnt/
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LRP5 VARIANTS MAY CONTRIBUTE TO ADPKD 
CHAPTER 8
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ABSTRACT
Mutations in PKD1 or PKD2 are causative for autosomal dominant polycystic kidney disease 
(ADPKD). However, a small subset of ADPKD probands do not harbor a mutation in any of the 
known genes. LRP5 was recently associated with hepatic cystogenesis in isolated polycystic 
liver disease (PCLD). 
Here, we demonstrate that this gene may also have a role in unlinked and sporadic ADPKD 
patients. In a cohort of 79 unrelated patients with adult-onset ADPKD, we identified a total of 
four different LRP5 variants that were predicted to be pathogenic by in silico tools. One ADPKD 
patient has a positive family history for ADPKD and variant LRP5 c.1680G>T ; p.(Trp560Cys) 
segregated with the disease. Although also two PKD1 variants probably affecting protein 
function were identified, luciferase activity assays presented for three LRP5 variants significant 
decreased signal activation of canonical Wnt signaling.
This study contributes to the genetic spectrum of ADPKD. Introduction of the canonical 
Wnt signaling pathway provides new avenues for the study of the pathophysiology. 
Keywords
Autosomal dominant polycystic kidney disease; Hepatic cysts; LRP5; PKD1; Sequencing
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INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD; MIM 173900) is the most common 
renal Mendelian disorder  with a global prevalence of 1/400-1/1,000.1 Development of 
multiple fluid-filled cysts may cause bilateral enlarged kidneys and result in end-stage renal 
disease (ESRD). Renal replacement therapy is necessary in about ~5% of ADPKD patients.1 In 
addition, the majority of ADPKD patients have health care issues due to extrarenal features 
and complications such as polycystic liver disease (83%), hypertension (80%), cardiac valve 
abnormalities (25%), intracranial aneurysm (10%) and cysts in the pancreas and other organs.2, 3
There is a broad clinical expression of (extra-)renal manifestations and symptoms among 
ADPKD patients.1,3 The phenotype of affected individuals from single large pedigrees may 
cover the complete spectrum of ADPKD ranging from few renal cysts to grossly enlarged 
polycystic kidneys with renal failure.4 These observations suggest that modifying factors, in 
trans or multiple PKD mutations may influence the onset and course of renal cystogenesis.5, 6
The genotype-phenotype correlation is not completely understood in ADPKD.7 Linkage 
studies identified two disease-causing genes, PKD1 (Chr.16p13.3; NG_008617.1) and PKD2 
(Chr.4q22.1; NG_008604.1).8, 9 Molecular screening may confirm the clinical diagnosis with 
a mutation frequency of 76% PKD1 and 13% PKD2.10, 11 Despite thorough screening ~11% of 
families remain unlinked to either locus, which suggest genetic heterogeneity.10, 11 Approximately 
10% of ADPKD patients have no family history of renal disease.12 These solitary cases may have 
mild or severe polycystic kidneys due to incomplete disease penetrance, de novo (modifier) 
gene variants and environmental influences. 
Recently, we identified the LRP5 gene (Chr.11q13.2; NG_015835.1) as the third locus 
associated with isolated polycystic liver disease (PCLD; MIM 174050) by whole-exome 
sequencing in an extended family.13 Since polycystic liver disease is the most common 
extra-renal feature in ADPKD patients, we hypothesized that LRP5 variants may contribute 
to hepatic and renal disease heterogeneity in ADPKD. We addressed the role of LRP5 by 
screening all 23 exons in 79 unlinked and/or sporadic ADPKD patients, and performed 
some functional analyses.
METHODS
Patients
This study was approved by the institutional review board and ethics committee of the 
Radboud university medical center, Nijmegen. All participants provided informed consent. 
The families were recruited in The Netherlands, screened according to the Ravine criteria14 
and blood samples were collected. 
Polycystic Kidney Disease Mutation Analysis
Mutation screening of PKD1 (NM_001009944.2) and PKD2 (NM_000297.2) involved Sanger 
sequencing of exons and flanking intronic regions and multiplex ligation-dependent probe 
amplification analysis in all probands by using bidirectional Sanger sequencing on ABI3730 
Genetic Analyzers (Applied Biosystems). PKD1 variants were assessed using the Autosomal 
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Dominant Polycystic Kidney Disease mutation database v.3.0,  http://pkdb.mayo.edu/.15 
PRKCSH (NM_002743.3) and SEC63 (NM_007214.4) were analyzed in two probands with 
severe polycystic livers (109 from family A, and 101 from family D) and patient 102 (family B) 
was screened for PKHD1 (NM_138694.3) and HNF-1β (NM_000458.2). 
LRP5 Sequencing and In Silico Analysis
All 23 exons of the LRP5 gene (NM_002335.3) were screened using High Resolution Melting 
followed by Sanger sequencing. Scoring of LRP5 variants was performed with homology 
modeling, in silico analysis such as PolyPhen2, Mutpred, SIFT, Align GVGD, PhyloP and the 
Grantham score. Genome€-wide sequence data from the 1,000 Genomes Project, 6,500 
individuals from the National Heart, Lung and Blood Institute Exome Sequencing Project 
(version 0.0.27), ~500 individuals from the Genome of The Netherlands, exome data from 
~2,000 individuals of predominantly European ancestry sequenced in-house, and DNA samples 
from 525 Moroccan healthy, unrelated individuals served as controls. 
We reported 1 LRP5 variant (rs724159825) and 3 PKD1 variants (rs724159824; rs724159822; 
rs724159823) described in this manuscript to the public dbSNP database.
Immunofluorescence and quantative PCR
Subsequently, immunofluorescence studies, luciferase activity assays and quantative PCR (qPCR) 
experiments with wild-type and four mutant LRP5 constructs were conducted. Transfected 
HeLa cells were stained in order to elucidate the co-localization of LRP5 to the endoplasmic 
reticulum, Golgi apparatus and the plasma membrane (Supplementary Methods).  
Luciferase Activity Assay and Real-Time PCR
Wnt signaling activity was assessed using the Cignal Reporter TCF/LEF Assay Kit (Qiagen) 
after transfecting CHO or HEK293 cells with wild-type or mutant constructs and addition of 
hWnt3a (R&D Systems).
Expression levels of Wnt target genes were assessed in Wnt3a-activated and non-activated 
transfected HEK293 cells by Real-Time PCR (RT-PCR). 
RESULTS
A subset of 29 ADPKD patients had genotypic prescreening. Molecular diagnostics was 
performed for PKD1, PKD2 and PKHD1 (Chr.6p12.2; NG_008753.1) in adults. Additional analysis 
of HNF1ß (Chr.17q12; NG_013019.1) was performed in adolescents when genotype screening 
of PKD1, PKD2 and PKHD1 were negative. No point mutations, CNV or large deletions were 
identified and all 29 affected individuals were designated as being unlinked. A group of 50 
patients had a clinical diagnosis of ADPKD with a symptomatic polycystic liver. Variants for 
PCLD in PRKCSH (Chr.19p13.2; NG_009300.1) and SEC63 (Chr.6q21; NG_008270.1) affecting 
protein function were excluded, but the PKD genotype was unknown in this group. In this 
heterogeneous cohort of 79 ADPKD patients, we identified four LRP5 variants by Sanger 
sequencing (Table 1). Both unique LRP5 variants were detected in the subgroup of ADPKD 
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with a severe polycystic liver. Here we present the data of 3 adult-onset ADPKD patients and 
1 adolescent ADPKD patient (Figure 1 and Figures S1, S2 and S3). 
Family A
The proband (109) presented to us with a symptomatic polycystic liver and renal cysts of 
various sizes at 51-years-of-age (Table 1). She was clinically diagnosed as ADPKD. Mutational 
screening of PRKCSH and SEC63 yielded no variants causing hepatic and renal cystogenesis. 
She was from Moroccan ancestry and her ancestors did not have renal disease suggestive 
for ADPKD. During the first pregnancy of her oldest daughter (202), polycystic kidneys and 
several small hepatic cysts were detected by abdominal ultrasonography. Renal failure was 
absent and mild hypertension was under control by use of an AT2-receptor antagonist. Both 
patients fulfilled the unified Ravine criteria for ADPKD.14 
By LRP5 variant analysis, we identified a unique missense variant c.1680G>T ; (p.(Trp560Cys); 
rs377144001) in both Moroccan patients (109 and 202). This LRP5 variant is not detected in 
genome-wide sequence data such as 1,000 Genomes Project, and ~2,000 in-house exome 
sequencing data from patients of European ancestry. In addition, LRP5 c.1680G>T is neither 
detected in 4,400 African-American exome sequencing cohort from the National Heart, 
Lung and Blood Institute (NHLBI) Exome Sequencing Project (ESP). This variant was recently 
identified once in an ESP European-American cohort with a total allele frequency of 1/12,988 
(rs377144001, dbSNP v.138). The variant LRP5 c.1680G>T was not present among 525 tested 
Moroccan DNAs of unrelated individuals. 
In silico analysis predicts this variant to be pathogenic and alters a conserved LRP5 amino 
acid (Table 2). Homology modeling indicated that this missense variant affects one of the 
tryptophans which are important for the core structure of this domain. Multiple hydrophobic 
interactions and a hydrogen bond will be lost by the tryptophane amino acid change into 
cysteine. This variant is highly likely to change the secondary and tertiary structure of the 
protein, and to disturb the function of the second WD40 domain function.
Table 1. Patient characteristics.
Baseline characteristics
At first presentation 
(diagnosis) Treatment for polycystic kidneys
Family Subject Age (y) Sex Age (y)
Creatinin 
(μmol/l) ESRD Medical/ Surgical
A 109 56 F 51 155 Yes Thiazide and AT2-receptor antagonist;
9-months octreotide 
202 33 F 24 79 No Antihypertensive treatment
B 101 60 M 55 80 No Antihypertensive treatment
C 102 18 F 14 64 No -
D 101 51 F 43 114 Yes Antihypertensive treatment; 
kidney transplantation
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Variants in the genes PKD2, PKHD1, PRKCSH and SEC63 affecting the protein function 
were absent, but molecular diagnostics of PKD1 revealed two unique variants. Both PKD1 
variants, c.1281_1283delGGC ; p.(Ala428del) (rs724159824) in exon 6 and c.3133G>C 
; p.(Val1045Leu) (rs724159822) in exon 13, were present in the proband (109). The 
p.(Ala428del) had been transmitted to the 33-year-old affected daughter (202), while the 
27-year-old healthy daughter (203) inherited p.(Val1045Leu). In addition, the 25-year-old 
healthy daughter (204) harbors also p.(Val1045Leu), but in a homozygous state (PKD1 
c.3133G>C homozygous). Both PKD1 variants are unreported in the literature (unclassified 
variants), online and in-house databases and are localized in evolutionarily moderately-low 
conserved domains. 
The PKD1 missense variant p.(Val1045Leu) may be a benign variant since this variant had 
been transmitted to the unaffected daughter (203). The consequence of this PKD1 variant is 
currently unclear, but non-penetrance or late-onset of ADPKD may play a role. The contributing 
effect of p.(Ala428del) is unclear, but homology modeling suggests that the nascent residues 
surrounding codon 248 are not conserved and that the C-type lectin domain is not pathogenic 
altered. It is well conceivable that the identified changes in this patient may exhibit their full 
pathogenic effect in concert.
Family B
A 57-year-old Dutch male came to our attention because of uncontrolled hypertension. 
Extensive clinical and radiological examination demonstrated large, complicated (multilocular) 
renal cysts (Figure S1). 
There was no family history for polycystic diseases, liver or renal disease. Therefore, no 
consent was retrieved for phenotype and genotype screening in family members. PKD1 and 
PKD2 variants were absent in the proband and Sanger sequencing of the LRP5 gene identified 
c.3107G>A ; p.(Arg1036Gln; rs61889560). This variant reported an incidence of 0.001-0.005 
Table 2. LRP5 variants in ADPKD patients. 
Family Ethnicity
Position 
(GRCh37; hg19)
Variant (c.DNA; 
NM_002335.2)
Exon 
(NG_015835.1)
Predicted 
effect on 
protein
Polyphen2 
(Class; score) Mutpred
SIFT (Class; 
score) Align GVGD PhyloP
Grantham 
score
Frequency in 
controls* (EVS) 
A Moroccan g.68171046 c.1680G>T 8 p.(Trp560Cys) Probably 
damaging 
(1.00)
0.770 Deleterious 
(0.00)
Class C65 
(GV:0.00-
GD:214.36)
5.54 215 1/12,988
B Dutch g.68191036 c.3107G>A 14 p.(Arg1036Gln) Possibly 
damaging 
(0.658)
0.785 Tolerated 
(0.06)
Class C0 
(GV:28.82-
GD:19.90)
1.74 42 1/245
C Dutch g.68192736 c.3403C>T 15 p.(Arg1135Cys) Probably 
damaging 
(1.00)
0.586 Deleterious 
(0.00)
Class C65 
(GV:0.00-
GD:179.53)
4.00 180 1/1,299
D Dutch g.68193486 c.3468G>C 16 p.(Gln1156His) Probably 
damaging 
(1.00)
0.702 Deleterious 
(0.00)
Class C15 
(GV:0.00-
GD:24.08)
3.76 24 -
*Allele frequency
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Table 2. LRP5 variants in ADPKD patients. 
Family Ethnicity
Position 
(GRCh37; hg19)
Variant (c.DNA; 
NM_002335.2)
Exon 
(NG_015835.1)
Predicted 
effect on 
protein
Polyphen2 
(Class; score) Mutpred
SIFT (Class; 
score) Align GVGD PhyloP
Grantham 
score
Frequency in 
controls* (EVS) 
A Moroccan g.68171046 c.1680G>T 8 p.(Trp560Cys) Probably 
damaging 
(1.00)
0.770 Deleterious 
(0.00)
Class C65 
(GV:0.00-
GD:214.36)
5.54 215 1/12,988
B Dutch g.68191036 c.3107G>A 14 p.(Arg1036Gln) Possibly 
damaging 
(0.658)
0.785 Tolerated 
(0.06)
Class C0 
(GV:28.82-
GD:19.90)
1.74 42 1/245
C Dutch g.68192736 c.3403C>T 15 p.(Arg1135Cys) Probably 
damaging 
(1.00)
0.586 Deleterious 
(0.00)
Class C65 
(GV:0.00-
GD:179.53)
4.00 180 1/1,299
D Dutch g.68193486 c.3468G>C 16 p.(Gln1156His) Probably 
damaging 
(1.00)
0.702 Deleterious 
(0.00)
Class C15 
(GV:0.00-
GD:24.08)
3.76 24 -
*Allele frequency
(1/245) in public databases. The missense variant is located at the fourth WD40 and may lead 
to a less stabilized domain due to loss of hydrogen and ion binding. 
Family C
A 14-year-old female (102) was diagnosed with 2 large, symptomatic cysts with a diameter 
of 4.5 cm each and a small (‘intrapolar’) cyst were present in the left kidney with a normal 
right kidney (Figure S2). Creatinine levels remained between 61-71 µmol/l within the normal 
range (50-90 µmol/l) during 4 years of follow-up. Her blood pressure was 130/70 mmHg 
and regularly monitored at home. Family history was negative for ADPKD, ARPKD and PCLD 
or other genomic disorders, but her mother was diagnosed at the age of 30 with nephrotic 
syndrome of unknown cause. Both parents were screened and there were no structural renal 
abnormalities on ultrasonography. 
Molecular diagnostics showed no evidence for the diagnosis of ADPKD or ARPKD by 
analyses of the PKD1, PKD2, PKHD1 and HNF1β gene. We identified the LRP5 variant c.3403C>T 
; p.(Arg1135Cys; rs143396225). This variant is reported with a frequency of 1/1,300 in the 
European American ESP cohort from the NHLBI, and absent in the 1,000 Genomes Project 
dataset and ~2,000 DNA exomes sequenced in-house. In silico analyses predicted LRP5 
c.3403C>T to be disease-associated with pathogenic effects for the protein function (Table 
2). Homology modeling showed that the arginine is located at the fourth WD40 domain. The 
p.(Arg1135Cys) variant results in a change of a hydrophilic molecule to an apolar hydrophobic 
amino acid which may contribute to a destabilized WD40 domain. The loss of ionic interactions 
is likely to affect the function of the protein domain.
Family D
Bilateral enlarged kidneys containing multiple fluid-filled cysts were an accidental finding on 
ultrasonography in the proband (101) at the age of 43 (Figure S3). Her blood pressure was 
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Figure 1. Clinical and genetic data of ADPKD family A. Pedigree of family A present two 
affected individuals, proband 109 and daughter 202. Affected individuals indicate those with 
confirmed ADPKD on CT scanning or abdominal ultrasound according to the Ravine criteria. (B) CT 
scanning in proband 109 presented a severe polycystic liver in segments 2, 3 and 8 and the kidney 
sizes were craniocaudal 19cm (left) and 21cm (right) in diameter. Abdominal ultrasonography in 
patient 202 assessed polycystic kidneys (white arrows) and multiple small hepatic cysts (dotted 
white arrows). (C) PKD1 c.1281_1283delGGC and PKD1 c.3133G>C were detected in the proband. 
Both PKD1 variants are located in low evolutionary conserved regions in contrast to LRP5 c.1680C>T. 
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(D) The in-frame PKD1 deletion is located on an extracellular C-type lectin domain at the end of 
a loop close to a double helix structure. The alanine deletion shortens the strand, but there is no 
destabilization of the domain which is closely located to a rigid double helix structure with many 
hydrogen bounds. Missense variant PKD1 p.(Val1045Leu) is located on the fifth tandem PKD domain 
without a difference in charge between wild-type and mutant protein. (E) Confocal imaging studies 
in transiently transfected HeLa cells identified co-localization of LRP5 in the endoplasmic reticulum. 
There were no differences between LRP5 localization compared to the wild-type LRP5 construct 
for all four LRP5 variants.
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under control (128/70 mmHg) with an antihypertensive ACE-inhibitor and she used antacid 
medication. Eight years after identification of polycystic kidneys, the 51-year-old patient 
received renal transplant from a living unrelated donor.
Family history for polycystic or renal diseases was unremarkable. No PRKCSH or SEC63 
variants affecting the protein function were present, but PKD screening revealed 2 PKD1 variants; 
c.8293C>T ; p.(R2765C) (rs144979397) on exon 23 and PKD1 c.11554delC ; p.(L3852Wfs*93) 
(rs724159823) on exon 42. The mother also harbors the PKD1 missense variant p.(R2765C) 
which is predicted to be likely hypomorphic.30,15, 16 Frameshift variant PKD1 c.11554delC is a 
recently reported variant with a clear pathogenic character.16 PKD1 analysis in genomic DNA 
from the father was unavailable.
Sequence analysis of the LRP5 gene yielded a unique LRP5 c.3468G>C ; p.(Gln1156His) 
(rs724159825) in the proband which was absent in the DNA from both parents. The LRP5 
variant p.(Gln1156His) was absent in dbSNP and all aforementioned online and in-house exome 
sequence datasets. This missense variant was predicted to be damaging and the amino acid 
is located between blades 5 and 6 of the fourth β-propeller domain. Glutamine may interact 
by hydrogen bonds with adjacent arginine, but shows hydrophobic features at this position. 
Histidine contains an imidazole functional group which stereometrically changes the position. 
The major effect of this missense variant is the change in electrostatic charge which may 
result in disturbed interactions at the surface of the protein domain. 
Functional studies
Confocal imaging studies identified co-localization of LRP5 in the endoplasmic reticulum, but 
no differences were identified between LRP5 localization compared to the wild-type LRP5 
construct for all four LRP5 variants (Figure 1).
Luciferase activity assays of variant LRP5 compared to wild type LRP5 constructs were 
conducted to estimate Wnt signaling defects. Addition of ligand Wnt3a reduced Wnt signaling 
activity in LRP5 variants p.(Trp560Cys), p.(Arg1036Gln) and p.(Gln1156His) (Figure 2). Wnt 
signaling activation showed an increasing tendency for AXIN2 and LEF1 gene expression 
(supplementary figures). LRP5 variant p.(Trp560Cys) compared to LRP5 wild-type presented 
significant increased AXIN1 and LEF1 expression by Wnt3a activation.  
DISCUSSION
The data presented here suggest  a role of LRP5  in ADPKD. We discovered two unique and 
two rare LRP5 variants in ADPKD patients regardless of family history or presence of PKD 
mutations. The association of LRP5 variants with hepatic cystogenesis was identified in an 
extended PCLD pedigree.13 The fact that polycystic livers are present in up to 94% of ADPKD 
patients2 prompted us to investigate the possible pathogenic role of LRP5 variants in ADPKD 
patients. There are a number of functional and animal studies that support the thinking that 
LRP5 variants may contribute to hepatic and renal cystogenesis.
LRP5 is a single transmembrane co-receptor involved in the canonical Wnt signaling pathway 
that orchestrates mammalian organogenesis. Northern blotting studies indicate that LRP5 is 
strongly expressed in both liver and kidneys.17 In addition, there is abundant LRP5 expression 
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by binding of a Wnt ligand to a cognate Frizzled receptor in the presence of LRP5. The role 
of canonical  Wnt signaling in ADPKD has been an area of research.19-24
Increased canonical Wnt signaling19-21 and diminished signal activation or stable β-catenin22-
24 that lead to an opposite effect of planar cell polarity/non-canonical signaling (PCP) have 
been reported in different ADPKD mouse models. These data suggests renal cystogenesis is 
initiated by imbalance between canonical and PCP signaling.25 Indeed, polycystins modulate 
Wnt activity and disruption of either pathway may lead to polycystic kidney disease.19, 20 During 
the late stage of nephron maturation polycystins are required for terminal differentiation of 
epithelial cells.26 This led to the model that put the canonical/β-catenin pathway as one of 
the downstream effectors for ADPKD.27
A targeted knock-out LRP5 mouse develops hepatobiliary abnormalities without specified 
hepatic nor renal morphology23, although it is known that LRP5 models have limited 
severity of Wnt disease phenotype compared to the almost identical LRP6 gene.28 The 
LRP6 knock-out mouse model is lethal, in view of severe developmental defects that 
affect skeleton, retina, ureter (E8.5). At E18.5 macroscopic small cystic kidneys are visible, 
suggesting a PKD phenotype.23 These findings support the notion that Wnt signaling is 
pivotal during early kidney development while polycystins appear to be critical during final 
stages of renal tubulogenesis.27
This paper provides evidence that the discovered variants affect LRP5 function. Luciferase 
activity assays of four LRP5 constructs decrease Wnt3a-induced signal activation across various 
cell lines (Figure 2).13 In addition, the expression of AXIN2, a Wnt signaling gene is enhanced in 
Figure 2. LRP5 variants present reduced activation of canonical Wnt signaling. Canonical Wnt 
signaling activity was analyzed by firefly luciferase activity and normalized to renilla luciferase activity 
without (white bar) and with (grey bar) addition of 250 ng/mLWnt3a. LRP5 constructs showed a 
significant increase in Wnt signaling activity compared with the empty vector. LRP5 variants p.(Trp560Cys), 
p.(Arg1036Gln) and p.(Gln1156His) presented a decreased Wnt3a-induced signal activity (*p<0.05; 
**p<0.01). (B) All LRP5 variants indicated only concordantly increased AXIN2 expression levels by Wnt3a 
activation. (C) LEF1 and others showed slightly increased gene expression. Significant increased AXIN1 
and LEF1 expression by Wnt3a activation was present in LRP5 variant p.(Trp560Cys) compared to LRP5 
wild-type (*p<0.05). The y-axis presents the relative gene expression level.
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the presence of 3 LRP5 mutants (Figure S5). This suggests that there is constitutive activation 
of the Wnt signaling as a result of these LRP5 variants.
Loss or gain of function of genes involved in Wnt signaling may lead to an imbalance 
between canonical and non-canonical signaling events.29 There is evidence that key players 
of Wnt signaling modulate the renal disease severity in ADPKD by antagonizing canonical 
Wnt signaling.5, 6 Three SNPs in DKK3 downregulate canonical Wnt signaling similar to 
our data for LRP5.5 In addition, HNF-1β which orchestrates Wnt signaling may aggravate 
congenital renal cystogenesis in mice and human ARPKD and ADPKD.6, 30 Failure of canonical 
Wnt signaling homeostasis will result in activated non-canonical signaling. It is likely that 
other genes or modifier genes in the Wnt signaling pathway are linked to hepatic and renal 
cystogenesis.19 
Multiple PKD variants may cause early and more severe renal disease in ADPKD.6 Although 
the pathogenic character of both PKD1 variants in family A remains unclear, we surmise that 
the resulting in-frame deletion of an alanine amino acid neighboring another alanine does 
not significantly affect the protein domain structure. A PKD1 missense variant p.(Val1045Met) 
(c.3133G>A) in the fifth PKD domain has been predicted to be likely hypomorphic.31 At the 
similar sequence position we detected PKD1 c.3133G>C leading to a hydrophobic amino 
acid change. Leucine and methionine are different regarding presence of a methyl group in 
leucine and a sulfide molecule in methonine which are both larger components compared 
to amino acid valine.
The case is different for the PKD1 variants identified in proband 101 from family D. PKD1 
c.8293C>T ; p.(Arg2765Cys) is present in an unaffected parent, but also probably hypomorphic 
and is weakly conserved.15, 32 The second PKD1 variant, c.11554delC ; p.(Leu3852Trpfs*93), is 
detected by next-generation sequencing and probably causative for the ADPKD phenotype.16 
This family had a negative history for ADPKD which suggests a de novo onset of the PKD1 
gene variant which has been described before.12 In order to detect the additional mutational 
effect of a LRP5 variant to the PKD1 c.1154delC, investigation of the severity of clinical ADPKD 
phenotype and subsequent functional studies are required.
Previous studies provided evidence that the type of PKD1 variant correlates strongly with 
renal survival. Carriers of a truncating PKD1 variant have an earlier age at onset of ESRD which 
supports the concept of a genotype phenotype correlation in ADPKD.33 
In conclusion, several in vitro and in vivo studies suggest involvement of aberrant Wnt 
signaling and unregulated β-catenin levels contribute to renal cystogenesis.22, 23 Our findings 
are in line with the hypothesis that genes encoding Wnt/β-catenin signaling partners may be 
candidate loci for cystic disorders.13, 19 We postulate that LRP5 variants may render ADPKD 
patients more susceptible to the development of polycystic liver although further studies are 
needed to validate our findings.
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SUPPLEMENTARY TEXT
Additional Information ADPKD Families
Family A
Family history
The proband (109) was the ninth child from a family of 13 from Moroccan ancestry. Almost 
all relatives emigrated to different countries in Europe and Africa, and therefore they had 
scarcely any familial contact. Her father died at the age of 53 years of an unknown cause. Her 
mother reached the age of 91 years. Both parents were unknown for PCLD, ADPKD, and no 
renal diseases or abdominal complaints are reported. The initial family history was negative 
for polycystic liver and kidney diseases. To our knowledge now, possibly one cousin (~40-
year-old nephew of 109) is known with hepatic cysts and referred for surgery in Morocco 
(meta-history). During the pregnancy of her oldest daughter (202), renal cystogenesis was 
detected by ultrasound screening.
Proband 109
The 56-year-old proband 109 from Moroccan ancestry was affected with multiple cysts 
spread throughout the liver and both kidneys. It remains unknown when the first diagnosis 
of ADPKD is established. Our information reaches until the moment she visited a secondary 
hospital ~5 years ago. There, she was clinically diagnosed as ADPKD patient according to 
the Ravine criteria. 
When she visited our hospital, renal failure was present with MDRD-GFR 24 ml/min/1.73m2 
(creatinin 188 µmol/l) at the age of 56-years-old. She had a history of H. bacter gastritis, 
short-term octreotide treatment (9 months). There was no indication for liver transplantation 
after consultation of a pre-liver transplant institution. Contraceptive medication had been 
administered during 20 years and she had seven pregnancies. She had major complaints 
due to the volume effect of multiple cysts. Superficially liver and kidney cysts were palpable 
during clinical examination and caused daily abdominal tenderness and pain. Furthermore, 
she complained of dyspnea, nausea, pyrosis and fatigue. The condition of proband 109 was 
not sufficient to enroll a clinical trial as treatment strategy. No renal replacement therapy has 
been started. Currently, renal function and hypertension are under control three-monthly in 
a secondary care hospital (Figure 1). 
Family member 202
Clinically, only her oldest daughter (202) presented several small hepatic cysts and bilaterally 
polycystic and enlarged kidneys. Renal failure is absent and she has no renal replacement 
therapy. She delivered three healthy children and used anticonceptive medication for 
several (about three) years until now. Recently, she had two times treatment for proven 
pyelonephritis. Her blood pressure is under control with an anti-hypertensive AT2-receptor 
antagonist. 
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Family members 203 and 204
We were able to contact two more daughters. After informed consent, we performed 
abdominal ultrasound screening of the liver and both kidneys. Family member 203 was a 
27-year-old female without a medical history. Family member 203 was a 25-year-old female 
without a medical history also. They had no symptoms associated with liver or renal disease 
nor used any medication (Table S1 and S2).  No hepatic or renal cysts were detected by 
using a 3.6MHz general-purpose clinical echo system (Acuson x150, Siemens AG, Germany) 
equipped with a curved linear array transducer.
Genotype analysis
In our hospital, we previously performed molecular diagnostics for PRKCSH and SEC63. We 
detected no pathogenic variants associated with PCLD. 
Screening of all 23 LRP5 exons identified a unique variant c.1680C>T ; p.(Trp560Cys) 
(Table 1 and S3). Molecular diagnostics of the PKD1 gene revealed 2 private PKD1 variants, 
c.1281_1283delGGC (p.(Ala428del)) and c.3133G>C (p.(Val1045Leu)) in the proband (109). 
The p.Ala428del had been transmitted to the 33-year-old affected daughter (202), while the 
27-year-old healthy daughter inherited p.(Val1045Leu) (205). Both PKD1 variants have not 
been reported in the literature, online and in-house databases before and are localized in 
evolutionarily moderately-low conserved domains. The PKD1 missense variant p.(Val1045Leu) 
can be regarded as a benign variant since this variant had been transmitted to the unaffected 
daughter. However, the exact character of the p.(Ala248delinsAla) is unclear (Table S4 and 
S5). Analysis of homology models demonstrated that the nascent residues surrounding codon 
248 are not conserved and that the C-type lectin domain is not pathogenic altered (Table S6 
and S7). In addition, only one PKD1 deletion (c.1273_1275delGAG; p.(Glu425del)) located on 
exon 6 has been described.15
We identified the missense variant c.1680G>T ; p.(Trp560Cys) in the LRP5 gene and 
confirmed presence of this variant in an 33-year-old affected child (202) using Sanger 
sequencing. 
Family B
Family history
There was no apparent family history for polycystic diseases, renal or hepatic diseases. The 
family origins from The Netherlands and present no familial disorders. Thirty-five years ago, 
the father of proband 101 deceased at the age of 66 because of colon cancer (Figure S1). His 
mother reached the age of 84 and died due to age. Additional inquires for hepatic or renal 
(cystic) disease was negative in brothers, sisters and cousins.
Proband
This 60-year-old male proband had no history of polycystic diseases, renal or hepatic disease 
nor ADPKD-related extra-renal manifestations before polycystic kidneys were detected. 
Two years after the clinical diagnosis of ADPKD, the patient developed paroxysmal atrial 
fibrillation, neutropenia e causa ignota and scarce urolithiasis. He administered a HMG-CoA 
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reductase inhibitor (statin), a combined antihypertensivum with an ACE-inhibitor and a calcium 
antagonist (coveram), a β-blocker, thiazide and aspirin. The blood pressure is under control 
and the patient presents no symptoms.
Genotype analysis
Unfortunately, there was no DNA from both parents available. Parentage screening of LRP5 
c.3107G>A could not be conducted.
Family C
Family history
No apparent family history was present for hepatic and/or renal disease, including polycystic 
diseases (Figure S2). Both parents had screening for cystogenesis when proband 202 was 
diagnosed with renal cysts. The mother and father presented normal kidneys and urinary 
system. No consent was provided to perform abdominal ultrasound screening for the liver 
and both kidneys. Only two cysts in the right adnex was detected in the mother. Additional 
family studies were not indicated. The history of the father of proband 202 presented 
an episode of liver function disturbances e causa ignota. Abdominal ultrasonography 
excluded steatosis and intrahepatic bile duct dilatations, and the liver function resolved 
spontaneously. 
Proband
Clinical examination indicated no liver disease which was confirmed by normal liver test 
values and MRI scan. She suffered from episodes of nausea and initially left-sided abdominal 
pain from unknown origin. The abdominal pain was frequently associated with vomiting 
and sustained after different treatment strategies. She presented non-dysmorphic features 
and additional clinical investigations of the heart, lung, extremities and development were 
unremarkable. Abdominal ultrasonography revealed unilateral renal cystogenesis, but no 
dysgenesis of the right kidney. Finally, this was the explanation for her abdominal complaints. 
Renography excluded ureteropelvic junction stenosis and presented 44% function of the left 
kidney and 56% of the right kidney. Recent radiological examination presented regular renal 
contour, normal cortex and medulla differentiation of both kidneys. The length of the left and 
right kidney was assessed at 13.4 cm and 11.7 cm respectively without development of novel 
renal cysts or other urinary tract anomalies. In addition, multicystistic ovaria were detected 
on ultrasonography. The patient is normotensive.
Genotype analysis
Molecular diagnostics for PKD1, PKD2, PKHD1 and HNF1β were negative in the proband. The 
only detected variant is LRP5 c.3403C>T ; p.(Arg1135Cys). 
Family D
Family history
Her father died at the age of 70 from metastasized urothelial carcinoma grade III. CT scanning 
showed normal liver and kidneys at that time. Her 75-year-old mother had hypertension and 
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suffered from vascular diseases. Proband 101 has no brothers or sisters. No consent was given 
for screening of her 18-year-old son. In addition, no apparent extra-renal ADPKD-associated 
manifestations were present by taking history.
Proband
Polycystic kidneys were identified in this index patient at the age of 43. The first sign was 
abdominal swelling. She administered oral contraconceptives for 15 years and had one 
pregnancy.  Four years after diagnosis was set she presented to us with pyrosis, fatigue, 
weight loss and anorectic problems (Figure S3). Major complaints included frequent right-sided 
pain attacks for 2-3 days and a decreased physical activity. Hepatomegaly and cysts were 
palpable in both flanks by clinical examination. Multiple hepatic cysts and polycystic kidneys 
were detected by abdominal ultrasonography. Her blood pressure was under control (128/70 
mmHg) with antihypertensive ACE-inhibitor and administered anti-acida. At presentation a 
pre-terminal renal insufficiency with GFR 21 ml/min/1.73m2 (creatinin 114 µmol/l) with normal 
liver parameters was assessed and renal function declined within 3 years. Patient 101 required 
a kidney donor and underwent pre-transplantation screening when her creatinin level was 
increased to 297 µmol/l in 2009. She underwent a living kidney donor transplantation at 
the age of 51. 
Genotype analysis
LRP5 c.3468C>G ; p.(Gln1156His) was detected in the proband. Although her father deceased 
13 years earlier, we were able to isolate DNA from paraffin-embedded tissue. CT scans before 
his death showed no cystogenesis.
The living kidney transplantation for proband 101 derived from an unrelated, healthy 
individual. PKD screening revealed two PKD1 variants; c.8293C>T (p.(Arg2765Cys); exon 23) 
and PKD1 c.11554delC (p.(Leu3852Trpfs*93); exon 42). The mother also harbors the PKD1 
missense variant (rs144979397) which is predicted to be likely hypomorphic. Frameshift variant 
PKD1 c.11554delC is a recently reported variant with a clear pathogenic character (Table S6 
and S7). PKD analysis in the father was not possible because genomic DNA was unavailable.
SUPPLEMENTARY METHODS
DNA Isolation
Genomic DNA was extracted from blood leukocytes using the HP-PCR Template Preparation 
kit (Roche Applied Science). DNA isolation from paraffin-embedded sections was performed 
in individual 002 from family D using the QIAamp DNA Micro-Kit (Qiagen).
LRP5 Variant Detection
For all 23 LRP5 coding exons primers were designed using Primer3 software.34 We performed 
high resolution melting curve analysis using the RotorGene-Q and ScreenClust software 
(Qiagen) and validated genotype variants by Sanger sequencing on ABI3730 Genetic Analyzers 
(Applied Biosystems) (GRCh37, hg19).35, 36 LRP5 primer sequences are available on request.
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LRP5 Variant Analysis
We created the LRP5 protein structure using a LRP6 template as start homology model and 
reconstruction by YASARA&WHAT-IF Twinset.37 For WD40 domains (β-propeller subdomains) 
PDB-files were available to incorporate the identified LRP5 variants for analysis of structural 
effects.38, 39
In silico analysis with PolyPhen2, Mutpred, SIFT, Align GVGD, PhyloP and the Grantham score.
Genome-wide sequence data from the 1,000 Genomes Project40, 6,500 individuals from 
the National Heart, Lung, and Blood Institute Exome Sequencing Project (EVS Release Version: 
v.0.0.27., April 18, 2014)41, ~500 Dutch individuals from the Genome of The Netherlands42, 
and exome data from 2,000 individuals of predominantly European ancestry sequenced 
in-house served as controls.43, 44
DNA samples from 525 Moroccan healthy, unrelated individuals were used as controls 
for LRP5 c.1680G>T ; p.(Trp560Cys) in family A from Moroccan ancestry.
Immunofluorescence Studies
5.0x104 HeLa cells per well were seeded on poly-L-lysine coated Ø12mm cover glasses in a 
24-wells plate and transiently transfected with 500ng of wild-type or mutant LRP5 construct. 
After 24 hours medium was refreshed and cells were cultured for another 24 hours followed 
by paraformaldehyde fixation and antibody immunofluorescence staining. 
Antibodies
A rabbit monoclonal anti-LRP5 antibody (Clone D23F7; 1:200; Cell Signaling) recognizing 
residues surrounding Pro1527 of human LRP5 protein (#3889; 200kDa) was conducted for 
imaging studies. 
For immunofluorescence assays rabbit anti-LRP5 was combined subsequently with primary 
antibodies against endoplasmic reticulum, golgi and cell membrane proteins. The following 
primary antibodies were used mouse monoclonal anti-protein-disulfide isomerase (PDI) (Clone 
1D3; 1:500; Stressgene Bioreagens), mouse monoclonal anti-giantin (Clone G1/133; 1:100; 
Enzo Life Sciences), mouse monoclonal anti-CD44 (Clone 15-3c11; 1:400; Thermo scientific). 
Secondary AlexaFluor-conjugated antibody immunostaining (Alexa488, Alexa568; 1:200 and 
Alexa647; 1:100; Invitrogen) and 4’,6-diamidine-2-phenylindole (DAPI) nucleus staining (1µg/
ml Sigma) were used for immunofluorescence image acquisition by a high content microscope 
(Leica TCS SP5 Microsystems) and a confocal laser scanning microscope (Fluoview FV1000, 
Olympus).
Mammalian Expression Constructs
Total RNA was isolated from liver tissue using Trizol Reagent (Invitrogen) and oligodT cDNA 
was obtained by RT Transcriptor First Strand cDNA synthesis kit (Roche Applied Sciences). 
Full length wild-type LRP5 was obtained using the Faststart High Fidelity PCR System (Roche). 
LRP5 was cloned into the mammalian expression vector pcDNA3.1V5His TOPO-TA (Invitrogen) 
and checked by sequence analysis. LRP5 mutants c.1680G>T, c.3107G>A, c.3403C>T and c. 
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3468C>G were constructed by mutating the pcDNA.LRP5.WT vector using the Quick Change-
II-XL Site-Directed Mutagenesis Kit (Agilent Technologies). Primers for LRP5 constructs are 
available on request. 
Luciferase Acitivity Assay
For the activity assay 5.0x103 CHO cells per well were seeded in a 96-wells plate in triplicates 
and cultured them for 24 hours. Cells were transiently transfected using X-tremeGeneHD 
(Roche) with 100ng LRP5 construct or empty vector and 100ng of Reporter or 100ng Negative 
control (Cignal Reporter TCF/LEF Assay Kit; Qiagen). After 16h cells were washed with PBS 
and medium with or without 250ng/ml hWnt3a (5036-WN, R&D Systems) was added to 
initiate the Wnt signaling. Cells were cultured for another 24 hours and luciferase activity was 
detected using the Dual-Glo Luciferase assay (Promega) in a TECAN M200 plate reader. Firefly 
luciferase activity was normalized to Renilla luciferase activity for variations in transfection 
efficiencies as reported previously.13 These experiments were repeated in HEK293 cells and 
presented identical results for LRP5R1135C and similar significant decreased activated signaling 
for LRP5W560C and LRP5R1156Q. Transiently transfected CHO and HEK293 cells expressed >1,000 
times more compared to the empty vector. These experiments were conducted in triplicates 
and performed three times and values present means ± standard deviation. 
Quantative PCR Experiments
We conducted transient transfections of human embryonal kidney cells (HEK293; ATCC 
CRL-1573) with LRP5 constructs as previously described.13 The signaling was activated by 
addition of Wnt3a for 24 hours. Total RNA was extracted with TRIzol (Invitrogen). Template 
cDNA was obtained using the iScript cDNA synthesis kit (Biorad). Expression levels of Wnt 
target genes were assessed twice by qPCR experiments (in triplicates). We researched genes 
associated with the canonical Wnt signaling pathway listed at the Wnt homepage; axis 
inhibitor-1 (AXIN-1), axis inhibitor-2 (AXIN-2), cyclin D1 (CCND1), lymphoid enhancer-binding 
factor 1 (LEF1) and other target genes. 
The transfected cells expressed LRP5 >1,000 times which indicates an adequate transfection 
efficiency. There was an increased basal gene expression for almost all mutant constructs and 
genes compared to the wild-type construct (Figure S4). Wnt3a-ctivated signaling resulted in 
significant increased AXIN2 gene expression for all LRP5 constructs (Figure S5).
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SUPPLEMENTARY FIGURES
Figure S1. Family B. Pedigree of family B. (B) CT scanning of proband 101 (axial and frontal). Renal 
cysts are indicated by white arrows. (C) LRP5 c.3107G>A results in an amino acid change located in a 
moderate-high conserved region. (D) Homology modeling presents the consequence of the missense 
variant. The amino acid change of arginine results in loss of hydrogen and ion binding interactions which 
may destabilize the WD40 domain.
Figure S2. Family C. Pedigree of family C. (B) CT scanning presents large renal cysts in the left kidney 
and a small cyst in the right kidney (white arrows). (C) LRP5 c.3403C>T  is located at an evolutionary 
highly conserved region. (D) Homology modeling  shows that the variant results in a WD40 domain 
with a diminished stability.
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Figure S3. Family D. Pedigree of family D. (B) CT scanning before kidney transplantation presents multiple 
fluid-filled hepatic cysts (dotted white arrows). Polycystic kidneys are indicated by white arrows. (C) The 
LRP5 c.3468C>G is located in a highly conserved region in contract to both PKD1 variants. (D) Change 
in electrostatic charge results in severely disturbed interactions at the surface of the protein domain.
Figure S4. Basal gene expression levels. Basal gene expression levels of genes associated with the 
canonical Wnt signaling pathway. No Wnt3a was added to activate signaling. We corrected results 
for LRP5WT levels. The y-axis presents the relative gene expression level. One LRP5 mutant construct 
showed significant GSK3β and c-Myc gene expression (*p<0.05). Significant decreased gene expression 
is presented in LRP5R1036Q (**p<0.01). 
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Figure S5. Gene expression levels associated with the canonical Wnt signaling pathway. Gene 
expression levels of (A) AXIN1, (B) AXIN2, (C) GSK3β involved in β-catenin degradation. Furthermore, 
gene expression levels of Wnt target genes SOX9 (D) and LGR5 (H). C-Myc (E), CCND1 (F) and LEF1 (G) 
function at the nuclear end point of the canonical Wnt signaling pathway. In all panels, the first bar 
presents the unstimulated situation (basal gene expression levels) for each LRP5 construct. Expression 
levels of the second bar are the result of activation of the Wnt signaling by extracellular ligand Wnt3a. 
Activated gene expression levels are corrected for basal gene expression of the respective LRP5 construct 
(*p<0.05). The y-axis presents the relative gene expression level. 
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Table S6. Location of LRP5 variants. We identified four LRP5 variants located at extracellular LRP5 
protein domains. A homology model of LRP5 protein was created using the YASARA&WHAT IF Twinset.37 
As a template,  several previously solved crystal structures were used to build separate models (Table S7). 
For four WD40 domains (β-propeller subdomains) PDB-files were available to incorporate the identified 
extracellularly located LRP5 variant.38, 39 For the PKD1 variant a minor domain model was available.46 
Separate models for these domains and the variants were visualized and analyzed using YASARA.
Family Amino acid change LRP5 domain LRP5 location
A p.(Trp560Cys) 2nd β-propeller; 4th blade Extracellular
B p.(Arg1036Q) 4th β-propeller; 3th blade Extracellular
C p.(Arg1135Cys) 4th β-propeller, 5th blade Extracellular
D p.(Gln1156His) 4th β-propeller, 5th blade Extracellular
Table S7. Templates of homology models for LRP5 and PKD1 protein domains.
LRP5 domain PDB ID code LRP5 identity (%) Reference 
2nd β-propeller 3S94 79 38
4th β-propeller 4A0P 65 39
PC-1 domain PDB ID code PC-1 identity (%) Reference
L-lectin 2XR5 29 46
Table S8. LRP5 variants reported in this manuscript.
Family
Position 
(GRCh37; hg19)
Variant (c.DNA; 
NM_002335.2) Exon 
Predicted effect 
on protein
Known 
SNP dbSNP (v.138)
A g.68171046 c.1680G>T 8 p.(Trp560Cys) Yes rs377144001
B g.68191036 c.3107G>A 14 p.(Arg1036Gln) Yes rs61889560
C g.68192736 c.3403C>T 15 p.(Arg1135Cys) Yes rs143396225
D g.68193486 c.3468G>C 16 p.(Gln1156His) No rs724159825
Table S9. PKD1 variants reported in this manuscript.
Family
Position 
(GRCh37; 
hg19)
PKD1 variant (c.DNA; 
NM_001009944.2) Exon
Predicted effect on 
protein
Known 
SNP
dbSNP 
(v.138)
A g.2117591 c.1281_1283delGGC 6 p.(Ala428del) No rs724159824
A g.2112816 c.3133G>C 13 p.(Val1045Leu) No rs724159822
D g.2153765 c.8293C>T 23 p.(Arg2765Cys) Yes rs144979397
D g.2091581 c.11554delC 42 p.(Leu3852Trpfs*93) No rs724159823
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 - Human gene mutation database (HGMD® Professional) (www.biobase-international.com/
hgmd)
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www.nlgenome.nl/?page_id=9;42
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DISCUSSION AND FUTURE PERSPECTIVES
Polycystic liver disease (PLD) consists of three major adult phenotypes: Von Meyenburg complexes 
(VMC), isolated polycystic liver disease (PCLD) and autosomal dominant polycystic kidney disease 
(ADPKD). These separated entities may be distinguished by clinical examination and radiological 
imaging. All three disorders have differences in epidemiology, intra-hepatic anatomical level, 
symptoms and presence of extra-hepatic features to classify the phenotype accordingly. The 
PLD phenotype may present with a large variety of hepatic cystogenesis. The location, number 
and size of cysts do not directly correspond to symptoms in affected individuals. 
VMC develop from dilated peripheral bile ducts into small hepatic cysts without growth 
advantages. In general, VMC patients remain asymptomatic. This contrasts clinical findings 
and patients’ presentation in PCLD and ADPKD. 
The clinical features and consequences of hepatic cysts trigger the clinical diagnosis 
of PCLD or ADPKD. Symptomatic PLD is mainly seen in these two autosomal dominantly 
inherited disorders. However, a proportion of asymptomatic PCLD and ADPKD patients are 
identified accidentally or remain unknown for hepatic cysts. Subsequently, radiological imaging 
such as abdominal ultrasonography is the first modality to confirm the clinical diagnosis. In 
order to confirm the clinical diagnosis molecular genetic testing is available. Identification 
of pathogenic mutations in the currently known genes for PCLD and ADPKD may provide 
valuable information for patients and clinicians. 
The primary aim of this thesis was to identify the genetic cause in PCLD patients without 
a previous molecular diagnosis, in order to elucidate the pathogenesis of hepatic cysts. 
In this chapter, I will first discuss the diagnostic criteria as well as the clinical phenotype 
assessment in probands and their family members. Next, results of the search for novel 
disease genes is discussed based on our identification of a novel gene associated with 
hepatic cystogenesis. Finally, the implications of these results are outlined to give directions 
for future research.
PART I POLYCYSTIC LIVER DISEASE PHENOTYPE
Diagnostic Criteria for Adult Polycystic Liver Disease
Polycystic livers are characterized by the presence of at least 20 cysts regardless of size 
and distribution. This practical definition is based on experience in clinical practice. 
Patients with severe PLD frequently visit hospitals for information and management in 
contrast to mildly affected individuals. Asymptomatic hepatic cysts are not extensively 
documented. The phenotypical expression may be different in PCLD and ADPKD and the 
diagnosis is primarily based on clinical features. In chapter 2 I provide an overview of 
the clinical features that establish the spectrum of PLD. In general, the clinical diagnosis 
of both PCLD and ADPKD consists of the following three aspects: number of hepatic/ 
renal cysts, age of the individual and family history. In view of these criteria, I highlight 
several considerations:
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Number of Hepatic Cysts in PCLD 
Fluid-filled cysts are sharply demarcated structures on radiological imaging such as abdominal 
ultrasonography, magnetic resonance imaging (MRI) and computed tomography (CT). 
Ultrasonography is commonly used as the primary imaging modality in many diseases and 
also the first tool for screening individuals suspected of renal or hepatic cystogenesis. 
The widespread use of ultrasonography has resulted in increased detection of cysts, and 
may refine the diagnosis. Abdominal ultrasonography is relatively easily diagnosis is done by 
counting the number of cysts of variable sizes. However, the detection sensitivity and specificity 
depends on the resolution of the mechanical sector probe. Regarding the diagnostic accuracy 
of ultrasonography a detection of hypo-echogenic cysts >1 cm is recommended.1 Moreover, 
a reliable determination of the number of hepatic cysts depends on the interpretation and 
experience of the sonographer. 
In addition, in young (<30-40-year-old) individuals with an indeterminate phenotype, other 
radiological imaging tools are more sensitive to detect the presence of hepatic or renal cysts. 
Moreover, differential diagnosis is needed for other cyst-like conditions such as echinococcal 
cysts, hemangioma, abscess, metastases and other hepatic malignancies.  
Age of Affected Individual
Since hepatic cysts have frequently a late-onset and may increase over time, the age at diagnosis 
is important. Hormonal and metabolic values may change during life and this may impact 
the development of hepatic cysts. Subsequently, this is related to disease development and 
severity. Long-term follow-up of the phenotype in family members may be useful for both 
individual’s health and insight in development of cysts during life. 
Although current diagnostic guidelines take the patient’s age into account, a strictly 
determined age cutoff for the clinical diagnosis may not always be useful. An exact age 
cutoffs may limit the clinical spectrum in a rare disorder with nonpenetrance. 
Family History 
A positive family history should be considered as a risk factor for developing autosomal 
dominant PLD, as offspring and siblings have 50% chance of developing cysts. Diagnosis of 
PLD in a patient may mandate screening for family members. During this screening process 
it is useful to obtain information of other liver and kidney diseases, renal failure, liver and/
or kidney transplantation, other cystic diseases, ciliopathies, and extra-renal non-hepatic 
features associated with ADPKD. In addition, a detailed family history comprises the origin/ 
lifestyle/ jobs of parents, consanguinity, causes of death in family members or autopsy 
information. Particular life-style factors are smoking, diet, caffeine intake, and estrogen 
administration (contraceptive steroids or female hormone replacement therapy). Although 
female steroid hormones and pregnancies are associated with hepatic cyst growth, for other 
environmental factors it remains unknown whether and to which degree they contribute to 
hepatic cystogenesis.
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Current Clinical Diagnosis
In chapter 2 the current diagnostic criteria are outlined for clinical practice. The first clinical 
criterion in ADPKD diagnosis consisted of bilateral renal cysts with at least two cysts in each 
Table 1. Ravine and unified Ravine ultrasonography criteria for the clinical diagnosis of 
ADPKD.1, 2, 6
Ravine criteria 2 Unified Ravine criteria 1
Age  
(y)
Negative family 
history Positive family history*
Age  
(y)
Positive family history 
and unknown genotype
<30 5 cysts bilaterally** 2 cysts bilaterally
(or unilaterally)
15-39 ≥3 cysts bilaterally 
(or unilaterally)
30-59 5 cysts bilaterally ≥2 cysts in each kidney
(4 cysts bilaterally)
40-59 ≥2 cysts in each kidney
≥60 8 cysts bilaterally ≥4 cysts in each kidney
(8 cysts bilaterally)
≥60 ≥4 cysts in each kidney
*Definition of a positive family history: at least one affected family member. **Bilaterally: at least 
both kidneys are affected.
kidney. Next, the Ravine criteria were established using 381 family members from 18 PKD1 
affected families. Clinical diagnostic criteria followed from standard ultrasonography screening 
criteria accompanied with DNA linkage analysis.2 These important results provided information 
about the required number of renal cysts in young individuals at-risk (Table 1). 
For screening families with an unknown genotype, age-dependent, unified Ravine criteria 
were determined by phenotyping 948 at-risk individuals from PKD1 and PKD2 families.1 The 
most essential finding of this study was that ≥40-year-old persons with only one renal cyst 
ADPKD may be excluded as being patients in at-risk individuals from unlinked families. In 
addition, exclusion of ADPKD is supported when no renal cysts are detected in individuals 
with an age between 30-39 years and an unknown familial genotype.
Clear diagnostic criteria for PLCD is absent and clinical PCLD studies used different criteria; 
Polycystic liver disease is characterized by the presence of >20 cysts spread throughout 
the liver.3
Table 2. Reynolds ultrasonographic criteria for the clinical diagnosis of PCLD.5 
Reynolds criteria 5
Age (y) Negative family history Positive family history*
<40 Unreported ≥1 cyst
≥40 Unreported ≥4 cysts
*Definition of a positive family history: at least 1 family member with PCLD and a clear autosomal 
dominant inheritance pattern.
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For genotype-phenotype analysis of PCLD, patients were categorized following the number 
of detected hepatic cysts: (I) 1-10 cysts, (II) 11-20 cysts, and (III) >20 cysts.4
A group of the Mayo Clinic proposed the following age-dependent criteria based on 
linkage analysis study in two PCLD families (Table 2).5 Individuals >40 years of age with one 
to three hepatic cyst(s) were considered as indeterminate. The reason for this definition is 
because of the late-onset of disease in PCLD. These are the most commonly used criteria.
Several issues question the sensitivity and specificity of current clinical diagnostic criteria 
in PCLD. First, both PCLD families 5 used for establishing these criteria stem from a cohort 
where PRKCSH mutations were identified.7 This may very likely have introduced a bias in the 
establishment of the clinical criteria in PCLD. In addition, there is less evidence that the severity 
of hepatomegaly is related to the mutated gene PRKCSH in PCLD in contrast to ADPKD.8 
It is therefore unclear whether similar diagnostic criteria should be used for PCLD patients 
without PRKCSH mutations. In addition, there is an evidence for nonpenetrance in PCLD.4
High Clinical Heterogeneity in PCLD Families
For the identification of mutation-negative families 32 PCLD probands without a PRKCSH 
or SEC63 mutation were assessed. Chapter 3 describes clinical information in all available 
family members and abdominal ultrasonography performance according to the Reynolds 
criteria for PCLD.5 These diagnostic criteria have several limitations as described previously, 
but are still the most sensible guidelines for PCLD diagnosis. Assessment of the cyst number, 
age and taking family history are three aspects evident in both ADPKD and PCLD diagnosis.
Although renal cystogenesis is rare in PCLD and polycystic livers are common in ADPKD, 
the current criteria include no statements about involvement of cysts in other organs. The 
Reynolds criteria are relevant for hepatic cysts and vice versa the Ravine criteria are relevant 
for assessment of renal cystogenesis.2, 5 
When few renal cysts in a polycystic liver patient are identified, first the ADPKD criteria 
should be consulted. This approach is justified because up to 94% of ADPKD patients had a 
polycystic liver as extra-renal manifestation.9 Secondly, evidence from PKD1 and PKD2 affected 
individuals showed that ADPKD patients are at-risk for early and progressive renal disease.10 
In general, PCLD patients do not meet the Ravine criteria for renal cystogenesis. This 
contrasts ADPKD patients that meet both the Reynolds and the (unified) Ravine criteria. 
According to these diagnostic guidelines and clinical features in ADPKD patients, there is an 
important overlap between PCLD and ADPKD. 
In only ~10% of ADPKD the family history was negative, but clinical characteristics of 
patients with sporadic and familial ADPKD were similar.11 In line with these findings, a clinical 
PCLD study describes that PCLD patients without PRKCSH or SEC63 mutation (~80%) present 
similar phenotypes with respect to symptoms compared to patients with a known PCLD 
mutation.4 In chapter 3, clinical characterization of PCLD probands and family members 
showed large differences in disease severity and symptoms. Therefore, this study identified 
a significant intrafamilial heterogeneity in multiple PCLD families. 
Clinical symptoms may be considered as the most important feature in the diagnostic 
work-up of PLD patients. Affected individuals may present symptoms of abdominal distension 
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and/or pain, dyspnea, early satiety, pyrosis and rarely abnormal liver function tests. All 32 PCLD 
probands showed at least one of these features described in chapter 3. Screening family 
members showed a higher incidence of hepatic cysts. From this group 5 out of 49 patients 
(10.2%) had symptoms of PLD. This suggests that clinical features are not indicative for PLD. 
The most important implication of this study is that if an individual develops abdominal 
symptoms, knowledge about family members with hepatic cystogenesis is important (Figure 
1). In case hepatic cysts are detected by abdominal ultrasonography genetic counseling may 
be considered. If the genetic cause for PCLD is known in the proband, molecular genetic 
diagnostics may confirm the clinical diagnosis in family members. The proposed algorithm as 
illustrated in figure 1 is more simple and conservative in contrast to flowcharts in ADPKD.12
For both PCLD and ADPKD it is true that hepatic cysts are more massively enlarged in 
females.13, 14 Pregnancies and female steroid hormones (estrogens) may contribute to hepatic 
cyst growth. This additional factor has no place at this moment in the diagnostic work-up 
and this should perhaps be changed. Also, it remains unclear whether the disease severity 
increases in subsequent generations. A prospective follow-up of patients, family members 
and unaffected individuals may provide more information about the extent of this influencing 
factor in PLD patients. 
In conclusion, this study proves that the incidence is underestimated in PCLD by a 
high clinical heterogeneity (Figure 2). Clinical diagnosis of PCLD is cumbersome when hepatic 
and renal cystogenesis are overlapping in 
affected individuals (Figure 3). Taking a 
comprehensive family history is strongly 
recommended for future research and 
health care.15
Figure 1. Diagnostic approach for individuals 
with PCLD-associated symptoms suspected 
for a polycystic liver.
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of patients remain unknown for hepatic cysts because of several main reasons; late-onset of disease, 
absence of symptoms and unrecognized presence of cysts.
Figure 3. Clinical heterogeneity. A high clinical heterogeneity in PCLD suggests an underestimated 
incidence of hepatic cystogenesis. (A) PCLD patient with a mild polycystic liver. (B) Severe PCLD without 
involvement of renal cysts. (C) Multiple renal cysts meets the Ravine criteria, but hepatic cysts are 
additionally present. (D) ADPKD patient with a severe polycystic liver and renal disease meets the Ravine 
and Reynolds criteria.
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PART II GENETIC RESEARCH FOR POLYCYSTIC LIVER DISEASE GENES
Supporting Evidence for the Search of Unknown PCLD Genes
Until now, only two genes are known to cause PCLD. PRKCSH has been suggested as the 
most important gene for PCLD because of its high mutation frequency.4, 16 Ever since the 
identification of the PRKCSH and SEC63 gene in 2003 and 2004, no additional PCLD gene has 
been described, but also no comprehensive genetic studies were performed in this field.7, 17, 18 
I hypothesized that mutation-negative PCLD patients may be explained by CNVs in the 
PRKCSH gene. Large pathogenic CNVs are not detected by conventional Sanger sequencing 
which is routinely used for PCLD diagnosis. 
I performed MLPA assays in DNA derived from hepatic cyst epithelium, but identified 
no exon deletions or duplications. This was probably due to an originally heterogeneous cell 
population (or mosaicism) and secondly, DNA was amplified from small numbers of cells which 
may reduce CNV detection sensitivity. In conclusion, no pathogenic deletions of the PRKCSH 
gene on genomic and somatic level were identified. These findings indicate that MLPA analysis 
of the PRKCSH gene has no additional value for inclusion in the diagnostic work-up of PCLD. 
The question remains whether or not PCLD patients harbor CNVs affecting other genes. 
The results in chapter 4 suggest that pathogenic deletions and duplications are generally 
rare in genomic DNA from PLD patients. However, detailed large scale CNV screen have not 
routinely been performed. In ADPKD, up to 4% of patients from the CRISP cohort showed 
genomic rearrangements.19 This included cases with extensive deletions affecting both the 
TSC2 and PKD1 gene (PKD1/TSC2 contiguous gene deletion syndrome).19 In addition, deletions 
in the PRKCSH gene on the somatic level were identified previously.20 Based on this work in 
ADPKD, further research into the role of CNVs in PCLD patients is also warranted.
Genomic and Somatic Loss of Alleles Identifies Candidate PCLD Genes
The second hit hypothesis in polycystic liver disease was first proposed in renal cystic 
tissues from ADPKD patients.21, 22  Homozygous inactivation of PLD genes at the cellular 
level by a second hit mechanism has been implicated in hepatic cyst formation. The purpose 
of chapter 5 was to outline a synopsis of second hits in polycystic liver tissues derived from 
ADPKD and PCLD patients. 
In ADPKD patients only a subset of hepatic cysts showed somatic hits. Identification of somatic 
mutations and deletions in hepatic cyst epithelium cells was determined by microsatellite studies 
and fragment analysis.22-24 Tissue specific homozygous regions were identified by amplification 
and comparison of cyst-derived DNA and control DNA derived from blood. 
Recently, somatic hits have also been identified in PCLD liver tissue, resulting in the 
inactivation of the second PRKCSH allele. These results confirmed the cellular recessive 
mechanism for cyst formation.20, 25 Evidence for a digenic inheritance model was not obtained 
after screening the PKD2 and SEC63 genes in hepatic cyst DNA.26
This molecular mechanism of loss of heterozygosity (LOH) was used to our advantage: LOH 
regions can directly point to the location of the germline mutation on the other allele. A 
novel approach for a large-scale identification of unknown PCLD genes was designed based 
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on this observation. In chapter 6 hepatic cyst fluid derived from aspiration sclerotherapy was 
collected. Hepatic cyst fluid was used to retrieve DNA derived from hepatic cyst epithelium 
cells. Normally, the cyst fluid is a waste after the aspiration procedure. In chapter 6 I describe 
the identification of large regions of somatic LOH in 2 out of 8 cases and a large CNV. These 
preliminary data may point us to novel PCLD genes. As an alternative disease gene identification 
strategy, direct screening of somatic events in hepatic cyst DNA from ADPKD and PCLD 
patients with exome or genome sequencing approaches may reveal novel disease genes.27
The Connection between the LRP5 Gene and PCLD
Identification of the genetic cause in an extended family with a clear autosomal dominant 
inheritance pattern of PCLD is outlined in chapter 7. For a rare disorder, this large family is very 
unique. Since the traditional approach of linkage analysis hampered significant progress of disease 
identification, whole-exome sequencing revealed the LRP5 gene causing hepatic cystogenesis. 
Clinical Heterogeneity
The 40-member family presented with a spectrum of severe and mild PCLD largely fulfilling the 
Reynolds criteria.5 Abdominal distension and mechanical symptoms were also present in six family 
members with severe PCLD, but these affected individuals were not referred for management. 
Abdominal ultrasonography detected in 16 individuals a PCLD phenotype, but 22 individuals 
carried LRP5 c.3562C>T (p.R1188W). This discrepancy is probably explained by late-onset of 
disease in three family members <40-years-old. Two males with the age of 50 and 78 years 
presented few renal cyst not meeting the (unified) Ravine criteria. In addition, another 49-
year-old male is an example of incomplete penetrance. Since all three individuals that showed 
no symptoms (yet) are males, the reduced phenotype expression may also be related to the 
gender. This contrasts the findings in a 51-year-old male with severe polycystic liver and 
polycystic kidneys. His clinical features meet the Ravine criteria. This affected member was 
under treatment for hypertension, but had no abdominal symptoms. 
Functional Analysis
The primary aim was to investigate the consequences of the identified LRP5 variants on the 
signaling cascade and to compare previous functional analyses of LRP5 variants. The functional 
effects of other pathogenic LRP5 variants in eye and bone disorder have been investigated 
previously (Table 3). For familial exsudative vitreoretinopathy (FEVR) as well as osteoporosis 
pseudoglioma (OPPG) in vitro analyses in different cell line systems were performed to 
determine their effect on the Wnt signaling activity. For example, monkey fibroblast COS-7 
cell line 28 and the mouse fibroblast cell line NIH3T3 have been applied for the study of OPPG 
29, and  the HEK293 cell line were used to establish the mechanism in FEVR.30 Preferably, the 
consequences of LRP5 variants have to be studied in the tissue of origin.
Pathogenic LRP5 Mutations in 8 Allelic Diseases (MIM*603506)
An important question is why multiple phenotypes are caused by variation in the LRP5 gene. 
There is no straightforward answer to this question and I consider several possible options 
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Table 3. Reports and results of luciferase activity assays of nascent LRP5 variants from 
different disorders.
c.DNA LRP5 
mutation 
Protein 
change Functional effect on Wnt signaling
Disease 
[Reference]
Protein domain: 3rd blade of the 2nd β-propeller domain  
c.1300G>A p.Asp434Asn Dual luciferase assay (HEK293 cells expressing WT):
Measuring firefly luciferase activity from Topflash 
reporter
<50% Wnt1 or Wnt10b induced activity compared to 
LRP5-WT
Subsequent addition of LRP5-WT restored activity
OPPG 30
c.1321G>A p.Glu441Lys Evolutionary highly conserved position
Change to lysine is likely to disturb normal protein 
function
FEVR 31
c.1330C>T p.Arg444Cys Evolutionary highly conserved position
Predicted outcome of amino acid change is loss of 
activity
FEVR 32
c.1360G>A p.Val454Met Dual-Glo luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant increased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT
PCLD 
c.1364C>T p.Ser455Leu Dual luciferase reporter assay (HEK293T cells):
Significantly 40% reduced Wnt1 induced signaling 
activity compared to LRP5-WT
Evolutionary highly conserved position
Idiopathic 
osteoporosis 
33
c.1378G>A p.Glu460Lys No functional analysis OPPG 30
Protein domain: 4th blade of the 2nd β-propeller domain  
c.1680G>T p.Trp560Cys Dual-Glo Luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant decreased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT
ADPKD 
[chapter 8]
c.1709G>A p.Arg570Gln No functional analysis
Dual luciferase assay (HEK293 cells expressing WT):
<50% Wnt1 or Wnt10b induced activity 
AR FEVR 34
OPPG 30
c.1708C>T p.Arg570Trp Dual luciferase assay (COS-7):
Decreased Wnt3a induced Wnt signaling activity of 
LRP5∆C and LRP5∆TM compared to LRP5-WT
OPPG 28
c.1750C>T p.Gln584Term No functional analysis OPPG 30
Protein domain: 3rd blade of the 4th β-propeller domain  
c.3107G>A p.Arg1036Gln Dual-Glo luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant decreased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT
ADPKD 
[chapter 8]
c.3107G>A p.Arg1036Gln Evolutionary highly conserved amino acid position
No functional analysis
Luciferase gene reporter assay (CHO cells with Wnt3a-
conditioned medium):
24% reduced Wnt signaling activity compared to 
the control
Primary 
osteoporosis 
35
36
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Table 3. Continued.
c.DNA LRP5 
mutation 
Protein 
change Functional effect on Wnt signaling
Disease 
[Reference]
c.3232C>T p.Arg1078Term No functional analysis OPPG 30
c.3295G>T p.Asp1099Tyr; 
(4th blade)
No functional analysis OPPG 30
Protein domain: 5th blade of the 4th β-propeller domain 
c.3403C>T p.Arg1135Cys Dual-Glo luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Decreased Wnt3a induced Wnt activity compared to 
LRP5-WT
ADPKD 
[chapter 8]
c.3468G>C p.Gln1156His Dual-Glo Luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant decreased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT 
ADPKD 
[chapter 8]
Protein domain: 6th blade of the 4th β-propeller domain (AA 1165-1207)
c.3502T>C p.Tyr1168His In silico analysis:
Highly conserved residues
Homology modeling: 
Mutations in the core of the protein are likely
to cause destabilization of the protein fold
Dual-Glo Luciferase reporter assay (HEK293T cells):
Decreased Wnt1 induced Wnt signaling
activity compared to LRP5-WT 
Increased Wnt1+ extra LRP5 WT induced
Wnt signaling activity compared to Wnt1 induced Wnt 
signaling activity (=restoration of the activity)
Dual luciferase assay (HEK293 cells expressing WT):
Addition of Wnt1 or Wnt10b showed no activity
FEVR 37
FEVR 30
OPPG 30
c.3553G>A p.Gly1185Arg Super TOP Flash reporter assay (CHO cells):
Wnt3a-CM medium increased the Wnt signaling
activity compared to corresponding constructs with 
10% FBS-DMEM
No Wnt signaling activity change of Wnt3a-CM
compared to Wnt3a-CM LRP5-WT 
Autosomal 
dominant 
primary 
osteoporosis 
36
c.3562C>T p.Arg1188Trp Dual-Glo Luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant decreased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT (30-45%)
PCLD 38
Intracellular protein domain: Between PPPSP motif A – B  
c.4574C>T p.Ala1525Val Topflash luciferase reporter assay (C3H10T1/2 cells): 39
70% increased LRP5 signaling compared to LRP5-WT 
(intracellular constructs)
Normal proliferation, altered osteoblastic 
differentiation
FEVR 37
Variable 
BMD 40
c.4587G>C p.Arg1529Ser Dual-Glo Luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant increased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT 
PCLD 
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that help to understand why the identified LRP5 mutations are linked to a liver phenotype. 
These arguments are based on published data, specific LRP5 gene-related characteristics and 
examples from common genetic mechanisms in affected tissues.
Osteoporosis pseudoglioma (OPPG) syndrome is the first disease that was linked to LRP5 
mutations.28 This autosomal recessive disease is characterized by a very low bone mass and 
ocular pathology. The authors reported that obligate carriers (parents of OPPG patients) 
have only a reduced bone mass, but they went further to state that they did not perform 
a systematic search for eye abnormalities in OPPG patients and their family members.28 
The same is true for other clinical investigations of the human body. In general, patients 
report symptoms, but other malformations remain unknown during life until these develop 
into symptomatic disease. Affected PCLD individuals may also remain asymptomatic until late 
adulthood. I investigated the 40-member PCLD family for any bone or eye disorders and was 
able to exclude these. Vice versa, individuals affected with familial exsudative vitreoretinopathy 
(FEVR) or osteoporosis associated with LRP5 variants are not systematically screened for 
liver or kidney disease (cystogenesis). 
A previous study hypothesized that the pathogenesis of visual loss in OPPG is distinct 
from that observed in FEVR and neovascular inflammatory retinopathy (VRNI).28 It is therefore 
reasonable to speculate that LRP5 mutations could cause a spectrum of eye pathologies 
through different mechanisms of mutational effect.28, 42 For example, dosage effects are 
proposed to be common in LRP5 because heterozygous LRP5 variants cause reduced bone 
mass in OPPG patients.28
How LRP5 mutations specifically give rise to developmental onset of blindness or FEVR and 
osteoporosis in OPPG patients is unresolved.30 Studies in Lrp5-/- mouse models indicate that the 
LRP5 protein uses different molecular mechanisms to regulate bone formation and eye 
vascularization.43 Defective LRP5-signaling affects retinal vasculature through reduced level of 
capillary cell apoptosis and a defect in hyaloid vessel regression, resulting in a lower number of 
Table 3. Continued.
c.DNA LRP5 
mutation 
Protein 
change Functional effect on Wnt signaling
Disease 
[Reference]
c.4600C>T p.Arg1534Term No functional analysis OPPG 30
c.4609G>A p.Ala1537Thr Luciferase activity assay (HEK293T cells):
No altered Wnt1 induced Wnt signaling activity 
compared to LRP5-WT 
Idiopathic 
osteoporosis 
33
Intracellular protein domain: Between PPPSP motif B – C (AA 1546-1573)
c.4643G>T p.Cys1548Phe Super TOP Flash reporter assay (STF cells): 
29% reduced Wnt signaling activity compared to 
the control
FEVR 41
c.4651G>A p.Asp1551Asn Dual-Glo Luciferase reporter assay (CHO cells): 
Increased Wnt signaling activity compared to the 
empty vector
Significant decreased Wnt3a induced Wnt signaling 
activity compared to LRP5-WT (30-45%)
PCLD 38
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vessel branches.43, 44 One of the explanations is that the LRP5 signal transduction pathway, and 
downstream Wnt proteins, regulate both osteoblast proliferation, function, and eye vascularization.
An example is a Lrp6-/+ mouse model with a hypomorphic Wnt3a allele presenting a more 
severe phenotype in contrast to presence of a normal Wnt3a allele.45
Phenotypic Expression
Further, the incomplete penetrance (10-33%) of the ocular phenotype and high intra-
familial heterogeneity in FEVR families indicate that the LRP5 genotype-phenotype is not as 
straightforward as it would seem.46 To date, it remains unsolved why several family members 
with a bone disorder additionally develop FEVR.30 
LRP5 gene mutations are apparently associated with both extremes of bone density. 
Autosomal dominant high-bone-mass disease (HBM) was mapped to the LRP5 gene by two 
groups.29, 47 These authors identified clinical differences in this low density bone disease in 
affected family members and between non-related patients. Remarkably, one missense 
mutation (p.G171V) was present in both non-syndromic and syndromic HBM. This suggests 
that environmental factors may influence the expression of phenotypic manifestations.29, 
Figure 4. An overview of the LRP5 gene (NM_002335.2; 1,615 amino acids). On the x-axis 4,848 
protein-coding positions are depicted (c.DNA). Six rows present the characteristics of normal LRP5 gene 
variation in 13,000 exomes (based on 6,500 EVS exomes). The frequency of missense and synonymous 
variants are illustrated by height of two plots. The rows in between represent the density of missense 
variants, a region without significant missense variation by stringent analysis, weighted frequency boxes 
are regions with less variants than predicted, LRP5 mutations (HGMD) and LRP5 protein domains (Uniprot). 
This figure shows a clear locus heterogeneity for mutations. Although there are still regions without 
variation, the majority of mutations are extracellularly located. Figure 4 is kindly provided by dr. C. Gilissen.
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48 For example, LRP5 inactivation impairs postnatal bone formation by enhancing osteoblast-
directed bone resorption depending on the extracellular mediator serotonin in the gut.49 
In addition, the (various) effects of LRP5 mutations in bone diseases and FEVR might 
depend on the presence or absence of other genetic variants. In this respect, it is reasonable 
to speculate that genetic variation in other genes of the Wnt signaling pathway contribute 
to different phenotypes.34, 48
LRP5 Gene-related Characteristics
The LRP5 protein has a wide tissue expression such as in heart, liver, kidney, pancreas, 
spleen, prostate, ovary, small intestine and colon has been determined by northern blotting 
and in situ hybridization studies.42, 50 All known LRP5 variants for different phenotypes are 
spread over all protein domains and are not restricted to the extracellular part of the protein 
(Figure 4). Only for high bone mass disease there is a hot-spot to the first β-propellor domain.
Missense LRP5 mutations may cause a variety of clinical presentations and have been 
found in individuals with OPPG, autosomal dominant and autosomal recessive FEVR. It needs 
to be determined whether LRP5 mutations result in a protein loss-of-function or gain-of-
function of LRP5. From LRP5 knock-out mouse studies it is known that a variety of tissues 
can be affected and lead to a low bone mass, hyperlipidemia, hypercholesterolemia and an 
impaired glucose tolerance.45, 51, 52 Chapter 7 describes the gene expression results and staining 
experiments. Abundant LRP5 and β-catenin staining in hepatic cyst tissue sections showed 
that the proteins are present in this tissue. This may suggest that the underlying defect is a 
reduced LRP5 function due to abnormal protein structure. 
Other Examples of Allelic Diseases
Altogether, LRP5 seem to cause a spectrum of allelic disorders. This is not the first gene for 
which allelic heterogeneity exists. Other examples include p63 and PTPN11. Gene mutations 
in the p53 gene are associated with seven allelic diseases (five syndromic and two non-
syndromic).53 Missense mutations in the p63 gene lead to very different phenotypes such as 
ectodermal dysplasia and cleft lip/palate syndrome. The mutations seen in these disorders 
may result in either a gain-of-function or loss-of-function. This is consistent with significant 
genotype-phenotype variability. 
Similarly, missense mutations in the PTPN11 gene leads to spectrum of diseases. Gain-of-
function mutations may cause Noonan syndrome or juvenile myelomonocytic leukemia.54, 55 
The Leopard syndrome is an autosomal dominant disorder caused by PTPN11 gene mutations 
and is characterized by lentigines and cafe-au-lait spots, facial anomalies, and cardiac defects. 
ADPKD and LRP5 Variants
Polycystic liver disease is the most common extra-renal manifestation in ADPKD patients. The 
prevalence of hepatic cystogenesis in ADPKD increases by age. Hepatic cysts are present in 
94% of ADPKD patients older than 35 years.9 As a logical extension of previous findings, all 23 
exons of the LRP5 gene patients were sequenced in 79 ADPKD patients. This cohort consisted 
of ADPKD probands without a pathogenic variant on either PKD1 or PKD2 (n=29), and patients 
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with adult-onset disease with an apparently negative family history (n=50). In the latter group 
no mutation analysis of ADPKD genes were performed. Chapter 8 presents segregation analysis 
in several cases and functional analysis in order to identify the consequences of these LRP5 
variants. In total 4 rare LRP5 variants were identified that led to amino acid change.
To our knowledge these are the first ADPKD patient with identified LRP5 variants. The 
genotype-phenotype correlation however is not yet fully understood, but argues against a 
simple monogenic role of LRP5 in ADPKD. 
FUTURE PERSPECTIVES
Improvements of high-throughput sequencing technologies has shifted the laboratory work. 
Faster tools replaced conventional methods. Although these techniques are available, the use 
of the correct model for evaluating the clinical relevant hypotheses (or questions) should be 
critically considered.
Deep Phenotyping
Since sequencing technologies are developing rapidly, the work of the clinician should be to 
improve interpretation of the numerous variants detected. Detection of variants in novel genes 
requires validation in large cohorts, but importantly also in family members. A complete family 
history and follow-up, especially in first-degree related individuals is strongly recommended. This 
information is essential for the search of novel (modifier) genes and genotype-phenotype relations.
Next-Generation Sequencing
Whole-exome sequencing (WES) is at present the most important tool to identify disease 
genes. The study design in which WES is applied depends on the observed inheritance pattern. 
For autosomal dominantly inherited disorders large families are needed for a linkage based 
strategy. PCLD is a rare disease and such large families are infrequent. To bypass this issue 
there are more approaches available for disease gene identification. 
Exome sequencing in combination with a candidate gene approach: Candidate genes 
identified by exome sequencing in a small cohort of patients are screened by molecular 
inversion probes in very large cohorts of cases and controls.56 
Overlap based strategy: Exome sequencing of many single cases with a particular 
subtype of PCLD.57
Siblings strategy: Exome sequencing of affected siblings. 
Trio strategy: Exome sequencing of unaffected parents and affected offspring when a 
de novo mutation is suspected.
Of interest in this aspect, a genetic interaction network of PLD genes has been proposed.58 
This may argue for a candidate gene approach for PCLD genes with association of proteins 
in the canonical Wnt signaling, ciliary genes, animal models with hepatic and/or renal 
cystogenesis and proteins in the endoplasmic reticulum. A question, however, is how 
complete such a candidate gene approach is. Unbiased exome or even genome sequencing 
will be essential to complete the list of PLD genes and these approaches are becoming 
more and more affordable. 
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Functional Studies in LRP5
The identification of LRP5 is just the starting point for functional studies that may also result in 
the identification of more key players in the canonical and non-canonical Wnt signaling. The latter 
is associated with ADPKD and an imbalance between both may trigger cystogenesis.59 These 
functional studies may include protein-protein interaction studies, (b) LRP5 knock-down studies 
in human cell lines, as well as (c) LRP5 known-down studies in animal models such as zebrafish. 
In conclusion, the identification of the LRP5 gene sets another view on PCLD and 
cystogenesis in general. The role of LRP5 with a connection between the endoplasmatic 
reticulum and cilia is of great interest (Figure 5). Functional analysis in disease models may 
provide more clues to the dysregulated Wnt signaling pathway and currently studied pathways 
for treatment. Further research should be focused on the three aspects as described above; 
deep phenotyping, genetic research and functional studies. It is essential to move from the 
clinical studies to the molecular mechanisms and back to the patient, in order to correlate 
clinical and molecular findings in this field. This translational research may have major impact 
for management of cystogenesis in patients.
Figure 5. From patient to gene and molecular mechanism. In the opposite direction possible 
medical regiments may be tested for PLD management (figure partially derived from Bergmann et al.60). 
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SUMMARY
Polycystic liver disease (PLD) is a genetic disease characterized by multiple fluid-filled cysts 
spread throughout the liver. Patients may have an enlarged liver, but frequently a preserved liver 
function. Hepatic cysts may increase in number and size resulting in mechanical symptoms such 
as abdominal pain and pressure on surrounding organs (pyrosis and dyspnea). Complications 
mainly occur due to massive hepatomegaly. 
PLD is a clinical diagnosis and primarily assessed by abdominal ultrasonography. Genetic 
molecular testing may confirm the clinical diagnosis. Three major disorders are characterized by 
multiple hepatic cysts: Von Meyenburg complexes, isolated polycystic liver disease (PCLD) and 
autosomal dominant polycystic kidney disease (ADPKD) (chapter 2). Both PCLD and ADPKD 
are inherited in an autosomal dominant fashion which states that 50% off the offspring also 
carry the mutation (DNA sequence alteration). Almost all ADPKD patients harbor a mutation 
in the PKD1 or PKD2 gene (protein-coding DNA). In PCLD, about ~80% carry no mutation 
in the PRKCSH or SEC63 gene. The cause of hepatic cystogenesis remains unknown in the 
large majority of PCLD patients. Therefore, the aim of this thesis is to reveal the genetic cause 
in these patients.
Chapter 3 sets out how PCLD patients with unknown genomic cause often report a 
negative family history of liver and renal (cystic) disease. Screening family members presented 
frequently asymptomatic individuals and a high intrafamilial clinical heterogeneity for hepatic 
cystogenesis. This demonstrated an underestimated incidence of hepatic cystogenesis. 
Mutation analysis consists of Sanger sequencing to detect point mutations and small 
deletions or duplications. Chapter 4 examined large deletions and duplications of the 
PRKCSH gene in germline DNA. Multiplex ligation probe-dependent amplification assays 
were performed, but identified no copy number variations of the PRKCSH gene. These results 
argue for involvement of one or more novel genes in PCLD.
Among these PCLD patients and families of unknown genetic cause, I analyzed the DNA 
by using several approaches. The mechanisms of somatic inactivation in ADPKD and PCLD 
are discussed in chapter 5. Besides a first hit, PCLD patients frequently harbor a second 
event in liver tissue responsible for hepatic cystogenesis. This information, and the fact that 
a minority of PCLD patients carry a mutation in the PRKCSH (15%) or SEC63 (5.7%) gene, 
triggered the studies described in the following chapters of the thesis. Furthermore, we 
searched for large homozygous regions in DNA of cyst-lining cholangiocytes derived from 
hepatic cyst fluid that occurred as somatic events. Chapter 6 reports a candidate gene list 
(first hit) associated with PCLD.
In chapter 7 we identified an extended PCLD family and performed whole-exome 
sequencing in two affected individuals. Our study presented that the only private non-
synonymous variant that segregated completely with the disease is a missense mutation located 
on chromosome 11q13.2 in the low-density lipoprotein receptor-related protein 5 (LRP5) gene. 
Screening of a PCLD cohort revealed 3 additional LRP5 mutations in unrelated PCLD families 
(2.7%). Histology studies showed that the LRP5 protein was abundantly present in hepatic 
cyst tissue. In addition, functional analyses demonstrated the protein to be less functional 
because of a reduced activated canonical Wnt signaling pathway.
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Subsequently, we investigated the role of the LRP5 gene in ADPKD patients in chapter 8. 
Direct Sanger sequencing showed one novel and three previously reported LRP5 variants. In 
addition, we reported three novel and one known PKD1 variants. All LRP5 variants are located 
on highly conservative domains and three variants are assessed to be pathogenic. Functional 
studies presented a decreased signal activation of canonical Wnt signaling. Gene variants may 
change the protein product functionally or structurally, but may also impact other interacting 
genes and proteins in the network. In the context of LRP5 variants, a defective  Wnt signaling 
may lead to an imbalance between canonical and non-canonical signaling events resulting 
in hepatic and/or renal cystogenesis.
In conclusion, my thesis shows that phenotyping is important in PCLD. Secondly, the genetic 
heterogeneity is even broader than expected. Finally, the LRP5 gene is a new PCLD gene.
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SAMENVATTING
Polycysteuze leverziekte (PLD) is een genetische aandoening waarbij meerdere met vocht 
gevulde cysten verdeeld in de lever aanwezig zijn. Patiënten hebben vaak een vergrote 
lever, maar de leverfunctie blijft intact. Levercysten kunnen in aantal en grootte toenemen 
met mechanische klachten als gevolg, zoals buikpijn en druk op omliggende organen 
(maagklachten en kortademigheid). Sterke toename van de levergrootte kan leiden tot 
ernstige complicaties.
PLD is een klinische diagnose en wordt dikwijls met een echo van de buik vastgesteld. 
Genetisch onderzoek kan de diagnose bevestigen. Met name drie aandoeningen zijn bekend 
met het ontwikkelen van vele levercysten: Von Meyenburg complexen in de lever, geïsoleerde 
polycysteuze leverziekte (PCLD) en autosomaal dominante polycysteuze nierziekte (ADPKD) 
(hoofdstuk 2). Voor PCLD en ADPKD geldt dat beide ziekten autosomaal dominant worden 
overgeërfd. Dit betekent dat één ouder een mutatie (afwijking) heeft in het PRKCSH gen of 
SEC63 gen (deel van het DNA coderend voor een eiwit). De kans om de ziekte PCLD door te 
geven aan een kind is dan 50%. Bij ADPKD patiënten is er een mutatie in het PKD1 of PKD2 
gen aanwezig die de ziekte veroorzaakt. Bijna alle ADPKD patiënten ontwikkelen de ziekte 
door een mutatie in het PKD1 of PKD2 gen. Voor PCLD geldt dat er geen mutatie is gevonden 
in het PRKCSH of SEC63 gen bij ongeveer ~80% van de patiënten. De oorzaak van levercysten 
bij deze grote groep is onbekend. Het doel van dit proefschrift is om de genetische oorzaak 
te achterhalen bij deze patiënten.
Hoofdstuk 3 beschrijft hoe PCLD patiënten met een onbekende genetische oorzaak 
vaak geen familieleden met een polycysteuze lever- of nierziekte hebben. Bij screening met 
een buikecho worden alsnog cysten gevonden bij familieleden zonder klachten. Dit toont 
aan dat het ziektebeeld heterogeen is binnen families. Eveneens wordt de incidentie van 
levercysten onderschat. 
Mutatie analyse (genetisch onderzoek) wordt uitgevoerd met behulp van de Sanger 
sequencing techniek om eenvoudige mutaties, zoals puntmutaties, deleties of duplicaties 
op te sporen. In hoofdstuk 4 is onderzoek gedaan naar grote DNA veranderingen van het 
PRKCSH gen met behulp van multiplex ligation probe-dependent amplification assays. Echter, 
er werden geen grote deleties of duplicaties gevonden in het PRKCSH gen. Dit leidde tot de 
vraagstelling of een mutatie op één of meerdere andere genen verantwoordelijk is voor het 
ontwikkelen van PCLD.
Met behulp van verschillende benaderingen werd het DNA van PCLD patiënten en 
familieleden onderzocht. Hoofdstuk 5 geeft aan welke mechanismen betrokken zijn bij 
cystevorming in de lever bij PCLD en ADPKD patiënten. Zij hebben een mutatie die aanleg 
geeft tot het ontwikkelen van cysten. Daarnaast is er een tweede mutatie aanwezig in het 
leverweefsel (somatische inactivatie; second hit), hetgeen leidt tot levercysten. Deze informatie 
leidde tot onderzoek van de epitheelcellen (cholangiocyten) die de cysterand bedekken en 
aanwezig zijn in het cystevocht. Microarray studies werden uitgevoerd om grote genetische 
veranderingen in het DNA van cholangiocyten uit cystevocht te onderzoeken. Hoofdstuk 6 
toont onder andere de identificatie van deze somatische deleties en geeft aanwijzingen voor 
mogelijke kandidaat genen.
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In hoofdstuk 7 wordt een unieke, grote PCLD familie beschreven waarbij whole-exome 
sequencing ten aanzien van twee aangedane familieleden is uitgevoerd. Deze studie leidde 
tot de identificatie van een mutatie op chromosoom 11q13.2 in het low-density lipoprotein 
receptor-related protein 5  (LRP5) gen. Bij alle familieleden met PCLD werd deze mutatie 
gevonden. Screenen van het LRP5 gen in PCLD patiënten leidde tot de ontdekking van 
drie nieuwe mutaties in drie verschillende families. Weefselonderzoek toonde aan dat het 
gemuteerde LRP5 eiwit aanwezig is in epitheelcellen van levercysten. Functioneel onderzoek 
wees uit dat het LRP5 eiwit minder functioneel is en leidde tot een verminderde geactiveerde 
Wnt cascade.
Eveneens is onderzocht of ADPKD patiënten mutaties in het LRP5 gen hebben. Sanger 
sequencing toonde één nieuwe en drie bekende LRP5 varianten waarvan wordt voorspeld 
dat drie varianten een rol hebben bij het ontwikkelen van cysten. Hoofdstuk 8 beschrijft het 
functioneel onderzoek waarbij eveneens een verminderde geactiveerde Wnt signaleringsroute 
wordt gevonden. 
Concluderend, genetische varianten kunnen de functie van een eiwit functioneel of 
structureel veranderen. Daarnaast zou een mutatie impact kunnen hebben op andere 
genen of eiwitten die betrokken zijn in dezelfde route. Met betrekking tot PCLD leiden de 
geïdentificeerde LRP5 varianten hoogstwaarschijnlijk tot een verstoord evenwicht tussen 
canonical en non-canonical Wnt signaleringsroute. Deze Wnt cascade is betrokken bij 
processen van celgroei en celontwikkeling. Een ontregelde signalering leidt tot de vorming 
en de groei van lever- en niercysten.
Concluderend, mijn proefschrift geeft aan dat het in kaart brengen van het klinisch beeld 
(fenotype) van PCLD belangrijk is. Ten tweede, PCLD is meer genetisch heterogeen ten opzichte 
van eerder werd aangenomen. Tenslotte, het LRP5 gen is een nieuw PCLD gen. 
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Stellingen behorend tot het proefschrift
Novel Genetic Approaches in Polycystic Liver Disease 
1. Het fenotype van autosomaal dominante polycysteuze leverziekte is heterogeen. 
2. Levercysten zijn dikwijls miskend en onder-gediagnosticeerd in de klinische praktijk.
3. DNA veranderingen in het lever- en nierweefsel zijn een essentieel mechanisme in het 
ontstaan van de ziektebeelden PCLD en ADPKD.
4. Identificatie van vele deleties in het DNA van cyste-epitheelcellen waaronder bekende 
tumorgenen wijzen op overeenkomstige eigenschappen betreffende tumorgenese. 
5. Unieke mutaties in het LRP5 gen zijn geassocieerd met diverse botafwijkingen, oogziekten 
en het ontstaan van levercysten. 
6. Er zijn meer onbekende genen verantwoordelijk voor het ontwikkelen van autosomaal 
dominante polycysteuze levers.
7. ADPKD en PCLD patiënten hebben op klinisch vlak meer overeenkomsten dan genetisch. 
8. Labwork is teamwork. 
9. The energy of the mind is the essence of life. (Artistoteles)
10. Het leven is zo kort, men kan het niet wel genoeg verleven. (Guido Gezelle, Vlaams 
dichter 1830-1899)
11. Wa’t himsels weismyt, wurdt fan in oar net opkrigen. (Sytse ten Hoeve, Fries historicus 
en schrijver)
12. It ein fan eltse reis is it paad werom. (Piter Wilkens, Friese troubadour)
13. Finis coronat opus. 

219
+
A
D
D
EN
D
U
M
DANKWOORD
Wetenschappelijk onderzoek is mogelijk door deelname van patiënten en hun familieleden, 
inspanningen van collega´s en samenwerkingsverbanden met diverse disciplines. Op deze plaats 
wil ik dank zeggen aan alle patiënten, de PCLD en ADPKD families die vrijwillig hebben 
deelgenomen aan diverse klinische en genetische onderzoeken. Dit is een belangrijke bijdrage 
geweest en vormt de basis van dit proefschrift. Daarnaast zijn er een aantal personen in het 
bijzonder die ik wil dankzeggen.
Prof. dr. Joost P.H. Drenth, beste Joost. Vanaf het eerste moment heb ik aangegeven wat 
mijn doel was, namelijk wetenschappelijk onderzoek doen en daarna specialiseren. Goede 
begeleiding en een uitdagend project waren de twee relevante ingrediënten. “Make it happen”, 
zei Joost eind 2010. Hierbij wil ik je danken voor de vrijheid en de kans om dit project te 
mogen vormgeven in de afgelopen jaren. Dank voor de goede onderwijsmomenten en het 
ontwikkelen van mooie papers.
Prof. dr. ir. Joris A. Veltman, beste Joris. Dank dat ik deel mocht uitmaken van de Genomic 
Disorders Group (GDG), een enthousiaste en gezellige onderzoeksgroep. Van meetings, 
retraites tot literature of theme discussions, het zijn zeer leerzame en leuke jaren geweest. 
Veel dank voor het uitwisselen van ideeën en goede commentaren. Als ik denk aan de mooie 
projecten en resultaten van de GDG, dan heb ik de woorden van eind 2011 in gedachten: 
“We only just started…”
Dr. Alexander Hoischen, beste Alex. Jouw inzet is eveneens van grote waarde geweest bij 
het tot stand komen van diverse projecten en met name de laatste projecten in de afrondende 
fase. Het verwerven en verbeteren van de kennis over nieuwe sequencing mogelijkheden 
binnen de genetica heeft geleid tot meer inzicht. Dank voor de vlotte samenwerking, het 
delen van kennis en jouw kritische blik. 
Ing. René H.M. te Morsche, beste René. Vrijwel dagelijks stond ik aan jouw bureau voor 
overleg, vragen en feedback over experimenten. Dankzij jouw brede kennis en hulp bij de 
projecten hebben we samen mooie data kunnen opschrijven. Je bent een stabiele factor 
voor het basale PCLD onderzoek. Samen met Hennie en Jody vormen jullie een sterk team. 
Daarnaast heb je vele andere taken en fungeer je al lange tijd als “het orakel van het lab”. 
Mijn dank is groot voor jouw inzet en de geweldige samenwerking. Super dat je erbij bent 
als mijn paranimf!
Dr. Christian Gilissen, beste Christian. De tak van sport die jij beoefent binnen het onderzoek 
is steeds belangrijker geworden. Jouw deelname en analyses aan deze projecten hebben het 
bewijs van de resultaten vergroot. Mijn dank is dan ook groot voor het geven van uitleg over 
datasets, beantwoorden van eenvoudige vragen, jouw betrokkenheid bij dit onderzoek en 
de muzikale avonden van het Symfonisch Blaasorkest Nijmegen. 
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Dr. Wilbert Peters, Ing. Hennie Schaap-Roelofs, Ing. Jody Salomon, beste collega’s 
van het lab. Graag wil ik jullie enorm bedanken voor de fijne sfeer in het lab, een open deur 
voor overleg of raad, maar eveneens voor de gezellige onderzoeksperiode die ik heb mogen 
ervaren. Jody, ik vond het heel tof om met jou samen te werken in het lab. Fijn dat we de 
nodige chemicaliën konden ‘delen’. Je bent één van mijn zeer gewaardeerde collega’s en 
daarom sta je naast mij tijdens de promotieplechtigheid als mijn paranimf. Beste Dr. Hopman, 
wat is (verstandig) rikken en een vriendschappelijke sfeer toch belangrijk op de werkvloer, 
dankjewel voor je gezelschap op congressen en de eindeloze grappen over Friezen! Beste 
Evelyn, bedankt dat je mijn kamergenoot bent geweest op onze ‘aflex-werkplek’. Dank 
voor je adviezen over posters, leuke gesprekken, zwemavonden en het nakijken van tekst en 
presentaties. Beste Edgar, bedankt voor de discussies over de basale vraagstukken. Veel succes 
met het afronden van jouw uitdagende, meer experimentele tak van het PCLD onderzoek. 
Je gaat dat goed doen! 
Beste studenten, Ceriel, Scott, Dorian en Julia. Dank voor jullie inzet voor de verschillende 
projecten, gezellige momenten in het lab, maar ook buiten het lab!
Dank aan de leden van de PCLD groep, Edgar, Titus, Myrte, Marten en Hedwig, keep up the 
good work! Tom, gezellig dat we collega’s zijn gebleven in Arnhem. Melissa, onze ‘uitstapjes 
met het echo-apparaat en de TomTom van Joost’ zijn memorabele weekenden geworden, fijn 
dat het gelukt is! Esmé, dank voor het blijven meedenken bij het PCLD-onderzoek. Manoe, 
succes in de onderzoekswereld, we komen elkaar vast weer tegen. Loes en Jannes, fijn dat 
ik jullie heb leren kennen gedurende een korte tijd.  
The Genomic Disorders Group, dear Jayne, Konny, Lisenka, Irene, Ferry,  Nienke, Michael, 
Peer, Rocío, Anneke, Marloes, Eugène, Petra, Tjie, Joep, Bert, Rick, Sharita, Steven, Marisol, 
Thank you very much for the discussions, teaching, jokes and fun retreats. I appreciate the 
collaboration with you all and envy your strong drive to contribute to a “significant impact 
on health care”. In addition, I learned many aspects in genetics thanks to you. This motivated 
me and brought this research topic to the next level.
Mijn waarde co-auteurs, Prof. dr. Dorien Peters, Dr. Monique Losekoot en Prof. dr. Martijn 
Breuning. Dank voor de fijne samenwerking en vlotte communicatie. Dit heeft bijgedragen 
aan nieuwe inzichten, maar ook vragen voor vervolgonderzoek. Dr. Hanka Venselaar, dank 
voor jouw talent om nieuwe varianten in een beter perspectief te kunnen plaatsen. 
Dear foreign colleagues, Prof. dr. Carsten Bergmann, thank you for the analyses and 
the collaboration with our group and joining the corona. Dr. Soufi Mehdi, thank you for your 
contribution to our research projects. Dr. Jesús M. Banales, dear Txus, I enjoyed the discussions 
with you about basic research on PLD. I wish you all the best to pursue excellent research in 
the field of (polycystic) liver diseases!
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Manuscriptcommissie, Prof. dr. Leo Joosten, Prof. dr. Joost Hoenderop en Prof. dr. Dorien 
Peters, dank voor het nalezen van de dissertatie. 
Radboudumc collega’s met diverse expertises van verschillende afdelingen wil ik graag 
dankzeggen. Rob Woestenenk, Marij Leenders van de afdeling Hematologie, dank voor de 
gesprekken over het opzetten en het samen uitvoeren van het project over het cystevocht. 
Ing. Irene Otte-Höller, veel dank voor de adviezen en het gebruik omtrent antilichamen, 
protocollen en microscopie van preparaten. Ing. Huib Croes, dank voor uw tijd en de instructies 
van de confocale microscoop en andere praktische tips. Dr. Rob Collin, dank voor de diverse 
overlegmomenten en uw bijdrage aan het LRP5-onderzoek. Ing. Simon van Reijmersdal, dank 
voor je tijd en adviezen. Dr. David Koolen, dank voor het meedenken met het onderzoek als 
klinisch geneticus. Dr. Van Nouhuys, Ing. mw. Marjo van de Ven, Ing. mw. Saskia van der Velde-
Visser, fijn dat u heeft deelgenomen aan een belangrijk onderdeel van een onderzoeksproject. 
Vanaf deze plaats wil ik ook dr. Erwin van Geffen (JBZ) danken voor zijn belangstelling en 
medewerking bij het verzamelen van cysteweefsel voor het PCLD onderzoek.
Beste collega´s van de afdeling MDL die regelmatig belangstelling toonden of indirect 
hebben bijgedragen. Hierbij denk ik aan Ricky, Maria, Maja, Geeralien, Jessica, secretaresses 
van de MDL, Manon en andere diëtisten. Eveneens dank aan de stafleden en AIOS-en van 
de afdeling MDL voor hun aandacht en tijd voor het PCLD onderzoek.
Beste (gepromoveerde) onderzoekers van de afdeling MDL, het was een fantastische 
tijd! Hilbert, Bjorn, Geert, Robin, Polat, Merel, Mieke, Monique, Mark Lamberts, Yasmijn 
het ga jullie goed als artsen in opleiding. Aan Mark Hess, Mark Broekman, Lauranne, Floor, 
Heidi, Jos en Angelique; het leven als onderzoeker bevat veel bijzondere momenten, deel 
deze ervaring samen met fijne collega’s.
Collega’s Rijnstate, collega arts-assistenten, internisten en opleiders, dank voor jullie 
belangstelling een leerzame omgeving. 
From this position, I would like to acknowledge several national and international societies. 
Thanks to their organization of congresses and courses, I was able to present our work, 
to engage with science and to meet colleague young investigators. They provided young 
investigator bursaries and awarded dedicated and original work. Therefore, I would like 
to thank the Dutch societies: Nederlandse Vereniging voor Gastroenterologie (NVGE), 
Nederlandse Vereniging voor Hepatologie (NVH) and the Genetica Retraite. I also enjoyed 
very much the schools, masterclass and congresses of the European Association for the 
Study of the Liver (EASL), the summer school and congress weeks of the United European 
Gastroenterology (UEG). The congress of the European Society for Human Genetics (ESHG) 
was a great experience.
Dank aan de Maag-, Lever-, Darmstichting (MLDS) en het voormalig Institute for 
Genetic and Metabolic Disease (IGMD), Nathalie Bovy voor de financiële middelen om deze 
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onderzoeksprojecten te bewerkstelligen. Margret Archour en de leden van het NCMLS (RIMLS) 
dank voor de vele events en up-dates. 
Beste vrienden uit verschillende windstreken, wat fijn om te ervaren dat vriendschappen 
op afstand juist sterk blijken te zijn. Familie Beullens, dank voor jullie hartelijke gastvrijheid 
destijds in België, jullie belangstelling voor mijn werk. Er zullen nog veel gezellige verjaardagen 
volgen van de jongens! Ingrid, Maarten, Marijke, Linda en Martijn, Sofie, fietsmaatjes Corrie 
en Wytze, hopelijk tot binnenkort! Beste Ellen, dank voor de zon. 
Beste (pro-)senioren en praesidiumleden van A.S.K.-Stuwer, vrienden uit Wilrijk en 
omstreken. Wat een geweldige tijd is het geweest aan’t Unief, ’t stad en Fort VI! Dank voor 
jullie belangstelling, weekendjes en regelmatige up-dates uit Antwerpen. Ut vivat, crescat 
et floreat A.S.K.-Stuwer!
Freonen om útens. Maaike, ik bin tige wiis mei ús freonskip! Ad, tank foar dyn ynset 
foar in moaie print foar dit boek. De froulju fan it fuotbaljen en freondinnen (fan eartiids) fan 
Snits, tank foar de gesellige wykeinen en útsjes mei elkoar. Stichting Tegearre Op Fakânsje 
(TOF), wat een geweldig tof team zijn jullie! Bedankt voor de onvergetelijke, mooie en 
bijzondere vakanties. 
Lieve Mémé, Linda Sabbe en Wim Kortbeek, dank voor jullie goede zorgen, interesse en 
mooie zeiltochten. Koen en Joke, dank voor jullie belangstelling voor dit onderzoek.
Ik bin grutsk op de hertlikens and waarmte fan de hiele famylje Cnossen en kunde út 
Snits. Leave Nynke en Pytrich, myn grutte susters, dy’t my faak oanstjoerd hawwe as twa 
memmen. Wat bin ik wiis mei jimme, lykas ek mei jimme manlju, leave sweagers Geert en 
Niels. Ik wol jimme betankje foar jimme niget oan myn wurk en foar de oanhâldende stipe, 
al wie it ek mar by myn reizgerij. Hooplik belibje wy noch in soad feestlike dingen mei elkoar. 
Myn alderleafste muoikesizzers, Jelle, Wybe, Hidde, Fedde, Jitske, Rinske en Hylke, 
wat stekt jimme fleurigens en entûsiasme my altiten wer oan. Jimme binne in rykdom yn ús 
famylje!
Myn âlden, leave Heit en Mem. Jimme binne de grûnslach fan myn bestean. Troch de krêft 
en kânsen, dy’t jimme my joegen, koe ik my  ûntjaan yn de wrâld. Jimme hawwe foar my fan 
ûnskatbere wearde west yn de tiid fan myn stúdzje yn Antwerpen. Mei de wurden fan Piter 
Wilkens:  “It ein fan eltse reis is it paad werom.” Us thús fielt altiten as in waarm en feilich honk. 
Tank foar jimme omtinken, leafde, soarch en  waarme wurden. Yn myn eagen binne jimme 
ek promovearre. Hjirby draach ik myn dissertaasje op oan jimme, myn leafste Heit en Mem.
Leave Pieter, wat bin ik tankber dasto de sinne bist yn myn libben.  
 
Dixit, Wybrich Cnossen
Utrecht, augustus 2015
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CURRICULUM VITAE
Naam:  Wybrich Riemke Cnossen
Woonplaats: Utrecht
Geboortedatum:  26-05-1985
Wybrich Cnossen is geboren en opgegroeid in Sneek. Ze bezocht het Christelijk 
Scholengemeenschap Bogerman te Sneek en behaalde in 2003 het Gymnasium  diploma 
(profiel Natuur en Gezondheid, fysica 1,2 en chemie 1,2).
Zij studeerde eerste kandidatuur biomedische wetenschappen aan de Universiteit Antwerpen 
(UA). Vervolgens startte zij in het tweede jaar geneeskunde aan de UA en voltooide deze 
opleiding in 2010. Gedurende deze periode zetelde zij in diverse studentenraden van de UA. 
Zij was hoofdredactrice van de UA Snelkrant, vice-voorzitter en later voorzitter (praeses) van de 
overkoepelende studentenvereniging A.S.K.-Stuwer vzw en verantwoordelijk voor de organisatie 
van diverse studentgerichte activiteiten op de campussen en de studentenvertegenwoordiging. 
Per oktober 2010 werkte zij als junior onderzoeker aan een uitdagend project onder supervisie 
van Prof. dr. Joost P.H. Drenth en Prof. dr. ir. Joris A. Veltman. Dit onderzoek heeft geleid tot 
het huidige proefschrift. De identificatie van een nieuw gen geassocieerd met PCLD leidde 
tot diverse presentaties en prijzen.
Op 1 juli 2014 startte Wybrich met de opleiding tot maag-, darm- en leverarts waarbij de 
vooropleiding interne geneeskunde wordt gevolgd in het Rijnstate ziekenhuis te Arnhem 
(opleider dr. Louis Reichert).

225
+
A
D
D
EN
D
U
M
LIST OF PUBLICATIONS
Wills ES*, Cnossen WR*, Hoischen A, te Morsche RHM, Salomon J, Steehouwer M, de Wilt JH, 
Clevers H, Huch M, Hehir-Kwa J, Pfundt R, Roepman R§, Veltman JA§, Drenth JPH§. Presence 
of multiple infrequent germline and somatic chromosomal abnormalities underlie liver cyst 
development. In preparation,*Shared first authorship, §Shared authorship
Cnossen WR, Salomon J, te Morsche RHM, Koolen D, Drenth JPH. High clinical heterogeneity 
in isolated polycystic liver disease families. Submitted
Cnossen WR, Maurits JSM, Salomon J, te Morsche RHM, Waanders E, Drenth JPH. Severe 
polycystic liver disease is not caused by PRKCSH deletions. Journal of Clinical Laboratory 
Analysis, 2015 September 13.
Cnossen WR, te Morsche RHM, Hoischen A, Gilissen C, Venselaar H, Mehdi S, Bergmann 
C, Breuning M, Losekoot M, Peters DJM, Veltman JA, Drenth JPH. LRP5 may contribute to 
ADPKD. European Journal of Human Genetics, 2015 April 29.
Janssen MJ, Salomon J, Cnossen WR, Bergmann C, Pfundt R, Drenth JP. Somatic loss of 
polycystic disease genes contributes to the formation of isolated and polycystic liver cysts. 
Gut, 2014 October 63(10):1533-4.
Cnossen WR, Drenth JPH. Polycystic liver disease: an overview of pathogenesis, clinical 
manifestations and management. Orphanet Journal of Rare Diseases, 2014 May 1;9:69.
Cnossen WR, te Morsche RHM, Hoischen A, Gilissen C, Chrispijn M, Venselaar H, Mehdi S, 
Bergmann C, Veltman JA, Drenth JPH. Whole-exome sequencing reveals LRP5 mutations and 
canonical Wnt signaling associated with hepatic cystogenesis. Proceedings of the National 
Academy of Sciences of the United States of America, 2014 April 8;111(14):5343-8.
Cnossen WR, Drenth JPH. A novel twist in polycystic liver disease. Gut, 2014 January 24. 
Cnossen WR, Drenth JPH. Somatic hits in polycystic liver diseases. Journal of carcinogenesis 
and mutagenesis, 2013 December 5:154.
Van de Vijver E, Schreuder AB, Cnossen WR, Muller Kobold AC, Van Rheenen PF. Safely ruling 
out inflammatory bowel disease in children and teenagers without referral for endoscopy. 
Archives of Disease in Childhood, 2012 December 97(12):1014-8. 
Wolf M, Cnossen W, Rutsaert R, Kersschot I. Chronic total occlusion of the left main coronary 
artery in a 31-year-old man. Tijdschrift voor Geneeskunde, 2011 February 67(3):141-145.

227
+
A
D
D
EN
D
U
M
ABSTRACTS AND CONFERENCES
Cnossen WR, te Morsche RHM, Hoischen A, Gilissen C, Chrispijn M, Venselaar H, Mehdi S, 
Bergmann C, Veltman JA, Drenth JPH. Whole-exome sequencing reveals LRP5 mutations and 
canonical Wnt signaling associated with hepatic cystogenesis.
Nomination for a battle, oral presentation, at the annual meeting of the Dutch Society 
for Gastroenterology (NVGE), March 19, 2015. Veldhoven, The Netherlands.
NVH Young Hepatologist Award 2014
Cnossen WR, Hoischen A, Woestenenk R, Steehouwer M, Leenders M, te Morsche RHM, 
Veltman JA, Drenth JPH. Somatic loss of alleles from hepatic cyst epithelium allow identification 
of candidate genes in polycystic liver disease.
Oral presentation, symposium session, at the 22th United European Gastroenterology Week 
(UEGW), October 18-22, 2014. Vienna, Austria.
Young investigators bursary
Published in supplemental file of the United European Gastroenterology Journal
Cnossen WR, te Morsche RHM, Hoischen A, Gilissen C, Venselaar H, Mehdi S, Bergmann 
C, Breuning M, Losekoot M, Peters DJM, Veltman JA, Drenth JPH. LRP5 variants associated 
with development of polycystic kidney and liver disease.
Oral presentation at the European Society for Human Genetics (ESHG), May 30th - June 
3rd, 2014. Milan, Italy.
Award nomination 
Cnossen WR, Salomon J, te Morsche RHM, Drenth JPH. Clinical heterogeneity in polycystic 
liver disease families.
Poster presentation at the 49th annual meeting, the International Liver Congress of the European 
Association for the Study of the Liver (ILC EASL), April 9-13, 2014. London, United Kingdom.
Top 10% abstract and full bursary
Published in supplemental file of the Journal of Hepatology
Oral presentation at the annual meeting of the NVGE, October 3-4, 2013. Veldhoven, 
The Netherlands.
Cnossen WR, te Morsche RHM, Hoischen A, Gilissen C, Chrispijn M, Venselaar H, Mehdi S, 
Bergmann C, Veltman JA, Drenth JPH. Whole-exome sequencing identifies LRP5 variants in 
polycystic liver disease.
Selected for oral presentation at the 1st Masterclass dedicated to ‘Hot topics in hepatology’ 
of the EASL, November 14-16, 2013. Bordeaux, France. 
Oral presentation at the 21th UEGW, October 14-16, 2013. Berlin, Germany.
‘Oral Free Paper Prize’ of the Free Paper Session: Genetics and pathogenesis.
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Young investigators bursary
Published in supplemental file of the United European Gastroenterology Journal
Oral presentation at the 1st Clinical PhD retreat, Radboud university medical center, 
Wageningen, The Netherlands, February, 2013.
Cnossen WR, te Morsche RHM, Hoischen A, Gilissen C, Chrispijn M, Venselaar H, Mehdi S, 
Bergmann C, Veltman JA, Drenth JPH. Identification of a novel gene associated with polycystic 
liver and kidney disease.
Poster presentation at the 48th annual ILC EASL, April 24-28, 2013. Amsterdam, The 
Netherlands.
Top 10% abstract and full bursary
Published in supplemental file of the Journal of Hepatology
Poster presentation at the annual meeting of the NVGE, March 21-22, 2013. Veldhoven, 
The Netherlands.
Oral presentation at the Genetica Retraite, March 21-22, 2013. Kerkrade, The Netherlands.
First speaker’s prize, ‘Rolduc Award’
Cnossen WR, Maurits JSM, te Morsche RHM, Waanders E, Drenth JPH. Multiplex ligation 
probe amplification in polycystic liver disease.
Poster presentation at the 48th annual meeting, the ILC EASL, April 24-28, 2013. Amsterdam, 
The Netherlands.
Full bursary
Published in supplemental file of the Journal of Hepatology
Poster presentation at the Monothematic Conference ‘Systems biology of the liver: 
Systems biology and clinics face à face’ of the EASL, February 21-23, 2013. Luxembourg, 
Luxembourg.
Cnossen WR, Schreuder AB, Muller Kobold AC, Van de Vijver E, Van Rheenen PF. On behalf of 
the North Netherland Pediatric Inflammatory Bowel Disease Consortium.  Faecal calprotectin 
for screening children with suspected inflammatory bowel disease: a phase III diagnostic study.
Oral presentation at the annual meeting of the NVGE, October 7-8, 2010. Veldhoven, 
The Netherlands.
Cnossen WR*, Lenders E*, Van de Velde A, Berneman Z, Gadisseur A. Early detection of 
invasive pulmonary aspergillosis in neutropenic patients: value of the galactomannan test and 
high resolution computer tomography scan. 
Poster presentation at the XXXIII World congress of the International Society of Hematology, 
October 10-13, 2010. Jerusalem, Israel.
*shared first authorship
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Attendance of meetings and courses
UEG Research Course: Young Investigators Meeting, UEG, October 13, 2013. Berlin, Germany.
Abdominal ultrasound in clinical practice, Dutch Liver Week, June 12, 2012, Rotterdam.
Nijmegen Centre for Molecular Life Sciences (NCMLS) PhD retreat, Wageningen. May 2011 
and 2012, poster presentations.
47th annual meeting, the ILC EASL, April 18-22, 2012. Barcelona, Spain.
Annual meeting of the NVGE, March 17-18, 2011. Veldhoven.
ASNEMGE/EAGE Summer School of Gastroenterology, June 16-19, 2011. Prague, Czech 
Republic.
46th annual meeting, the ILC EASL, March 30-April 4, 2011. Berlin, Germany.
Monothematic Conference ‘Basic liver course’ of the EASL, February 2011. Groningen.
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ABBREVIATIONS
AAA  abdominal aorta aneurysm
ADPKD  autosomal dominant polycystic kidney disease
ADPLD  autosomal dominant polycystic liver disease 
AE2  anion exchanger 2
ARPKD  autosomal recessive polycystic kidney disease
AQP1  aquaporin 1
cAMP  adenosine 3’, 5’-cyclic monophosphate
CD  Caroli disease
CFTR  cystic fibrosis transmembrane conductance regulator
CHF  congenital hepatic fibrosis
CNA  copy number aberration
CNV  copy number variation
CS  Caroli syndrome
CT  computer tomography
DKK3  dickkopf Wnt signaling pathway inhibitor 3
DPM  ductal plate malformation
DQ  dosage quotient
ELAVL3  embryonic lethal abnormal vision drosophila homolog-like 3 
Epac  exchange protein 
ER  endoplasmic reticulum
ERK  extracellularly regulated kinase
ESRD  end stage renal disease
FACS  fluorescent-activated cell sorting
HNF1ß  hepatocyte nuclear factor-1-beta
HVOO  hepatic venous outflow obstruction
ICA  intracranial aneurysm
IVC  inferior vena cava
LOH  loss of heterozygosity
LPO  left probe oligonucleotide
LRP5  low density lipoprotein receptor-related protein 5
LVH  left ventricle hypertrophy
MAPK  mitogen-activated protein kinase
MELD  model for end-stage liver disease
MLPA  multiplex ligation-dependent probe amplification
MRI  magnetic resonance imaging
ORF  open reading frame
PC1, PC2 polycystin-1, -2
PCLD  autosomal dominant polycystic liver disease
PCP  planar cell polarity
PCR  polymerase chain reaction
PKA  protein kinase A
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PKD1, PKD2 polycystic kidney disease-1, -2 
PLD  polycystic liver diseases  
PKD1  polycystic kidney disease 1 
PKD2  polycystic kidney disease 2 
PKDTS   TSC2/PKD1 contiguous syndrome 
PKHD1  polycystic kidney and hepatic disease 1 
PRKCSH  protein kinase C substrate 80K-H (80 kDa protein, heavy chain)
RPO  right probe oligonucleotide
SEC63  Saccharomyces cerevisiae homolog 63
SNP  single nucleotide polymorphism
SR  secretin receptor
SSTR  somatostatin receptor
TSC  tuberous sclerosis complex
VMC  von Meyenburg complexes
Wnt  wingless-type MMTV integration site family member
WT  wild type

